{
    "testId": 389967301,
    "parentTestId": null,
    "userId": 4331736,
    "sequenceId": 58,
    "qbankId": 2,
    "isSim": 0,
    "testModeId": 0,
    "testModeName": "Timed",
    "questionModeId": 0,
    "questionModeName": "ALL",
    "testName": "",
    "totalQuestionCorrect": 29,
    "correctToIncorrect": 3,
    "incorrectToCorrect": 7,
    "incorrectToIncorrect": 1,
    "timeInSeconds": 253,
    "averageTimeSpentInSeconds": 84,
    "otherAverageTimeSpentInSeconds": 65,
    "isStarted": true,
    "isEnded": true,
    "formId": 0,
    "bLockId": 0,
    "subscriptionId": 13863865,
    "lastQuestionVisited": 40,
    "containsMediaQuestion": false,
    "sectionId": 1010,
    "sectionName": "Step 2 Review",
    "difficultyLevelId": null,
    "difficultyLevelName": null,
    "testTypeId": null,
    "testTypeName": null,
    "allottedTime": null,
    "allottedTimeTypeId": null,
    "canResume": null,
    "assignmentId": null,
    "canViewAssignmentResult": null,
    "questionModeIds": "1",
    "testSource": 1,
    "testTypes": "",
    "questionList": [
        {
            "exhibits": null,
            "sequenceId": 1,
            "questionId": 3807,
            "questionIndex": 3807,
            "questionText": "<p>A 48-year-old woman comes to the office for evaluation of elevated blood pressure, which was first noted at her dentist&#39;s office 4 weeks ago.&nbsp; Repeated home blood pressure measurements since then have remained around 150/90 mm Hg.&nbsp; The patient has had no symptoms and has no history of hypertension or other medical conditions.&nbsp; She takes no medications and does not use tobacco, alcohol, or illicit drugs.&nbsp; Family history is significant for hypertension in her father.&nbsp; Blood pressure is 152/88 mm Hg and pulse is 76/min.&nbsp; A repeat blood pressure measurement after 15 minutes shows a similar reading.&nbsp; BMI is 28.6 kg/m<font size=\"2\"><sup>2</sup></font>.&nbsp; Physical examination reveals clear lungs, normal heart sounds, a nontender abdomen with no organomegaly, and no lower extremity edema.&nbsp; There are no abnormalities on ECG.&nbsp; Laboratory testing shows normal serum electrolytes and creatinine and no proteinuria.&nbsp; Which of the following additional evaluations is most appropriate in this patient?</p>",
            "questionHeader": "",
            "explanationText": "<div id=\"div_t38622\"><table class=\"table-default-style\"><tbody><tr><td colspan=\"2\"><p align=\"center\"><strong>Laboratory evaluation of hypertension</strong></p></td></tr><tr><td><p align=\"center\"><strong>Renal function tests</strong></p></td><td><ul><li>Serum electrolytes (Na, K, Ca)</li><li>Serum creatinine</li><li>Urinalysis</li><li>Urine albumin/creatinine ratio (optional)</li></ul></td></tr><tr><td><p align=\"center\"><strong>Endocrine tests</strong></p></td><td><ul><li>Fasting glucose or hemoglobin A1c</li><li>Lipid profile</li><li>TSH</li></ul></td></tr><tr><td><p align=\"center\"><strong>Cardiac tests</strong></p></td><td><ul><li>ECG</li><li>Echocardiography (optional)</li></ul></td></tr><tr><td><p align=\"center\"><strong>Other tests</strong></p></td><td><ul><li>Complete blood count</li><li>Uric acid (optional)</li></ul></td></tr></tbody></table></div><p>This patient has hypertension, defined as a sustained blood pressure &#8805;130 mm Hg systolic or &#8805;80 mm Hg diastolic (some guidelines recommend &#8805;140/90 mm Hg for diagnosis); given her age, mildly elevated blood pressure, and family history of hypertension, this most likely represents <strong>primary (essential) hypertension</strong>.&nbsp; The initial evaluation should identify <strong>complications</strong> of hypertension (eg, chronic kidney disease) or <strong>comorbid conditions</strong> (eg, hyperlipidemia) that might influence management.&nbsp; Assessment should include a serum chemistry panel (including electrolytes and creatinine), hemoglobin/hematocrit, lipid panel, and urinalysis.</p><p>In addition, patients with hypertension should be screened for <strong>diabetes mellitus</strong> with either <strong>fasting blood glucose</strong>, which can be obtained as part of a serum chemistry panel, or <strong>hemoglobin A1c</strong>.&nbsp; Even in the absence of hypertension, screening is advised for patients age 35-70 with a <strong>BMI &#8805;25 kg/m<font size=\"2\"><sup>2</sup></font></strong> (ie, overweight or obesity).&nbsp; Screening at younger ages should be considered for those with additional risk factors (eg, family history of diabetes).</p><p><strong>(Choice A)</strong>&nbsp; Many experts recommend ECG to identify signs of left ventricular hypertrophy in patients with hypertension.&nbsp; Further assessment of ventricular function with echocardiography is more specific but is expensive and would have low yield in this young patient with mild hypertension and a normal ECG.</p><p><strong>(Choice B)</strong>&nbsp; Testing for sleep apnea is indicated for patients with symptoms (eg, daytime somnolence, witnessed apneic episodes) and can be considered for those with refractory hypertension.&nbsp; However, it is not indicated for asymptomatic patients with uncomplicated hypertension.</p><p><strong>(Choice C)</strong>&nbsp; Duplex Doppler ultrasonography can identify renal artery stenosis, which typically occurs in older men with diffuse atherosclerosis and causes severe or resistant hypertension requiring &#8805;3 medications.&nbsp; Other characteristic findings include recurrent flash pulmonary edema and unexplained renal failure after starting an ACE inhibitor.</p><p><strong>(Choice D)</strong>&nbsp; Plasma renin activity is used to evaluate primary hyperaldosteronism.&nbsp; However, patients typically have severe or resistant hypertension; hypokalemia is common.&nbsp; Primary hyperaldosteronism is unlikely in this patient with mild hypertension and normal serum electrolytes.</p><p><strong>Educational objective:</strong><br>Patients with hypertension should be screened for diabetes mellitus with either fasting blood glucose or hemoglobin A1c.&nbsp; Even in the absence of hypertension, screening for diabetes is advised for patients age 35-70 with a BMI &#8805;25.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 102,
            "subject": "Medicine",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 211,
            "system": "Endocrine, Diabetes & Metabolism",
            "topicId": 2603,
            "topic": "Diabetes mellitus",
            "titleId": 2603,
            "title": "Diabetes mellitus",
            "topicAttributeId": 330582,
            "topicAttribute": "Diabetes mellitus",
            "correctAnswer": "5",
            "userAnswer": "5",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Assessment of left ventricular function",
                    "choiceNumber": 1,
                    "correctTaken": 516,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Home sleep apnea testing",
                    "choiceNumber": 2,
                    "correctTaken": 2016,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Imaging for atherosclerotic renovascular disease",
                    "choiceNumber": 3,
                    "correctTaken": 1924,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Measurement of plasma renin activity",
                    "choiceNumber": 4,
                    "correctTaken": 3568,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Screening for diabetes mellitus",
                    "choiceNumber": 5,
                    "correctTaken": 10383,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": "148,189,true,-1,1*276,303,true,-1,1*337,357,true,-1,1*1186,1437,true,-1,1",
            "isCorrect": true,
            "isIncorrect": false,
            "isMarked": false,
            "isOmitted": false,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "524",
                    "mediaDataId": 0,
                    "title": "Essential hypertension",
                    "referenceTypeId": 18,
                    "referenceLink": null,
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 62,
            "othersAvgTimeSpent": 63,
            "notes": null,
            "peopleTaken": 18407,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 56,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 1839,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 1,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 2,
            "questionId": 4239,
            "questionIndex": 4239,
            "questionText": "<p>A 7-year-old boy is brought to the office for evaluation of severe facial acne that has developed over the past few months.&nbsp; His mother treated it with topical benzoyl peroxide and a salicylic acid face wash with no improvement.&nbsp; She also reports a significant increase in her son&#39;s height and says he is now much taller than his fraternal twin brother.&nbsp; The patient is otherwise healthy with no chronic medical conditions.&nbsp; He takes no medications.&nbsp; Height is at the 98th percentile for age and sex, and weight is at the 85th percentile.&nbsp; Neurologic examination is normal.&nbsp; Skin examination is notable for severe cystic acne involving the face and shoulders.&nbsp; Coarse pubic and axillary hair are noted.&nbsp; Testicular volume is consistent with prepubertal staging.&nbsp; Bone age is 2 standard deviations higher than chronologic age.&nbsp; Additional evaluation reveals that baseline LH level is low and does not increase after administration of a GnRH agonist.&nbsp; Which of the following is the most likely diagnosis in this patient?</p>",
            "questionHeader": "",
            "explanationText": "<p><img  draggable=\"false\" id=\"7168\" src=\"https://www.uworld.com/media/highresdefault/L17403.png\"  ></p><p>This 7-year-old patient with cystic acne, accelerated growth, and coarse pubic and axillary hair has <strong>precocious puberty</strong>, defined as the onset of secondary sexual characteristics in girls age &lt;8 and <strong>boys age &lt;9</strong>.</p><p>Initial evaluation includes bone age determination, which assesses skeletal maturity via x-ray examination of the wrist and differentiates true precocious puberty (advanced bone age) from isolated premature thelarche/adrenarche (normal bone age).&nbsp; In children with <strong>advanced bone age</strong> (&gt;2 standard deviations above chronologic age), as in this patient, LH level is then determined to differentiate peripheral and central causes:</p><ul><li><p>Central precocious puberty is characterized by high LH (or LH responsive to GnRH) due to activation of the hypothalamic-pituitary-gonadal (HPG) axis (gonadotropin dependent).&nbsp; Examples include idiopathic central precocious puberty and gonadotropin-secreting pituitary microadenoma <strong>(Choices A and E)</strong>.</p></li><li><p><strong>Peripheral</strong> precocious puberty is characterized by <strong>low basal LH</strong> that does not increase with GnRH stimulation (gonadotropin independent), as in this case.&nbsp; LH level is persistently low because excess circulating <strong>androgens</strong> produced by the <strong>adrenal glands or testes</strong> suppress pituitary LH secretion.</p></li></ul><p>This patient&#39;s peripheral precocious puberty (low LH persisting despite GnRH stimulation) is most likely from&nbsp;<strong>nonclassic congenital adrenal hyperplasia</strong> (CAH).&nbsp; Nonclassic CAH is typically due to a partial <a href=\"678\">21-hydroxylase deficiency</a>, in which adrenal glucocorticoid and mineralocorticoid synthesis is low but adequate, preventing the adrenal crises and salt wasting seen in classic CAH.&nbsp; Instead, symptoms are due only to excess 17-hydroxyprogesterone, which is converted to <strong>adrenal androgens</strong>, causing premature development of secondary sexual characteristics.&nbsp; Because the HPG axis is not activated prematurely, testicular volume is often at a prepubertal stage at presentation.&nbsp; Nonclassic CAH tends to present in childhood rather than in infancy (as with classic CAH).</p><p><strong>(Choice B)</strong>&nbsp; Klinefelter syndrome (47,XXY) causes primary hypogonadism, which is characterized by low testosterone and elevated LH.&nbsp; This patient has low LH and signs of excess androgen.</p><p><strong>(Choice C)</strong>&nbsp; McCune-Albright syndrome is a rare cause of peripheral precocious puberty that causes caf&eacute; au lait macules and fibrous dysplasia of bone (eg, bone pain, pathologic fractures), which are not seen here.</p><p><strong>Educational objective:</strong><br>Nonclassic congenital adrenal hyperplasia is a cause of peripheral (gonadotropin-independent) precocious puberty in which LH level is low and does not increase in response to GnRH stimulation.&nbsp; Patients exhibit early-onset secondary sexual characteristics (eg, pubic hair, cystic acne), accelerated growth, and advanced bone age.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 104,
            "subject": "Pediatrics",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 211,
            "system": "Endocrine, Diabetes & Metabolism",
            "topicId": 10495,
            "topic": "Congenital adrenal hyperplasia",
            "titleId": 10495,
            "title": "Congenital adrenal hyperplasia",
            "topicAttributeId": 330576,
            "topicAttribute": "Congenital and developmental anomalies",
            "correctAnswer": "4",
            "userAnswer": "2",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Idiopathic central precocious puberty",
                    "choiceNumber": 1,
                    "correctTaken": 1008,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Klinefelter syndrome",
                    "choiceNumber": 2,
                    "correctTaken": 418,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "McCune-Albright syndrome",
                    "choiceNumber": 3,
                    "correctTaken": 440,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Nonclassic congenital adrenal hyperplasia",
                    "choiceNumber": 4,
                    "correctTaken": 2525,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Pituitary microadenoma",
                    "choiceNumber": 5,
                    "correctTaken": 644,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": "507,574,true,-1,1*671,1265,true,-1,1*1507,1824,true,-1,1*1826,1943,true,-1,1*2133,2167,true,-1,1*2233,2434,true,-1,1",
            "isCorrect": false,
            "isIncorrect": true,
            "isMarked": false,
            "isOmitted": false,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "100",
                    "mediaDataId": 0,
                    "title": "Precocious puberty",
                    "referenceTypeId": 18,
                    "referenceLink": null,
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "27180336",
                    "mediaDataId": 0,
                    "title": "Unusual phenotype of congenital adrenal hyperplasia (CAH) with a novel mutation of the CYP21A2 gene.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/27180336",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "26082286",
                    "mediaDataId": 0,
                    "title": "Nonclassic congenital adrenal hyperplasia due to 21-hydroxylase deficiency: clinical presentation, diagnosis, treatment, and outcome.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/26082286",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 114,
            "othersAvgTimeSpent": 97,
            "notes": null,
            "peopleTaken": 5050,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 50,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 2126,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 1,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 3,
            "questionId": 3800,
            "questionIndex": 3800,
            "questionText": "<p>A 66-year-old man with a 10-year history of type 2 diabetes mellitus comes to the office due to burning and stabbing pain in his feet for the past few months.&nbsp; The pain is severe enough to interfere with his daily activities and is worse at night.&nbsp; His medical history is notable for hypertension, hyperlipidemia, and coronary artery disease with a non-ST elevation myocardial infarction 4 years ago.&nbsp; The patient is on a mixed regimen of insulin glargine and insulin aspart, in addition to other medications, including metoprolol, valsartan, atorvastatin, and aspirin.&nbsp; On physical examination, there is loss of ankle reflexes bilaterally, with loss of vibratory sensation and altered proprioception below the knees.&nbsp; Hemoglobin A1c is 8.6% and serum creatinine is 1.55 mg/dL.&nbsp; In addition to optimizing glycemic control, which of the following is the most appropriate medication for management of this patient&#39;s current symptoms?</p>",
            "questionHeader": "",
            "explanationText": "<p><div id=\"div_t62534\"><table class=\"table-default-style table-header-footer-style\"><tbody><tr><td colspan=\"2\"><p align=\"center\"><strong>Drugs for neuropathic pain</strong></p></td></tr><tr><td><p align=\"center\"><strong>Drug</strong></p></td><td><p align=\"center\"><strong>Mechanism of action</strong></p></td></tr><tr><td><p align=\"center\"><strong>Tricyclic antidepressants</strong><br />(eg, amitriptyline, nortriptyline)</p>&nbsp;<p align=\"center\"><strong>SNRIs</strong> (eg, duloxetine)</p></td><td><ul><li>&darr; Reuptake of serotonin &amp; norepinephrine</li><li>Inhibition of pain signals</li></ul></td></tr><tr><td><p align=\"center\"><strong>Anticonvulsants</strong><br />(eg, gabapentin, pregabalin)</p></td><td><ul><li>Decreased depolarization of neurons in the CNS</li></ul></td></tr><tr><td><p align=\"center\"><strong>Opioids</strong></p></td><td><ul><li>Activation of central opioid receptors</li></ul></td></tr><tr><td><p align=\"center\"><strong>Capsaicin</strong> (topical)</p></td><td><ul><li>Loss of membrane potential in nociceptive fibers</li></ul></td></tr><tr><td><p align=\"center\"><strong>Lidocaine</strong> (topical)</p></td><td><ul><li>Decreased depolarization of neurons in peripheral nerves</li></ul></td></tr><tr><td colspan=\"2\"><p><strong>SNRIs</strong> = serotonin-norepinephrine reuptake inhibitors.</p></td></tr></tbody></table></div></p><p>This patient with uncontrolled diabetes mellitus (elevated hemoglobin A1c) has neuropathic pain and symmetric distal neurologic deficits (eg, loss of reflexes, altered vibration and proprioception) consistent with sensorimotor <strong>polyneuropathy due to diabetes mellitus</strong>.&nbsp; The clinical features of diabetic neuropathy depend on the type of nerve fibers involved; small fiber neuropathy predominantly causes pain, allodynia, and paresthesias, whereas large fiber involvement causes more numbness, loss of proprioception, diminished vibration sense, and loss of ankle reflexes.&nbsp; Both types are commonly seen together.&nbsp; As diabetic neuropathy progresses, the pain may diminish but the sensory deficits persist.</p><p>Initial treatment options for painful diabetic neuropathy include tricyclic antidepressants (eg, amitriptyline), dual serotonin norepinephrine reuptake inhibitors (eg, duloxetine), and anticonvulsants (eg, pregabalin, gabapentin).&nbsp; <strong>Pregabalin</strong> is a structural analogue of gamma-aminobutyric acid and decreases pain by inhibiting the release of excitatory neurotransmitters by binding to voltage-gated calcium modulators on nerve terminals.&nbsp; Common side effects are drowsiness, weight gain, and fluid retention.</p><p><strong>(Choice A)</strong>&nbsp; Although amitriptyline is effective for reducing neuropathic pain, it should be used with caution in patients age &gt;65 due to its anticholinergic effects, and it is not recommended in patients with pre-existing cardiac disease due to the risk of precipitating conduction abnormalities.</p><p><strong>(Choice B)</strong>&nbsp; NSAIDs (eg, ketorolac) are more effective for somatic (eg, joint pain) than neuropathic pain.&nbsp; Also, they are relatively contraindicated in patients on antiplatelet therapy for coronary artery disease and those with renal insufficiency.</p><p><strong>(Choice C)</strong>&nbsp; Opioids (eg, oxycodone) are possibly effective for painful diabetic neuropathy, but evidence for their effectiveness is limited, and they are not recommended as initial treatment due to the risk of abuse and dependence.</p><p><strong>(Choice D)</strong>&nbsp; Systemic glucocorticoids (eg, prednisone) can be used for chronic inflammatory demyelinating neuropathy, a rare disorder that can cause distal paresthesias and numbness; these patients typically have motor weakness in the upper and lower extremities.</p><p><strong>Educational objective:</strong><br>Initial treatment options for painful diabetic neuropathy include tricyclic antidepressants, dual serotonin norepinephrine reuptake inhibitors, and anticonvulsants.&nbsp; Pregabalin decreases pain by inhibiting the release of excitatory neurotransmitters.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 102,
            "subject": "Medicine",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 211,
            "system": "Endocrine, Diabetes & Metabolism",
            "topicId": 6440,
            "topic": "Diabetic neuropathy",
            "titleId": 6440,
            "title": "Diabetic neuropathy",
            "topicAttributeId": 330582,
            "topicAttribute": "Diabetes mellitus",
            "correctAnswer": "5",
            "userAnswer": "5",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Amitriptyline",
                    "choiceNumber": 1,
                    "correctTaken": 3026,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Ketorolac",
                    "choiceNumber": 2,
                    "correctTaken": 167,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Oxycodone",
                    "choiceNumber": 3,
                    "correctTaken": 114,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Prednisone",
                    "choiceNumber": 4,
                    "correctTaken": 141,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Pregabalin",
                    "choiceNumber": 5,
                    "correctTaken": 12643,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": "933,1279,true,-1,1*1811,1825,true,-1,1*1871,2085,true,-1,1",
            "isCorrect": true,
            "isIncorrect": false,
            "isMarked": false,
            "isOmitted": false,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "465",
                    "mediaDataId": 0,
                    "title": "Diabetic neuropathy",
                    "referenceTypeId": 18,
                    "referenceLink": null,
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "21482920",
                    "mediaDataId": 0,
                    "title": "Evidence-based guideline: treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/21482920",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 39,
            "othersAvgTimeSpent": 42,
            "notes": null,
            "peopleTaken": 16091,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 79,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 1340,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 1,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 4,
            "questionId": 7010,
            "questionIndex": 7010,
            "questionText": "<p>A 62-year-old man comes to the office for a follow-up visit.&nbsp; He recently had episodes of sweating, headache, tremor, and palpitation while working in his backyard; his wife has noticed that he seems confused during these episodes.&nbsp; Medical history is notable for long-standing type 2 diabetes mellitus treated with insulin glargine and glipizide, hypertension, peripheral vascular disease, and hyperlipidemia.&nbsp; The patient also has chronic kidney disease, and his renal function has declined significantly over the past 2 years despite optimal glycemic control.&nbsp; Which of the following is most likely responsible for this patient&#39;s symptoms?</p>",
            "questionHeader": "",
            "explanationText": "<p><img draggable=\"false\" id=\"6817\" src=\"https://www.uworld.com/media/L24676.jpg\" ></p><p>This patient is likely experiencing recurrent <strong>hypoglycemia</strong>, presenting with both neurogenic (eg, sweating, tremor, palpitation due to autonomic activation) and neuroglycopenic (eg, confusion, impaired consciousness due to inadequate CNS glucose supply) symptoms.&nbsp; Hypoglycemia generally occurs when circulating <strong>insulin levels are excessive</strong> for the associated glucose levels.</p><p>As blood glucose levels fall during activity or fasting, insulin secretion normally decreases.&nbsp; At the same time, the production of counterregulatory hormones (eg, glucagon) increases to stimulate glycogenolysis and gluconeogenesis in the liver.&nbsp; However, patients taking <strong>exogenous insulin</strong> are vulnerable to exercise-induced hypoglycemia because insulin <strong>continues to be released</strong> from the injection site despite falling glucose levels.&nbsp; In addition, strenuous exertion may cause changes in skin perfusion that can lead to increased insulin absorption.</p><p>Patients with chronic kidney disease are at increased risk of hypoglycemia due to <strong>delayed clearance of insulin</strong> by the kidneys.&nbsp; These patients often also have additional factors, such as altered nutrition and autonomic dysfunction, that can delay the normal physiologic compensation.</p><p><strong>(Choice A)</strong>&nbsp; Patients with diabetes and coronary artery disease may experience atypical anginal symptoms such as fatigue, dyspnea, and nausea.&nbsp; However, this patient&#39;s mental confusion is more consistent with the neuroglycopenic effects of hypoglycemia.</p><p><strong>(Choice B)</strong>&nbsp; Pheochromocytoma is an uncommon catecholamine-secreting tumor that presents with headache, palpitations, diaphoresis, and severe hypertension.&nbsp; However, confusion is less typical and more characteristic of hypoglycemia.</p><p><strong>(Choices D and G)</strong>&nbsp; Orthostatic hypotension or a vasovagal reaction would cause symptoms of presyncope (eg, light-headedness, darkening of vision) or syncope.&nbsp; Tremor is also uncommon.</p><p><strong>(Choice E)</strong>&nbsp; Panic attacks can present with tachycardia and diaphoresis, but confusion is atypical.&nbsp; In addition, working in the yard is not a common trigger for panic attacks.</p><p><strong>(Choice F)</strong>&nbsp; Hyperthyroidism can cause tachycardia and sweating, but symptoms are typically chronic rather than episodic and are often associated with goiter.</p><p><strong>Educational objective:</strong><br>Patients taking exogenous insulin for diabetes are vulnerable to exercise-induced hypoglycemia because insulin continues to be released from the injection site despite falling glucose levels.&nbsp; Patients with chronic kidney disease are at increased risk due to delayed clearance of insulin by the kidneys.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 102,
            "subject": "Medicine",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 211,
            "system": "Endocrine, Diabetes & Metabolism",
            "topicId": 2740,
            "topic": "Hypoglycemia",
            "titleId": 2740,
            "title": "Hypoglycemia",
            "topicAttributeId": 330582,
            "topicAttribute": "Diabetes mellitus",
            "correctAnswer": "3",
            "userAnswer": "3",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Angina pectoris",
                    "choiceNumber": 1,
                    "correctTaken": 402,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Catecholamine-secreting tumor",
                    "choiceNumber": 2,
                    "correctTaken": 3056,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Insulin excess",
                    "choiceNumber": 3,
                    "correctTaken": 9061,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Orthostatic hypotension",
                    "choiceNumber": 4,
                    "correctTaken": 293,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Panic attacks",
                    "choiceNumber": 5,
                    "correctTaken": 39,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Thyroid hormone overproduction",
                    "choiceNumber": 6,
                    "correctTaken": 361,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Vasovagal reaction",
                    "choiceNumber": 7,
                    "correctTaken": 512,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": "112,293,true,-1,1*856,957,true,-1,1",
            "isCorrect": true,
            "isIncorrect": false,
            "isMarked": false,
            "isOmitted": false,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "527",
                    "mediaDataId": 0,
                    "title": "Insulin therapy in diabetes mellitus management",
                    "referenceTypeId": 18,
                    "referenceLink": null,
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "26239457",
                    "mediaDataId": 0,
                    "title": "Hypoglycemia in patients with diabetes and renal disease.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/26239457",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 42,
            "othersAvgTimeSpent": 58,
            "notes": null,
            "peopleTaken": 13724,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 66,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 1651,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 1,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 5,
            "questionId": 3451,
            "questionIndex": 3451,
            "questionText": "<p>A 58-year-old man comes to the urgent care center with a 2-week history of an ulcer on his right foot.&nbsp; He recalls no injury and found a &#x22;dime sized&#x22; ulcer on the bottom of the foot after noticing soakage on his sock.&nbsp; The patient has been cleaning the wound with antiseptics and applying topical antibiotics, but it has failed to heal.&nbsp; He has had no pain, surrounding redness, fever, or chills.&nbsp; The patient was diagnosed with hypertension several years ago but had no follow-up with a physician.&nbsp; He takes ibuprofen for occasional back pain.&nbsp; The patient has a 30-pack-year smoking history and drinks 1 or 2 beers daily.&nbsp; He works in a warehouse, where he is &#x22;constantly on the move&#x22; and considers himself to be in good health.&nbsp; Temperature is 36.7 C (98.1 F), blood pressure is 156/98 mm Hg, and pulse is 88/min.&nbsp; BMI is 32 kg/m<font size=\"2\"><sup>2</sup></font>.&nbsp; On examination, the feet are warm and dry.&nbsp; A 2-cm nontender ulcer is present on the sole of the foot just below the head of the first metatarsal bone.&nbsp; There is scant discharge and necrotic tissue at the ulcer bed, but the bone probe is negative.&nbsp; Which of the following will most likely diagnose the underlying cause of this patient&#39;s foot ulcer?</p>",
            "questionHeader": "",
            "explanationText": "<div id=\"div_T61708\"><table class=\"table-default-style\"><tbody><tr><td colspan=\"2\"><p align=\"center\"><strong>Diabetic foot ulcers</strong></p></td></tr><tr><td><p><strong>Risk factors</strong></p></td><td><ul><li>Chronically uncontrolled diabetes</li><li>Diabetic neuropathy (decreased protective sensation)</li><li>Foot deformity &amp; small muscle atrophy</li><li>End-stage renal disease/dialysis</li></ul></td></tr><tr><td><p align=\"center\"><strong>Presentation</strong></p></td><td><ul><li>Plantar surface under pressure points (eg, bony prominences)</li><li>Painless ulcer</li><li>&#x22;Punched out&#x22; appearance with necrotic base</li><li>Often with adjacent callus</li></ul></td></tr></tbody></table></div><p><strong>Neuropathic ulcers</strong> are caused by repeated pressure, friction, or trauma due to lack of sensation in the local tissues.&nbsp; They typically occur at <strong>weight-bearing sites</strong> (eg, head of the first metatarsal) on the <a href=\"20220\">sole of the foot</a>.&nbsp; The location of this patient&#39;s ulcer and the lack of associated pain are consistent with a neuropathic ulcer.</p><p><strong>Diabetes mellitus</strong> is the most common cause of <strong>neuropathic ulcers</strong>.&nbsp; Whereas neuropathy involving small nerve fibers typically causes pain and paresthesia, involvement of large fibers produces sensory loss that can allow minor injuries to go unrecognized until the development of an ulcer.&nbsp; Associated autonomic dysregulation can lead to decreased sweating and skin fissuring and further increase the risk for ulceration.</p><p>In addition to the ulcer, this patient has other risk factors for diabetes (eg, obesity, hypertension).&nbsp; Peripheral neuropathy can be present at the time of type 2 diabetes mellitus diagnosis in some patients and can often be asymptomatic.&nbsp; He should therefore be screened for diabetes with a <strong>hemoglobin A1c</strong> or <strong>fasting glucose</strong> measurement.</p><p><strong>(Choice A)</strong>&nbsp; The ankle-brachial index can diagnose peripheral artery disease.&nbsp; Features suggesting an <a href=\"3259\">arterial ulcer</a> include location at the tips of the digits (least perfused areas); cool, pale skin with dermal atrophy; and diminished pulses.&nbsp; Unlike this patient&#39;s ulcer, arterial ulcers are typically painful.</p><p><strong>(Choice B)</strong>&nbsp; Culture from an ulcer bed typically finds polymicrobial colonization but does not indicate true infection in the absence of more specific symptoms (eg, fever, erythema, purulent drainage) and would not establish the underlying cause of the ulcer.</p><p><strong>(Choice C)</strong>&nbsp; Duplex ultrasonography can identify venous insufficiency or obstruction.&nbsp; <a href=\"5758\">Venous ulcers</a> typically occur on the medial aspect of the leg above the malleolus and are usually associated with edema and stasis dermatitis.</p><p><strong>(Choice E)</strong>&nbsp; MRI of the spine is used in evaluation of lumbosacral radiculopathy, which typically presents with pain in the low back that radiates to the foot.&nbsp; This patient has no radicular pain, and radiculopathy is not a common cause of neuropathic ulcers.</p><p><strong>(Choice F)</strong>&nbsp; Vasculitic ulcers (eg, cryoglobulinemia, granulomatosis with polyangiitis) are typically painful and are usually associated with additional skin features, such as nonblanching petechiae or purpura.</p><p><strong>Educational objective:</strong><br>Neuropathic ulcers are caused by repeated pressure, friction, or trauma due to lack of sensation in the local tissues.&nbsp; They typically occur at weight-bearing sites on the sole of the foot.&nbsp; Diabetes mellitus is the most common cause of neuropathic ulcers.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 106,
            "subject": "Surgery",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 211,
            "system": "Endocrine, Diabetes & Metabolism",
            "topicId": 1573,
            "topic": "Peripheral neuropathy",
            "titleId": 1573,
            "title": "Peripheral neuropathy",
            "topicAttributeId": 330582,
            "topicAttribute": "Diabetes mellitus",
            "correctAnswer": "4",
            "userAnswer": "4",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Ankle-brachial index measurement",
                    "choiceNumber": 1,
                    "correctTaken": 2790,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Culture from the ulcer bed",
                    "choiceNumber": 2,
                    "correctTaken": 377,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Duplex venous ultrasonography",
                    "choiceNumber": 3,
                    "correctTaken": 794,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Hemoglobin A1c assay",
                    "choiceNumber": 4,
                    "correctTaken": 17189,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "MRI of the lumbosacral spine",
                    "choiceNumber": 5,
                    "correctTaken": 45,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Vasculitis serologic markers",
                    "choiceNumber": 6,
                    "correctTaken": 286,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": "1750,1789,true,-1,1*189,221,true,-1,1*296,354,true,-1,1*1006,1137,true,-1,1",
            "isCorrect": true,
            "isIncorrect": false,
            "isMarked": false,
            "isOmitted": false,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "465",
                    "mediaDataId": 0,
                    "title": "Diabetic neuropathy",
                    "referenceTypeId": 18,
                    "referenceLink": null,
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 132,
            "othersAvgTimeSpent": 57,
            "notes": null,
            "peopleTaken": 21481,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 80,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 1830,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 1,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 6,
            "questionId": 2171,
            "questionIndex": 2171,
            "questionText": "<p>A 20-year-old previously healthy woman is brought to the emergency department due to lethargy.&nbsp; According to her mother, the patient had a &#x22;stomach bug&#x22; 2 days ago, with nausea, vomiting, and abdominal pain that began after eating in a restaurant.&nbsp; Her vomiting has resolved since that time, but she continues to have nausea and abdominal pain.&nbsp; Review of systems is positive for excessive thirst and a 4-kg (9-lb) weight loss over the past 2 weeks.&nbsp; She is not sexually active, and her last menstrual period was 10 days ago.&nbsp; The patient occasionally drinks beer but does not smoke or use illicit drugs.&nbsp; Temperature is 37.2 C (99 F), blood pressure is 100/56 mm Hg, pulse is 120/min, and respirations are 28/min.&nbsp; Pulse oximetry is 97% on room air.&nbsp; On examination, the patient is lethargic but easily arousable; she responds to questions in short sentences and moves all extremities spontaneously.&nbsp; Mucous membranes are dry, and the neck is supple.&nbsp; Other than tachycardia, cardiopulmonary examination is normal.&nbsp; There is diffuse abdominal tenderness without rebound tenderness, guarding, or rigidity.&nbsp; Which of the following is the best immediate next step in management of this patient&#39;s illness?</p>",
            "questionHeader": "",
            "explanationText": "<div id=\"div_t43859\"><table class=\"table-default-style table-header-footer-style\"><tbody><tr><td colspan=\"2\"><p align=\"center\"><strong>Diabetic ketoacidosis</strong></p></td></tr><tr><td><p align=\"center\"><strong>Patient characteristics</strong></p></td><td><ul><li>Young age</li><li>Brittle type 1 diabetes mellitus</li><li>May be initial manifestation of diabetes</li></ul></td></tr><tr><td><p align=\"center\"><strong>Clinical symptoms</strong></p></td><td><ul><li>Acute to subacute onset<ul style=\"list-style-type:circle;\"><li><strong>Initial:</strong> polydipsia/polyuria, blurred vision, weight loss</li><li><strong>Later:</strong> altered mentation, hyperventilation, abdominal pain</li></ul></li></ul></td></tr><tr><td><p align=\"center\"><strong>Diagnosis</strong></p></td><td><ul><li><strong>&uarr;</strong><strong>Glucose (typically 300-800 mg/dL)</strong></li><li>Metabolic acidosis (bicarbonate &lt;18 mEq/L)</li><li>&uarr; Anion gap</li><li>Positive serum ketones</li></ul></td></tr><tr><td><p align=\"center\"><strong>Treatment</strong></p></td><td><ul><li>High-flow IV fluids (normal saline)</li><li>IV insulin</li><li>Follow &amp; replace potassium</li></ul></td></tr><tr><td colspan=\"2\"><p><strong>IV</strong> = intravenous.</p></td></tr></tbody></table></div><p>This patient&#39;s presentation suggests <strong>diabetic ketoacidosis (DKA)</strong> from new-onset <strong>type 1 diabetes mellitus (T1DM)</strong>.&nbsp; DKA was likely triggered by her recent gastrointestinal illness (ie, nausea and vomiting), which exacerbated dehydration and precipitated ketosis.&nbsp; Features of this patient&#39;s illness consistent with DKA include:</p><ul><li><strong>Young age:</strong>&nbsp; Although T1DM is classically associated with childhood onset, one-fourth of new cases are diagnosed in young adults.&nbsp; DKA is the second most common initial presentation of T1DM.&nbsp;</li><li>Symptoms:&nbsp; Rapid onset of <strong>weight loss, polydipsia</strong> (increased thirst), and diffuse <strong>abdominal pain</strong> occurs, possibly from acidosis and electrolyte abnormalities impairing gastrointestinal function (eg, delayed gastric emptying, ileus).</li><li>Clinical signs:&nbsp; <strong>Dehydration</strong> (evidenced by tachycardia and hypotension) and <strong>hyperventilation</strong> (ie, compensation for metabolic acidosis) are prominent.</li></ul><p>Therefore, <strong>checking fingerstick glucose</strong> is the appropriate next step in management.&nbsp; This test is rapid and minimally invasive; it can narrow the differential diagnosis and initial treatment for this patient&#39;s gastrointestinal symptoms and lethargy.&nbsp; Glucose levels of 300-800 mg/dL should prompt empiric treatment for DKA (eg, insulin, intravenous fluids) and confirmatory testing (eg, serum ketones, arterial blood gas).</p><p><strong>(Choice A)</strong>&nbsp; Although infection is a common trigger of DKA, blood glucose measurement should be performed first because it can rapidly confirm a presumptive diagnosis and guide management.</p><p><strong>(Choice B)</strong>&nbsp; Abdominal pain, hypotension, and vomiting can be seen in primary adrenal insufficiency, diagnosed via cosyntropin stimulation testing.&nbsp; However, adrenal insufficiency is unlikely to explain polydypsia and hyperventilation; moreover, it is associated with hypoglycemia.&nbsp; Assessing fingerstick glucose is a more optimal approach to narrowing the diagnosis.</p><p><strong>(Choices C and E)</strong>&nbsp; Severe upper gastrointestinal bleed and mesenteric ischemia can cause acute abdominal pain and hypotension, and may be detected on CT scan of the abdomen and endoscopy.&nbsp; However, neither condition explains this patient&#39;s polydypsia or hyperventilation, and her young age and absence of associated risk factors (eg, excessive alcohol intake, atrial fibrillation) make either diagnosis unlikely.</p><p><strong>(Choice F)</strong>&nbsp; Although salicylate poisoning (detectable on urine toxicology screen) may lead to abdominal pain, lethargy, and nausea, associated symptoms of tinnitus and vertigo are absent in this patient.&nbsp; Moreover, her 2-week prodrome of polydipsia and weight loss point to diabetes mellitus.</p><p><strong>Educational objective:</strong><br>Diabetic ketoacidosis can be the initial manifestation of type 1 diabetes mellitus.&nbsp; Typical symptoms include acute onset of weight loss, polydipsia, abdominal pain, hyperventilation, and altered mentation.&nbsp; Fingerstick blood glucose can rapidly provide a presumptive diagnosis, and treatment should begin immediately with intravenous fluids and insulin.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 102,
            "subject": "Medicine",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 211,
            "system": "Endocrine, Diabetes & Metabolism",
            "topicId": 6575,
            "topic": "Diabetic ketoacidosis",
            "titleId": 6575,
            "title": "Diabetic ketoacidosis",
            "topicAttributeId": 330582,
            "topicAttribute": "Diabetes mellitus",
            "correctAnswer": "4",
            "userAnswer": "4",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Blood cultures and empiric antibiotics",
                    "choiceNumber": 1,
                    "correctTaken": 1158,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Cosyntropin stimulation test",
                    "choiceNumber": 2,
                    "correctTaken": 1322,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "CT scan of the abdomen",
                    "choiceNumber": 3,
                    "correctTaken": 1241,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Fingerstick glucose",
                    "choiceNumber": 4,
                    "correctTaken": 13000,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Upper gastrointestinal endoscopy",
                    "choiceNumber": 5,
                    "correctTaken": 210,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Urine toxicology screen",
                    "choiceNumber": 6,
                    "correctTaken": 782,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": "285,303,true,-1,1*338,363,true,-1,1*383,406,true,-1,1*1135,1293,true,-1,1*407,441,true,-1,1*1693,1866,true,-1,1",
            "isCorrect": true,
            "isIncorrect": false,
            "isMarked": false,
            "isOmitted": false,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "521",
                    "mediaDataId": 0,
                    "title": "Diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic state (HHS)",
                    "referenceTypeId": 18,
                    "referenceLink": null,
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "26975543",
                    "mediaDataId": 0,
                    "title": "The evolution of diabetic ketoacidosis: an update of its etiology, pathogenesis and management.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/26975543",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "21978840",
                    "mediaDataId": 0,
                    "title": "Evidence-based management of hyperglycemic emergencies in diabetes mellitus.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/21978840",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 88,
            "othersAvgTimeSpent": 77,
            "notes": null,
            "peopleTaken": 17713,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 73,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 661,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 1,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 7,
            "questionId": 4289,
            "questionIndex": 4289,
            "questionText": "<p>A 59-year-old woman is brought to the emergency department by her husband due to increasing fatigue and drowsiness for the past week.&nbsp; The patient has also been urinating frequently with several episodes of incontinence.&nbsp; Medical history is significant for type 2 diabetes mellitus, primary hypothyroidism, and bipolar disorder.&nbsp; Four weeks ago, the patient was prescribed olanzapine for refractory depression.&nbsp; Temperature is 36.7 C (98.1 F), blood pressure is 110/65 mm Hg, pulse is 100/min, and respirations are 12/min.&nbsp; Physical examination shows dry mucous membranes and decreased skin turgor.&nbsp; The patient is confused and disoriented but moves all extremities on command.&nbsp; There is no nuchal rigidity.&nbsp; The rest of the examination is unremarkable.&nbsp; Which of the following tests is most likely to reveal the underlying cause of this patient&#39;s symptoms?</p>",
            "questionHeader": "",
            "explanationText": "<div id=\"div_T39702\"><table class=\"table-default-style\"><tbody><tr><td colspan=\"2\"><p align=\"center\"><strong>Hyperosmolar hyperglycemic state</strong></p></td></tr><tr><td><p align=\"center\"><strong>Patient<br>characteristics</strong></p></td><td><ul><li>Type 2 diabetes mellitus</li><li>Older age</li></ul></td></tr><tr><td><p align=\"center\"><strong>Inciting<br>factors</strong></p></td><td><ul><li>Acute illness, trauma, infection</li><li>Insulin nonadherence</li><li>Medications: glucocorticoids, diuretics, atypical antipsychotics</li></ul></td></tr><tr><td><p align=\"center\"><strong>Clinical<br>features</strong></p></td><td><p>Subacute or acute onset of:</p><ul><li>Altered mentation</li><li>Hyperglycemic symptoms (eg, polyuria)</li><li>Volume depletion</li></ul></td></tr><tr><td><p align=\"center\"><strong>Laboratory<br>studies</strong></p></td><td><ul><li>Glucose &gt;600 mg/dL (33.3 mmol/L)</li><li>Bicarbonate &gt;18 mEq/L (18 mmol/L)</li><li>Normal anion gap</li><li>Negative or small serum ketones</li><li>Serum osmolality &gt;320 mOsm/kg (320 mmol/kg)</li></ul></td></tr></tbody></table></div><p>This patient has <strong>altered mental status</strong> (eg, confusion), <strong>volume depletion</strong> (eg, dry mucous membranes, decreased skin turgor), and <strong>polyuria</strong> in the setting of type 2 diabetes mellitus; <strong>hyperosmolar hyperglycemic state (HHS)</strong> is the most likely cause.&nbsp; HHS can be triggered in patients with type 2 diabetes mellitus by use of atypical antipsychotics, such as <strong>olanzapine</strong>; these drugs can cause hyperglycemia acutely, possibly due to decreased insulin secretion or signaling, or chronically due to weight gain and insulin resistance.</p><p>Patients with suspected HHS should have an urgent <strong>serum chemistry profile</strong>, which shows <strong>markedly elevated serum glucose</strong> (often &gt;600 mg/dL) and can be used to calculate the <a href=\"34222\">anion gap</a> (typically normal, unlike in diabetic ketoacidosis) and <a href=\"57778\">serum osmolality</a> (typically &gt;320 mOsm/L).&nbsp; Urinalysis typically demonstrates absent ketones.</p><p><strong>(Choice A)</strong>&nbsp; Adrenal insufficiency can cause fatigue and dehydration.&nbsp; However, altered mentation is typically a sign of severe disease (eg, adrenal crisis), which would be accompanied by marked hypotension.&nbsp; This patient&#39;s blood pressure is within normal limits.</p><p><strong>(Choice B)</strong>&nbsp; Hypoxia (eg, due to pneumonia, pulmonary embolus) can cause acute alterations in mental status.&nbsp; However, this patient has no symptoms (eg, chest pain, cough, dyspnea) or signs (eg, tachypnea, abnormal lung examination) to suggest an acute respiratory disorder.</p><p><strong>(Choices C and D)</strong>&nbsp; Severe systemic infection (eg, sepsis, meningitis) can cause altered mentation but is less likely in this patient who lacks expected signs of bacteremia (eg, fever, rigors, hypotension) or meningitis (eg, nuchal rigidity, headache).</p><p><strong>(Choice F)</strong>&nbsp; Hypothyroid crisis (myxedema coma) can cause altered mentation; however, this patient does not have the expected features of hypothermia, bradycardia, hypoventilation, and hypotension.</p><p><strong>(Choice G)</strong>&nbsp; Drug toxicity can be associated with confusion and altered mental status, and risk for overdose (eg, potential suicide attempt) is higher in patients with refractory depression.&nbsp; However, this patient&#39;s weeklong course of symptoms is not typical for drug overdose, which typically manifests rapidly (eg, minutes to hours).&nbsp; Moreover, expected anticholinergic features of olanzapine overdose (eg, pupillary changes, extrapyramidal adverse effects such as dystonia, urinary retention) are absent.</p><p><strong>Educational objective:</strong><br>Hyperosmolar hyperglycemic state (HHS) is characterized by altered mental status and volume depletion, marked hyperglycemia (&gt;600 mg/dL) and hyperosmolarity, and absence of ketones.&nbsp; Olanzapine, an atypical antipsychotic, is a potential trigger for HHS because it can precipitate hyperglycemia and metabolic derangements.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 102,
            "subject": "Medicine",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 211,
            "system": "Endocrine, Diabetes & Metabolism",
            "topicId": 11854,
            "topic": "Hyperosmolar hyperglycemic state",
            "titleId": 11854,
            "title": "Hyperosmolar hyperglycemic state",
            "topicAttributeId": 330582,
            "topicAttribute": "Diabetes mellitus",
            "correctAnswer": "5",
            "userAnswer": "5",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "ACTH stimulation test",
                    "choiceNumber": 1,
                    "correctTaken": 702,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Arterial blood gas analysis",
                    "choiceNumber": 2,
                    "correctTaken": 542,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Blood culture",
                    "choiceNumber": 3,
                    "correctTaken": 63,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Lumbar puncture",
                    "choiceNumber": 4,
                    "correctTaken": 223,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Serum chemistry profile and urinalysis",
                    "choiceNumber": 5,
                    "correctTaken": 12490,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Serum TSH level",
                    "choiceNumber": 6,
                    "correctTaken": 837,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Urine toxicology screen",
                    "choiceNumber": 7,
                    "correctTaken": 1353,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": "396,479,true,-1,1*512,555,true,-1,1*193,257,true,-1,1*908,1081,true,-1,1*2213,2397,true,-1,1",
            "isCorrect": true,
            "isIncorrect": false,
            "isMarked": false,
            "isOmitted": false,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "521",
                    "mediaDataId": 0,
                    "title": "Diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic state (HHS)",
                    "referenceTypeId": 18,
                    "referenceLink": null,
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "28923179",
                    "mediaDataId": 0,
                    "title": "Drugs and hyperglycemia: a practical guide.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/28923179",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 151,
            "othersAvgTimeSpent": 77,
            "notes": null,
            "peopleTaken": 16210,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 77,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 1274,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 1,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 8,
            "questionId": 15296,
            "questionIndex": 16721,
            "questionText": "<p>A 16-year-old girl is brought to the office for evaluation of hyperglycemia.&nbsp; Yesterday, the patient was seen at an urgent care clinic due to vaginal discharge and dysuria.&nbsp; She was diagnosed with candidal vulvovaginitis, and her urine dipstick was positive for glucose and negative for ketones.&nbsp; Finger-stick blood glucose was 200 mg/dL and a subsequent hemoglobin A1c level was 7.6%.&nbsp; The patient has been excessively thirsty over the past several weeks but has had no abdominal pain, nausea, or vomiting.&nbsp; She has no previous medical conditions and takes no medications.&nbsp; Family history is significant for diabetes mellitus and hypertension in both parents.&nbsp; Vital signs are within normal limits, and BMI is at the 95th percentile for her age.&nbsp; Examination shows velvety, hyperpigmented plaques over the nape of the neck.&nbsp; What is the most likely cause of her current condition?</p>",
            "questionHeader": "",
            "explanationText": "<div id=\"div_t35444\"><table class=\"table-default-style table-header-footer-style\" style=\"width:598px\"><tbody><tr><td colspan=\"3\"><p align=\"center\"><strong>Differentiating type 1 from type 2 diabetes mellitus</strong></p></td></tr><tr><td></td><td><p align=\"center\"><strong>Type 1</strong></p></td><td><p align=\"center\"><strong>Type 2</strong></p></td></tr><tr><td><p align=\"center\"><strong>Pathophysiology</strong></p></td><td><ul><li>Insulin deficiency</li></ul></td><td><ul><li>Insulin resistance with relative insulin deficiency</li></ul></td></tr><tr><td><p align=\"center\"><strong>Epidemiology</strong></p></td><td><ul><li>Children; less frequently, young adults</li><li>Family history less common</li><li>Often thin habitus</li></ul></td><td><ul><li>Adults; less frequently, adolescents</li><li>Family history common</li><li>Often obese</li></ul></td></tr><tr><td><p align=\"center\"><strong>Presentation</strong></p></td><td><ul><li>Acute/severe (eg,&nbsp;polyuria, polydipsia, weight loss)</li><li>Ketoacidosis common</li></ul></td><td><ul><li>Usually asymptomatic/insidious</li><li>Ketoacidosis uncommon</li></ul></td></tr><tr><td><p align=\"center\"><strong>Associated<br />conditions</strong></p></td><td><ul><li>Other autoimmune disorders (eg,&nbsp;thyroiditis, celiac disease)</li></ul></td><td><ul><li>Dyslipidemia, hypertension, acanthosis nigricans</li></ul></td></tr><tr><td><p align=\"center\"><strong>C-peptide levels</strong></p></td><td><ul><li>Low</li></ul></td><td><ul><li>Usually elevated</li></ul></td></tr><tr><td><p align=\"center\"><strong>Autoantibodies*</strong></p></td><td><ul><li>Usually present</li></ul></td><td><ul><li>Usually absent</li></ul></td></tr><tr><td colspan=\"3\"><p>*For example, glutamic acid decarboxylase.</p></td></tr></tbody></table></div><p>This patient has symptomatic hyperglycemia (eg, polydipsia) and an elevated hemoglobin A1c consistent with <strong>diabetes mellitus</strong> (DM).&nbsp; Although children most commonly have type 1 DM (T1DM), the incidence of T2DM in <strong>older adolescents</strong> is increasing with the rise in childhood obesity (BMI &#8805;95th percentile).&nbsp; This patient&#39;s age, BMI, <strong>family history</strong> of DM, and <a href=\"25315\">acanthosis nigricans</a> make <strong>T2DM</strong> the most likely diagnosis.</p><p>Pathogenesis involves environmental and genetic factors.&nbsp; Excess adiposity contributes to <strong>insulin resistance</strong>; in adolescents, this resistance is potentiated by rising growth hormone during puberty.&nbsp; Pancreatic beta cells initially produce more insulin to compensate but become dysfunctional over time and produce less insulin, resulting in hyperglycemia.&nbsp; Insulin resistance alone does not always correlate with the development of diabetes, and genetic factors likely also play a role in <strong>impaired insulin secretion</strong> in susceptible individuals.</p><p>Findings associated with insulin resistance include central (visceral) <strong>obesity</strong>, hypertension, and dyslipidemia; <strong>acanthosis nigricans</strong> is common (possibly reflecting insulin effects of keratinocytes and fibroblasts) and manifests as velvety, hyperpigmented patches in intertriginous areas (eg, neck, axillae).&nbsp; Patients are at increased risk for candidiasis, as seen in this adolescent, because hyperglycemia allows for increased adhesion of <em>Candida</em> to the epithelium.</p><p><strong>(Choice A)</strong>&nbsp; Pathogenesis of T1DM involves pancreatic autoantibodies causing islet cell destruction and low/absent insulin production.&nbsp; Insulin resistance (eg, acanthosis nigricans) is uncommon, and patients are less likely to be obese than with T2DM.&nbsp; In addition, presentation is usually acute (ketoacidosis, ketonuria) in early childhood or early puberty.</p><p><strong>(Choice B)</strong>&nbsp; Anti-insulin receptor antibodies may cause severe insulin resistance by blocking the action of insulin.&nbsp; This condition is exceedingly rare and often coexists with autoimmune disorders (eg, systemic lupus erythematosus), making it far less likely than T2DM in this patient.</p><p><strong>(Choice C)</strong>&nbsp; Glucokinase mutations cause monogenic diabetes (previously maturity-onset diabetes of the young), in which mildly defective glucose sensing results in relatively low insulin secretion for any given glucose level.&nbsp; Unlike in T2DM, hyperglycemia is mild (&lt;140 mg/dL), and patients typically lack signs of insulin resistance.</p><p><strong>(Choice D)</strong>&nbsp; Glucagonoma is a rare tumor that produces excessive glucagon, causing hyperglycemia.&nbsp; Beta cells function normally, and signs of insulin resistance would not be expected.&nbsp; Patients also usually have weight loss, rash, and diarrhea, none of which are seen in this adolescent.</p><p><strong>Educational objective:</strong><br>The incidence of type 2 diabetes mellitus in adolescents is increasing in association with a rise in childhood obesity; a positive family history and acanthosis nigricans are common.&nbsp; Pathogenesis involves insulin resistance and impaired insulin secretion.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 104,
            "subject": "Pediatrics",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 211,
            "system": "Endocrine, Diabetes & Metabolism",
            "topicId": 2603,
            "topic": "Diabetes mellitus",
            "titleId": 2603,
            "title": "Diabetes mellitus",
            "topicAttributeId": 330582,
            "topicAttribute": "Diabetes mellitus",
            "correctAnswer": "5",
            "userAnswer": "5",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Absent insulin production",
                    "choiceNumber": 1,
                    "correctTaken": 1748,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Anti-insulin receptor antibodies",
                    "choiceNumber": 2,
                    "correctTaken": 847,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Glucokinase gene mutation",
                    "choiceNumber": 3,
                    "correctTaken": 353,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Increased production of glucagon",
                    "choiceNumber": 4,
                    "correctTaken": 215,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Peripheral resistance to the effects of insulin",
                    "choiceNumber": 5,
                    "correctTaken": 13183,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": "516,576,true,-1,1*577,625,true,-1,1*643,646,true,-1,1*647,663,true,-1,1*680,695,true,-1,1*696,710,true,-1,1*1366,1709,true,-1,1*1225,1365,true,-1,1*2832,3155,true,-1,1",
            "isCorrect": true,
            "isIncorrect": false,
            "isMarked": false,
            "isOmitted": false,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "461",
                    "mediaDataId": 0,
                    "title": "Type 2 diabetes mellitus: an overview",
                    "referenceTypeId": 18,
                    "referenceLink": null,
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "527",
                    "mediaDataId": 0,
                    "title": "Insulin therapy in diabetes mellitus management",
                    "referenceTypeId": 18,
                    "referenceLink": null,
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "27622231",
                    "mediaDataId": 0,
                    "title": "Type 2 diabetes mellitus in children and adolescents.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/27622231",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "27974926",
                    "mediaDataId": 0,
                    "title": "Type 2 diabetes mellitus in children and adolescents: a relatively new clinical problem within pediatric practice.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/27974926",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 77,
            "othersAvgTimeSpent": 44,
            "notes": null,
            "peopleTaken": 16346,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 81,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 846,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 1,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 9,
            "questionId": 14701,
            "questionIndex": 16118,
            "questionText": "<p>A 5-day-old girl is brought to the emergency department due to fussiness.&nbsp; The patient was born at home to a 36-year-old woman, gravida 5 para 5, via spontaneous vaginal delivery.&nbsp; The mother received no prenatal care.&nbsp; The patient has been breastfeeding exclusively and has had nonbloody, nonbilious vomiting after feeds for the past 2 days.&nbsp; Head circumference and length are at the 50th percentile.&nbsp; Weight is at the 20th percentile.&nbsp; Temperature is 37.2 C (99 F) and pulse is 180/min.&nbsp; The patient appears lethargic and has poor tone.&nbsp; The skin is jaundiced.&nbsp; The anterior fontanelle is sunken with overriding sutures.&nbsp; Eye examination shows bilateral cataracts.&nbsp; The ears are in the normal position, and the palate is intact with a normal tongue.&nbsp; Cardiopulmonary examination is normal.&nbsp; The liver is palpable 4 cm below the costal margin.&nbsp; Which of the following is the most likely cause of this patient&#39;s presentation?</p>",
            "questionHeader": "",
            "explanationText": "<div id=\"div_t53446\"><table class=\"table-default-style table-footer-only-style\"><tbody><tr><td colspan=\"2\"><p align=\"center\"><strong>Galactosemia</strong></p></td></tr><tr><td style=\"width: 30%;\"><p align=\"center\"><strong>Etiology</strong></p></td><td><ul><li>GALT deficiency</li><li>Autosomal recessive</li><li>Galactose accumulation after lactose or galactose ingestion</li></ul></td></tr><tr><td><p align=\"center\"><strong>Clinical findings</strong></p></td><td><ul><li>Jaundice &amp; hepatomegaly</li><li>Vomiting &amp; poor feeding/failure to thrive</li><li>Cataracts</li><li>Increased risk for <em>Escherichia coli</em> sepsis</li></ul></td></tr><tr><td><p align=\"center\"><strong>Laboratory findings</strong></p></td><td><ul><li>&uarr; Bilirubin, AST, ALT</li><li>&darr; Glucose</li><li>Metabolic acidosis</li><li>+ Urine reducing substance</li></ul></td></tr><tr><td><p align=\"center\"><strong>Diagnosis</strong></p></td><td><ul><li>May be identified on newborn screening</li><li>Absent red blood cell GALT activity</li></ul></td></tr><tr><td><p align=\"center\"><strong>Treatment</strong></p></td><td><ul><li>Galactose-free diet (eg, soy-based formula)</li></ul></td></tr><tr><td colspan=\"2\"><p><strong>ALT</strong>&nbsp;=&nbsp;alanine aminotransferase; <strong>AST</strong>&nbsp;=&nbsp;aspartate aminotransferase; <strong>GALT</strong>&nbsp;=&nbsp;galactose 1-phosphate uridylyltransferase.</p></td></tr></tbody></table></div><p>This patient most likely has <strong>galactosemia</strong>, an inborn error of metabolism caused by a <strong>deficiency</strong> of the enzyme <a href=\"27637\">galactose-1-phosphate uridylyltransferase (GALT)</a>.&nbsp; GALT is responsible for the <strong>metabolization of galactose</strong>, which is found in <strong>breast milk</strong> and cow&#39;s milk&ndash;based formula, <strong>into glucose</strong>.&nbsp; Therefore, newborns with galactosemia develop hypoglycemia and accumulation of galactose.</p><p>The presentation typically occurs in the first week of life with <strong>vomiting</strong>, <strong>jaundice</strong>, and <strong>hepatomegaly</strong>.&nbsp; Poor feeding can lead to lethargy, <strong>hypotonia</strong>, and dehydration (eg, sunken fontanelle).&nbsp; Newborns with galactosemia often do not gain weight and are at risk for <em>Escherichia coli</em> sepsis.&nbsp; Severe hypoglycemia may also cause seizures in the neonatal period.&nbsp; A characteristic feature in about one-third of patients with galactosemia, <strong>cataracts</strong> may be present at birth but more commonly develop during the first few weeks of life as accumulated <strong>galactitol</strong> (a galactose by-product) deposits in the lens.</p><p>With prompt initiation of a <strong>galactose-free diet</strong> (eg, soy-based formula), symptoms (including cataracts) typically resolve.</p><p><strong>(Choice A)</strong>&nbsp; Advanced maternal age is a risk factor for Down syndrome, which can cause hypotonia, poor feeding, and cataracts.&nbsp; However, jaundice and hepatomegaly are not associated with Down syndrome, and individuals with this condition have <a href=\"2641\">characteristic dysmorphic features</a> not seen in this patient.</p><p><strong>(Choice B)</strong>&nbsp; <a href=\"757\">Fetal alcohol syndrome</a> is characterized by facial anomalies (eg, smooth philtrum, thin vermillion border, small palpebral fissures) that are not present in this patient.</p><p><strong>(Choice C)</strong>&nbsp; Jaundice, hepatomegaly, and cataracts may be seen in congenital rubella, which may be contracted during the first trimester if the mother has not had a rubella vaccination.&nbsp; However, this patient&#39;s lethargy, poor tone, and vomiting related to breastfeeding are more consistent with a metabolic disorder.&nbsp; Furthermore, she lacks other findings of congenital rubella (eg, microcephaly, growth restriction, heart defect).</p><p><strong>(Choice E)</strong>&nbsp; Congenital myotonic dystrophy, an autosomal dominant condition, may present with hypotonia and poor feeding.&nbsp; However, cataracts do not develop until adulthood in these patients.</p><p><strong>Educational objective:</strong><br>Galactosemia is an inborn error of metabolism that presents in the first week of life with vomiting, jaundice, hypotonia, and hepatomegaly.&nbsp; Progressive deposition of galactitol, a by-product of galactose, leads to cataracts.&nbsp; Management is a galactose-free diet (eg, soy-based formula).</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 104,
            "subject": "Pediatrics",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 211,
            "system": "Endocrine, Diabetes & Metabolism",
            "topicId": 21901,
            "topic": "Galactosemia",
            "titleId": 21901,
            "title": "Galactosemia",
            "topicAttributeId": 330576,
            "topicAttribute": "Congenital and developmental anomalies",
            "correctAnswer": "4",
            "userAnswer": "4",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Advanced maternal age",
                    "choiceNumber": 1,
                    "correctTaken": 300,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "In utero fetal alcohol exposure",
                    "choiceNumber": 2,
                    "correctTaken": 217,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Maternal nonadherence to vaccination schedule",
                    "choiceNumber": 3,
                    "correctTaken": 5697,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Newborn inability to metabolize breast milk",
                    "choiceNumber": 4,
                    "correctTaken": 7150,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Newborn inherited muscle dystrophy",
                    "choiceNumber": 5,
                    "correctTaken": 361,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": "242,284,true,-1,1*327,355,true,-1,1*393,467,true,-1,1*1455,1622,true,-1,1*1696,1745,true,-1,1*2242,2315,true,-1,1",
            "isCorrect": true,
            "isIncorrect": false,
            "isMarked": false,
            "isOmitted": false,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "426",
                    "mediaDataId": 0,
                    "title": "Galactosemia",
                    "referenceTypeId": 18,
                    "referenceLink": null,
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "28281081",
                    "mediaDataId": 0,
                    "title": "Sweet and sour: an update on classic galactosemia.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/28281081",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 92,
            "othersAvgTimeSpent": 58,
            "notes": null,
            "peopleTaken": 13725,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 52,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 1452,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 1,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 10,
            "questionId": 2425,
            "questionIndex": 2425,
            "questionText": "<p>A 16-year-old girl comes to the office for evaluation of excessive facial hair.&nbsp; The patient has used multiple creams and makeup over the last year but is still embarrassed by the facial hair.&nbsp; She also has had irregular menstrual cycles since menarche at age 12; her last menstrual period was 6 weeks ago.&nbsp; She is an avid runner.&nbsp; Blood pressure is 122/70 mm Hg and pulse is 87/min.&nbsp; BMI is 20 kg/m<font size=\"2\"><sup>2</sup></font>.&nbsp; Physical examination shows hirsutism.&nbsp; The patient has normal external female genitalia; the rest of the examination is unremarkable.&nbsp; Urine pregnancy test is negative.&nbsp; Laboratory results are as follows:</p><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\"><tbody><tr><td>17-hydroxyprogesterone</td><td>350 ng/mL (normal: &lt;15)</td></tr><tr><td>Serum testosterone</td><td>80 ng/mL (normal: 20-75)</td></tr><tr><td>Serum dehydroepiandrosterone sulfate</td><td>390 &micro;g/dL (normal: 37-307)</td></tr></tbody></table><p>Serum glucose and electrolytes are normal.&nbsp; Which of the following is the most likely diagnosis in this patient?</p>",
            "questionHeader": "",
            "explanationText": "<div id=\"div_t36016\"><table class=\"table-default-style\"><tbody><tr><td colspan=\"2\"><p align=\"center\"><strong>Nonclassic congenital adrenal hyperplasia</strong></p></td></tr><tr><td><p align=\"center\"><strong>Pathophysiology</strong></p></td><td><ul><li>Autosomal recessive</li><li>&darr; 21-Hydroxylase activity</li><li>Normal glucocorticoids &amp; mineralocorticoids&nbsp;&nbsp;</li><li>&uarr; Androgens</li></ul></td></tr><tr><td><p align=\"center\"><strong>Clinical features</strong></p></td><td><ul><li>Early pubic/axillary hair growth</li><li>Severe acne</li><li>Hirsutism &amp; oligomenorrhea in girls</li><li>&uarr; Growth velocity &amp; bone age</li><li>&uarr; 17-Hydroxyprogesterone level</li></ul></td></tr><tr><td><p align=\"center\"><strong>Treatment </strong></p></td><td><ul><li>Hydrocortisone</li></ul></td></tr></tbody></table></div><p>This patient has <strong>nonclassic</strong> (late-onset) <strong>congenital adrenal hyperplasia</strong> (CAH) based on hyperandrogenism and an <strong>elevated 17-hydroxyprogesterone</strong> (17-OHP) level.&nbsp; The majority of nonclassic CAH is due to a partial deficiency in <a href=\"678\">21-hydroxylase</a>, which results in impaired conversion of 17-OHP to 11-deoxycortisol.&nbsp; Buildup of 17-OHP is then diverted toward adrenal androgen synthesis, resulting in <strong>hyperandrogenism</strong>.</p><p>Girls with nonclassic CAH typically present in <strong>adolescence</strong> or early adulthood with <strong>irregular menses</strong>, severe acne, and <strong>hirsutism</strong>; virilization (eg, clitoromegaly, deepening of the voice) is rare.&nbsp; Since the enzyme deficiency in nonclassic CAH is relatively mild, sufficient glucocorticoids and mineralocorticoids are produced; therefore, patients do not have the salt-wasting seen in classic CAH, and electrolytes and blood pressure remain normal.&nbsp; Diagnosis is confirmed by an exaggerated 17-OHP response on ACTH stimulation test.</p><p><strong>(Choice A)</strong>&nbsp; Androgen-producing adrenal tumors typically present in adulthood with rapidly progressive hirsutism and virilization.&nbsp; Serum DHEAS is markedly elevated with concentrations &gt;700 &micro;g/dL.</p><p><strong>(Choice B)</strong>&nbsp; Cushing syndrome can cause hirsutism due to elevated adrenal androgens.&nbsp; However, this patient has no Cushingoid features such as moon facies, buffalo hump, central obesity, hypertension, or electrolyte abnormalities.&nbsp; 17-OHP levels are usually normal in Cushing syndrome.</p><p><strong>(Choice C)</strong>&nbsp; Ovarian germ cell tumors (eg, embryonal carcinoma, choriocarcinoma) typically present with abdominal ascites, pelvic mass, and pregnancy symptoms (eg, breast tenderness).&nbsp; However, they do not usually cause hirsutism.&nbsp; In addition, these tumors often secrete &#946;-hCG, creating a false-positive pregnancy test.</p><p><strong>(Choice D)</strong>&nbsp; Idiopathic hirsutism is due to excessive conversion of testosterone to dihydrotestosterone in the hair follicles.&nbsp; There is usually a positive family history and normal 17-OHP and androgen levels.</p><p><strong>(Choice F)</strong>&nbsp; Patients with polycystic ovary syndrome have menstrual irregularities and hyperandrogenism; however, 17-OHP is not elevated.</p><p><strong>(Choice G)</strong>&nbsp; Anabolic steroid use for performance enhancement presents with hirsutism, voice deepening, increased muscle bulk, and virilization.&nbsp; However, exogenous androgens would not cause elevated 17-OHP.</p><p><strong>Educational objective:</strong><br>Nonclassic congenital adrenal hyperplasia is caused by a partial deficiency of 21-hydroxylase and typically presents with hyperandrogenism (eg, irregular menses, hirsutism) and elevated 17-hydroxyprogesterone level.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 103,
            "subject": "Obstetrics & Gynecology",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 211,
            "system": "Endocrine, Diabetes & Metabolism",
            "topicId": 10495,
            "topic": "Congenital adrenal hyperplasia",
            "titleId": 10495,
            "title": "Congenital adrenal hyperplasia",
            "topicAttributeId": 330576,
            "topicAttribute": "Congenital and developmental anomalies",
            "correctAnswer": "5",
            "userAnswer": "3",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Adrenal carcinoma",
                    "choiceNumber": 1,
                    "correctTaken": 691,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Cushing syndrome",
                    "choiceNumber": 2,
                    "correctTaken": 93,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Germ cell tumor",
                    "choiceNumber": 3,
                    "correctTaken": 484,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Idiopathic hirsutism",
                    "choiceNumber": 4,
                    "correctTaken": 94,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Nonclassic congenital adrenal hyperplasia",
                    "choiceNumber": 5,
                    "correctTaken": 12483,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Polycystic ovary syndrome",
                    "choiceNumber": 6,
                    "correctTaken": 1924,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Use of performance-enhancing agents",
                    "choiceNumber": 7,
                    "correctTaken": 860,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": "108,133,true,-1,1*291,350,true,-1,1*362,376,true,-1,1*788,915,true,-1,1*1235,1318,true,-1,1*1450,1514,true,-1,1*1811,2119,true,-1,1",
            "isCorrect": false,
            "isIncorrect": true,
            "isMarked": false,
            "isOmitted": false,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "571",
                    "mediaDataId": 0,
                    "title": "Congenital adrenal hyperplasia",
                    "referenceTypeId": 18,
                    "referenceLink": null,
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "23044877",
                    "mediaDataId": 0,
                    "title": "Congenital adrenal hyperplasia due to 21 hydroxylase deficiency:  from birth to adulthood.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/23044877",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "23632099",
                    "mediaDataId": 0,
                    "title": "Non-classic congenital adrenal hyperplasia.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/23632099",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "24254335",
                    "mediaDataId": 0,
                    "title": "Congenital adrenal hyperplasia:  issues in diagnosis and treatment in children.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/24254335",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 147,
            "othersAvgTimeSpent": 57,
            "notes": null,
            "peopleTaken": 16629,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 75,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 1404,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 1,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 11,
            "questionId": 2185,
            "questionIndex": 2185,
            "questionText": "<p>A 75-year-old man with type 2 diabetes mellitus is brought to the emergency department due to weakness and blurred vision.&nbsp; Over the last several days, the patient has had a hacking cough, sore throat, and poor appetite.&nbsp; Temperature is 38 C (100.5 F), blood pressure is 100/60 mm Hg, pulse is 112/min, and respirations are 18/min.&nbsp; On physical examination, the patient is lethargic and has dry mucous membranes.&nbsp; Heart sounds are regular, and the lungs are clear to auscultation.&nbsp; The abdomen is soft, nontender, and nondistended.&nbsp; No rashes are present.&nbsp; There is mild, generalized weakness on neurologic examination.&nbsp; Laboratory results are as follows:</p><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\"><tbody><tr><td colspan=\"2\" style=\"vertical-align:middle;\">Serum chemistry</td></tr><tr><td style=\"vertical-align:middle;\">&nbsp;&nbsp;&nbsp;&nbsp;Sodium</td><td style=\"vertical-align:middle;\">134 mEq/L</td></tr><tr><td style=\"vertical-align:middle;\">&nbsp;&nbsp;&nbsp;&nbsp;Potassium</td><td style=\"vertical-align:middle;\">5.9 mEq/L</td></tr><tr><td style=\"vertical-align:middle;\">&nbsp;&nbsp;&nbsp;&nbsp;Chloride</td><td style=\"vertical-align:middle;\">101 mEq/L</td></tr><tr><td style=\"vertical-align:middle;\">&nbsp;&nbsp;&nbsp;&nbsp;Bicarbonate</td><td style=\"vertical-align:middle;\">22 mEq/L</td></tr><tr><td style=\"vertical-align:middle;\">&nbsp;&nbsp;&nbsp;&nbsp;Blood urea nitrogen</td><td style=\"vertical-align:middle;\">52 mg/dL</td></tr><tr><td style=\"vertical-align:middle;\">&nbsp;&nbsp;&nbsp;&nbsp;Creatinine</td><td style=\"vertical-align:middle;\">1.5 mg/dL</td></tr><tr><td style=\"vertical-align:middle;\">&nbsp;&nbsp;&nbsp;&nbsp;Calcium</td><td style=\"vertical-align:middle;\">9.1 mg/dL</td></tr><tr><td style=\"vertical-align:middle;\">&nbsp;&nbsp;&nbsp;&nbsp;Glucose</td><td colspan=\"2\" style=\"vertical-align:middle;\">1070 mg/dL</td></tr><tr><td colspan=\"2\" style=\"vertical-align:middle;\"></td></tr><tr><td colspan=\"2\" style=\"vertical-align:middle;\">Liver function studies</td></tr><tr><td style=\"vertical-align:middle;\">&nbsp;&nbsp;&nbsp;&nbsp;Aspartate aminotransferase (SGOT)</td><td style=\"vertical-align:middle;\">17 U/L</td></tr><tr><td style=\"vertical-align:middle;\">&nbsp;&nbsp;&nbsp;&nbsp;Alanine aminotransferase (SGPT)</td><td style=\"vertical-align:middle;\">15 U/L</td></tr></tbody></table><p>Which of the following is most likely present in this patient?</p>",
            "questionHeader": "",
            "explanationText": "<div id=\"div_t39702\"><table class=\"table-default-style\"><tbody><tr><td colspan=\"2\"><p align=\"center\"><strong>Hyperosmolar hyperglycemic state</strong></p></td></tr><tr><td><p align=\"center\"><strong>Patient<br />characteristics</strong></p></td><td><ul><li>Type 2 diabetes mellitus</li><li>Older age</li></ul></td></tr><tr><td><p align=\"center\"><strong>Inciting<br />factors</strong></p></td><td><ul><li>Acute illness, trauma, infection</li><li>Insulin nonadherence</li><li>Medications: glucocorticoids, diuretics, atypical antipsychotics</li></ul></td></tr><tr><td><p align=\"center\"><strong>Clinical<br />features</strong></p></td><td><p>Subacute or acute onset of:</p><ul><li>Altered mentation</li><li>Hyperglycemic symptoms (eg, polyuria)</li><li>Volume depletion</li></ul></td></tr><tr><td><p align=\"center\"><strong>Laboratory<br />studies</strong></p></td><td><ul><li>Glucose &gt;600 mg/dL (33.3 mmol/L)</li><li>Bicarbonate &gt;18 mEq/L (18 mmol/L)</li><li>Normal anion gap</li><li>Negative or small serum ketones</li><li>Serum osmolality &gt;320 mOsm/kg (320 mmol/kg)</li></ul></td></tr></tbody></table></div><p>This patient&#39;s clinical features are consistent with <strong>hyperosmolar hyperglycemic state</strong> (HHS), most likely precipitated by his recent upper respiratory tract infection.&nbsp; Diabetic ketoacidosis (DKA) and HHS are the 2 most serious acute complications of diabetes.&nbsp; HHS is more common in type 2 diabetes and is characterized by severe hyperglycemia and increased serum osmolality with little or no ketonemia or acidosis (most patients have pH &gt;7.3 and serum bicarbonate &gt;20 mEq/L).</p><p>Most patients with HHS or DKA have normal or mildly elevated serum potassium levels at initial evaluation due to the combined effects of insulin deficiency and hyperosmolality, which promote the movement of potassium out of cells into the extracellular space.&nbsp; However, patients frequently have a <strong>total body potassium deficit</strong> (3-6 mEq/kg) due to excessive urinary loss (caused by osmotic diuresis induced by hyperglycemia and urinary excretion of potassium ketoacid anion salts).&nbsp; <strong>Insulin therapy</strong> for HHS can shift potassium back into the cells, abruptly lowering circulating potassium levels, and cause severe <strong>hypokalemia</strong>.</p><p><strong>(Choice A)</strong>&nbsp; An increase in extracellular pH (alkalemia) promotes the binding of calcium to albumin and lowers serum ionized calcium concentration.&nbsp; Patients with HHS have normal to slightly acidic pH; therefore, serum ionized calcium concentration remains unchanged.</p><p><strong>(Choice B)</strong>&nbsp; Patients with severe hyperglycemia initially have phosphate depletion (not retention) due to phosphaturia caused by osmotic diuresis.&nbsp; However, relative renal phosphate retention may occur later if dehydration and prerenal acute kidney injury lead to more severe renal insufficiency (eg, glomerular filtration rate &lt;20-25 mL/min).</p><p><strong>(Choice C)</strong>&nbsp; Hyperglycemia and glucosuria-induced osmotic diuresis cause free water loss that exceeds sodium loss.</p><p><strong>(Choice D)</strong>&nbsp; Suppression of antidiuretic hormone (ADH) secretion is seen in patients with hyponatremia due to excess free water intake.&nbsp; The hyponatremia in HHS is due to the osmotic shift of water from the intracellular to extracellular space.&nbsp; In HHS, secretion of ADH by the posterior pituitary is stimulated by the increased plasma osmolality and hypovolemia/hypotension, although patients with chronic hyperglycemia will have a lesser ADH release and antidiuretic response.</p><p><strong>Educational objective:</strong><br>Patients with hyperosmolar hyperglycemic state or diabetic ketoacidosis have a total body potassium deficit due to excessive urinary loss caused by glucosuria-induced osmotic diuresis.&nbsp; However, serum potassium levels may be normal or mildly elevated due to the shift of potassium out of cells into the extracellular space.&nbsp; Insulin in these patients can rapidly lower potassium levels, leading to hypokalemia.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 102,
            "subject": "Medicine",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 211,
            "system": "Endocrine, Diabetes & Metabolism",
            "topicId": 11854,
            "topic": "Hyperosmolar hyperglycemic state",
            "titleId": 11854,
            "title": "Hyperosmolar hyperglycemic state",
            "topicAttributeId": 330582,
            "topicAttribute": "Diabetes mellitus",
            "correctAnswer": "5",
            "userAnswer": "5",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Decreased serum ionized calcium concentration",
                    "choiceNumber": 1,
                    "correctTaken": 427,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Renal phosphate retention",
                    "choiceNumber": 2,
                    "correctTaken": 1205,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Renal sodium loss that exceeds water loss",
                    "choiceNumber": 3,
                    "correctTaken": 1688,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Suppression of antidiuretic hormone release",
                    "choiceNumber": 4,
                    "correctTaken": 1391,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Total body potassium deficit",
                    "choiceNumber": 5,
                    "correctTaken": 11343,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": "1702,1803,true,-1,1*1934,2068,true,-1,1*2626,2755,true,-1,1",
            "isCorrect": true,
            "isIncorrect": false,
            "isMarked": false,
            "isOmitted": false,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "521",
                    "mediaDataId": 0,
                    "title": "Diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic state (HHS)",
                    "referenceTypeId": 18,
                    "referenceLink": null,
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "29431405",
                    "mediaDataId": 0,
                    "title": "Hyperosmolar hyperglycemic state.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/29431405",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "15292031",
                    "mediaDataId": 0,
                    "title": "Attenuation of vasopressin-induced antidiuresis in poorly controlled type 2 diabetes.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/15292031",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 75,
            "othersAvgTimeSpent": 85,
            "notes": null,
            "peopleTaken": 16054,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 71,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 879,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 1,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 12,
            "questionId": 15284,
            "questionIndex": 16709,
            "questionText": "<p>A 17-year-old boy comes to the office before participating in long-distance running.&nbsp; The patient has a 2-year history of type 1 diabetes mellitus and takes insulin glargine at bedtime and insulin lispro before meals.&nbsp; His fasting and premeal home blood glucose levels range from 90 to 130 mg/dL, and he has had no episodes of hypoglycemia.&nbsp; The patient wants to run a marathon.&nbsp; Physical examination is normal.&nbsp; Hemoglobin A1c is 6.5%.&nbsp; Which of the following is the most appropriate recommendation to manage his diabetes mellitus during long-distance training?</p>",
            "questionHeader": "",
            "explanationText": "<p><img  draggable=\"false\" id=\"6817\" src=\"https://www.uworld.com/media/highresdefault/L24676.jpg\"  ></p><p>Repeated muscle contraction during <strong>exercise</strong> induces <strong>increased uptake of glucose</strong> by skeletal muscle cells.&nbsp; In nondiabetic individuals, overt hypoglycemia does not occur because a drop in the blood glucose level suppresses insulin release from pancreatic beta cells, and counterregulatory hormones (eg, glucagon) increase endogenous glucose production (ie, glycogenolysis, gluconeogenesis).&nbsp; However, patients taking <strong>exogenous insulin</strong> are vulnerable to <strong>exercise-induced hypoglycemia</strong> because insulin will continue to be released from the injection site.&nbsp; In addition, exercise may cause changes in skin perfusion that can lead to erratic insulin absorption.</p><p>Because of the increased insulin sensitivity associated with exercise, a <strong>reduction in insulin dose</strong> is usually appropriate.&nbsp; For training sessions within 3 hours of a meal, the premeal bolus insulin dose preceding exercise should be reduced.&nbsp; For prolonged exercise (eg, distance running) the basal insulin will likely need reduction as well.&nbsp; Patients with diabetes who initiate a strenuous exercise regimen should also be counseled to <strong>increase carbohydrate intake</strong>, particularly if training sessions are &gt;60 minutes in duration.</p><p><strong>(Choice A)</strong>&nbsp; Some experts advise a mixed snack containing carbohydrate and protein during the recovery phase following (rather than before) exercise to promote muscle recovery.&nbsp; Protein intake (in the absence of sufficient carbohydrates) prior to exercise would not prevent hypoglycemia, the major risk in patients on exogenous insulin.</p><p><strong>(Choice B)</strong>&nbsp; Completion of a marathon requires hours of continuous exertion.&nbsp; Limiting training sessions to 30 minutes will not allow proper conditioning and may increase the risk of injury during the event.&nbsp; In addition, a gradual increase in training sessions beyond 30 minutes will allow the patient to learn how to adjust insulin doses appropriately.</p><p><strong>(Choice D)</strong>&nbsp; Eliminating basal insulin (eg, glargine) in patients with type 1 diabetes can lead to severe hyperglycemia and increase the risk of ketoacidosis.</p><p><strong>(Choice E)</strong>&nbsp; Testing for ketosis is not routinely needed for patients with type 1 diabetes but can be considered for those who are participating in strenuous exercise and have significant hyperglycemia (eg, glucose &gt;250 mg/dL).&nbsp; If feasible, home blood testing for beta-hydroxybutyrate is preferred to urine ketone testing.</p><p><strong>Educational objective:</strong><br>Exercise increases glucose uptake by skeletal muscle cells, leading to a physiologic decline in insulin that prevents hypoglycemia.&nbsp; Patients taking exogenous insulin are at risk for exercise-induced hypoglycemia due steady (nonphysiologic) insulin levels.&nbsp; Prior to exercise, patients with type 1 diabetes should increase carbohydrate intake and reduce bolus and basal (if exercise is prolonged) insulin doses to prevent hypoglycemia.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 104,
            "subject": "Pediatrics",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 211,
            "system": "Endocrine, Diabetes & Metabolism",
            "topicId": 2603,
            "topic": "Diabetes mellitus",
            "titleId": 2603,
            "title": "Diabetes mellitus",
            "topicAttributeId": 330582,
            "topicAttribute": "Diabetes mellitus",
            "correctAnswer": "3",
            "userAnswer": "3",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Consume high-protein drink before running",
                    "choiceNumber": 1,
                    "correctTaken": 3064,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Limit training to 30-minute sessions",
                    "choiceNumber": 2,
                    "correctTaken": 838,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Reduce dosage of basal and bolus insulins",
                    "choiceNumber": 3,
                    "correctTaken": 11759,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Stop glargine and continue lispro as sliding scale",
                    "choiceNumber": 4,
                    "correctTaken": 2661,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Test urine ketones before and after exercise",
                    "choiceNumber": 5,
                    "correctTaken": 1901,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": null,
            "isCorrect": true,
            "isIncorrect": false,
            "isMarked": false,
            "isOmitted": false,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "527",
                    "mediaDataId": 0,
                    "title": "Insulin therapy in diabetes mellitus management",
                    "referenceTypeId": 18,
                    "referenceLink": null,
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "31835538",
                    "mediaDataId": 0,
                    "title": "Carbohydrate intake in the context of exercise in people with type I diabetes.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/31835538",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "31785115",
                    "mediaDataId": 0,
                    "title": "Exercise-induced hypoglycaemia in type 1 diabetes.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/31785115",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 62,
            "othersAvgTimeSpent": 47,
            "notes": null,
            "peopleTaken": 20223,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 58,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 1114,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 1,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 13,
            "questionId": 3781,
            "questionIndex": 3781,
            "questionText": "<p>A 48-year-old overweight man comes to the physician for evaluation of a right foot ulcer that he first noticed 3 weeks ago.&nbsp; He has a history of hypertension, type 2 diabetes mellitus, and hypercholesterolemia.&nbsp; His current medications include ramipril, aspirin, metformin, sitagliptin, and rosuvastatin.&nbsp; He has a 20-pack-year smoking history and occasionally drinks alcohol but does not use illicit drugs.&nbsp; The patient is afebrile.&nbsp; His blood pressure is 132/80 mm Hg and pulse is 76/min.&nbsp; Examination shows a 1.7 x 2 cm ulcer on the plantar surface of the great toe.&nbsp; Which of the following tests will best assess this patient&#39;s risk of foot ulcers?</p>",
            "questionHeader": "",
            "explanationText": "<P><img id=\"7153\"  src=\"https://www.uworld.com/media/L21053.jpg\" draggable=\"false\" ></P><p>This patient has a diabetic foot ulcer, which can eventually lead to nontraumatic lower limb amputation.&nbsp; Risk factors for diabetic foot ulcers include diabetic neuropathy, previous foot ulceration, vascular disease, and foot deformity.&nbsp; <strong>Diabetic neuropathy</strong> is the most common underlying cause and is found in &gt;80% of patients with diabetic foot ulcers.&nbsp; Neuropathy decreases pain sensation and pressure perception, it causes muscle imbalance leading to foot deformities, and impairs the microcirculation and integrity of the skin.</p><p><a href=\"1775\">Neuropathic ulcers</a> most commonly occur in the feet under bony prominences, such as the metatarsal heads.&nbsp; They typically have a punched-out or undermined border.&nbsp; Peripheral sensory neuropathy can be documented by testing for pressure sensation with a 10-g <strong>monofilament</strong> (placed on the plantar surface at a right angle with increasing pressure until filament buckles).&nbsp; Patients with neuropathy have a higher pressure threshold and loss of monofilament sensation, which are associated with an increased risk of foot ulcerations.&nbsp; Other sensory deficits may include decreased vibratory sensation (tested with a tuning fork), decreased pinprick pain, or decreased temperature sensation.</p><p><strong>(Choice A)</strong>&nbsp; The 6-minute walk test is an assessment of functional status that measures how far a patient can walk in a standardized time.&nbsp; It is typically used for patients with chronic lung or heart disease or with chronic pain conditions (eg, fibromyalgia, osteoarthritis).&nbsp; It is not as useful for patients with diabetic neuropathy or foot ulcers.</p><p><strong>(Choice B)</strong>&nbsp; Peripheral arterial disease (PAD) can be assessed by calculating the <a href=\"1694\">ankle-brachial index (ABI)</a>.&nbsp; However, ABI is primarily a measure of large vessel PAD and does not accurately assess small vessel disease, which often contributes to ulcers in diabetic patients.&nbsp; In addition, <a href=\"1776\">arterial ulcers</a> are usually located on the tips of the toes, rather than the plantar surface.</p><p><strong>(Choice C)</strong>&nbsp; Delayed capillary refill time (&gt;3 seconds) indicates impaired limb perfusion and may suggest underlying peripheral arterial disease.&nbsp; However, delayed capillary refill is a nonspecific finding, and is also seen in hypotension or volume depletion.</p><p><strong>(Choice D)</strong>&nbsp; Diabetic neuropathy can affect the large nerve fibers in the lower extremities, causing decreased/absent ankle reflexes.&nbsp; However, the knee reflex is usually not affected.</p><p><strong>Educational objective:</strong><br>Risk factors for diabetic foot ulcers include diabetic neuropathy, previous foot ulceration, vascular disease, and foot deformity.&nbsp; Diabetic neuropathy is the most important contributing factor and is found in &gt;80% of patients with ulcers.&nbsp; Monofilament testing predicts the risk of future ulcers.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 102,
            "subject": "Medicine",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 211,
            "system": "Endocrine, Diabetes & Metabolism",
            "topicId": 6440,
            "topic": "Diabetic neuropathy",
            "titleId": 6440,
            "title": "Diabetic neuropathy",
            "topicAttributeId": 330582,
            "topicAttribute": "Diabetes mellitus",
            "correctAnswer": "5",
            "userAnswer": "5",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "6-minute walk test",
                    "choiceNumber": 1,
                    "correctTaken": 25,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Ankle-brachial index",
                    "choiceNumber": 2,
                    "correctTaken": 1014,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Capillary refill time",
                    "choiceNumber": 3,
                    "correctTaken": 231,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Knee reflex assessment",
                    "choiceNumber": 4,
                    "correctTaken": 87,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Monofilament testing",
                    "choiceNumber": 5,
                    "correctTaken": 3640,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": "385,563,true,-1,1*726,1091,true,-1,1*1259,1322,true,-1,1",
            "isCorrect": true,
            "isIncorrect": false,
            "isMarked": false,
            "isOmitted": false,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "465",
                    "mediaDataId": 0,
                    "title": "Diabetic neuropathy",
                    "referenceTypeId": 18,
                    "referenceLink": null,
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "16731996",
                    "mediaDataId": 0,
                    "title": "Prediction of diabetic foot ulcer occurrence using commonly available clinical information: the Seattle Diabetic Foot Study.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/16731996",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "19595541",
                    "mediaDataId": 0,
                    "title": "The Semmes Weinstein monofilament examination as a screening tool for diabetic peripheral neuropathy.  ",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/19595541",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "20804930",
                    "mediaDataId": 0,
                    "title": "What you can't feel can hurt you.  ",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/20804930",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 35,
            "othersAvgTimeSpent": 44,
            "notes": null,
            "peopleTaken": 5121,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 71,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 1231,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 1,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 14,
            "questionId": 11268,
            "questionIndex": 12423,
            "questionText": "<p>A newborn girl is evaluated in the delivery room 30 minutes after delivery.&nbsp; The infant was born at 41 weeks gestation to a 23-year-old woman, gravida 2 para 1, via uncomplicated vaginal delivery.&nbsp; The mother was previously healthy and had routine prenatal care.&nbsp; Serology was normal.&nbsp; The pregnancy was complicated by polyhydramnios and gestational diabetes necessitating insulin.&nbsp; The infant&#39;s vital signs are normal and birth weight is 4.2 kg (9 lb 4 oz).&nbsp; Apgar scores were 7 and 9 at 1 and 5 minutes, respectively.&nbsp; Physical examination shows an active, crying infant lying under the radiant warmer.&nbsp; Cardiac auscultation reveals a soft, 1/6 systolic murmur.&nbsp; The infant&#39;s hands and feet are cyanotic; the mucosal membranes are pink.&nbsp; Moro reflex is normal.&nbsp; The remainder of the examination is normal.&nbsp; Which of the following tests is most likely to be abnormal?</p>",
            "questionHeader": "",
            "explanationText": "<p><img draggable=\"false\" id=\"5247\" src=\"https://www.uworld.com/media/L16318.png\" ></p><p><strong>Infants of diabetic mothers (IDMs)</strong> are at increased risk for a variety of complications.&nbsp; Because glucose is actively transported across the placenta to the fetus, excessive maternal hyperglycemia leads to fetal hyperglycemia.&nbsp; The effects of <strong>fetal hyperglycemia</strong> vary depending on the developmental stage of the fetus:</p><ul><li>First trimester:&nbsp; The fetus cannot produce insulin during the first trimester and therefore cannot protect itself from hyperglycemia.&nbsp; Hyperglycemia during the first trimester can disrupt organogenesis, resulting in <strong>malformations</strong> (eg, congenital heart disease).&nbsp; Infants whose mothers have gestational diabetes are not at increased risk for malformations because maternal/fetal hyperglycemia does not develop until after organogenesis is complete.</li><li>Second and third trimesters:&nbsp; Once the fetal pancreas is sufficiently developed, hyperglycemia triggers the release of insulin, which results in increased glycogen and fat storage <strong>(organomegaly)</strong>, increased growth factor production (<strong>macrosomia</strong>, or birth weight &#8805;4 kg [8 lb 13 oz]), and increased oxygen consumption <strong>(polycythemia)</strong>.</li></ul><p>IDMs who are macrosomic are more difficult to deliver vaginally, leading to higher rates of cesarean delivery (due to failure to progress) and operative vaginal delivery (eg, forceps, vacuum); clavicle fractures, brachial plexus injuries, and asphyxia are associated with macrosomia.&nbsp; After delivery,&nbsp;fetal insulin production takes time to decrease whereas maternal glucose exposure ends as soon as the umbilical cord is clamped.&nbsp; This often results in a period of <strong>neonatal hypoglycemia</strong> until insulin levels normalize.&nbsp; Hypoglycemia is the most common complication among IDMs.</p><p><strong>(Choice A)</strong>&nbsp; Risk factors for neonatal sepsis include maternal colonization with group B <em>Streptococcus</em>, prolonged rupture of membranes, and chorioamnionitis.&nbsp; IDMs are not at increased risk for sepsis, which would be very unlikely in this well-appearing infant with a normal examination.</p><p><strong>(Choice B)</strong>&nbsp; Risk for clavicle fracture is increased in macrosomic infants such as this patient.&nbsp; However, the normal Moro reflex makes clavicle fracture unlikely.</p><p><strong>(Choice C)</strong>&nbsp; Infants exposed to hyperglycemia in the first trimester as a result of poorly controlled, prepregnancy diabetes are at higher risk for congenital malformations, including microcolon (diagnosed with contrast enema).&nbsp; However, this mother had gestational rather than prepregnancy diabetes, so this infant is not at increased risk for congenital malformations.</p><p><strong>(Choice E)</strong>&nbsp; Risk factors for congenital hearing loss include congenital cytomegalovirus infection and family history of hearing loss.&nbsp; IDMs are not at increased risk for hearing loss, although this infant should receive hearing screening as recommended for all newborns.</p><p><strong>(Choice F)</strong>&nbsp; Hyperglycemia in the first trimester is associated with congenital heart disease, which may cause cyanosis.&nbsp; However, this mother had gestational rather than prepregnancy diabetes.&nbsp; This infant has acrocyanosis, or cyanosis of the hands and feet due to benign peripheral vasospasm.&nbsp; Acrocyanosis is a normal finding in newborns, and pulse oximetry shows normal oxygen saturation levels.</p><p><strong>Educational objective:</strong><br>Fetal hyperglycemia during the first trimester is associated with malformations; fetal hyperglycemia after the first trimester is associated with perinatal complications such as macrosomia, birth injury, and hypoglycemia.&nbsp; Neonatal hypoglycemia is the most common complication among infants of diabetic mothers.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 104,
            "subject": "Pediatrics",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 211,
            "system": "Endocrine, Diabetes & Metabolism",
            "topicId": 13253,
            "topic": "Infant of diabetic mother",
            "titleId": 13253,
            "title": "Infant of diabetic mother",
            "topicAttributeId": 330582,
            "topicAttribute": "Diabetes mellitus",
            "correctAnswer": "4",
            "userAnswer": "4",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Blood culture",
                    "choiceNumber": 1,
                    "correctTaken": 23,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Clavicle x-ray",
                    "choiceNumber": 2,
                    "correctTaken": 852,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Contrast enema",
                    "choiceNumber": 3,
                    "correctTaken": 221,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Glucose level",
                    "choiceNumber": 4,
                    "correctTaken": 13107,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Hearing screening",
                    "choiceNumber": 5,
                    "correctTaken": 127,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Pulse oximetry",
                    "choiceNumber": 6,
                    "correctTaken": 2402,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": "369,483,true,-1,1*585,611,true,-1,1*612,798,true,-1,1*932,1128,true,-1,1*2004,2155,true,-1,1*2166,2383,true,-1,1",
            "isCorrect": true,
            "isIncorrect": false,
            "isMarked": false,
            "isOmitted": false,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "181",
                    "mediaDataId": 0,
                    "title": "Infant of a diabetic mother",
                    "referenceTypeId": 18,
                    "referenceLink": null,
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "22094826",
                    "mediaDataId": 0,
                    "title": "Care of the infant of the diabetic mother.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/22094826",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 58,
            "othersAvgTimeSpent": 59,
            "notes": null,
            "peopleTaken": 16732,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 78,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 1673,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 1,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 15,
            "questionId": 4247,
            "questionIndex": 4247,
            "questionText": "<p>A 23-year-old man is brought to the emergency department due to generalized weakness and abdominal pain.&nbsp; One week earlier, he began a diet challenge that involved a &#x22;juice cleanse&#x22; and exclusive consumption of raw vegetables.&nbsp; He does not use tobacco, alcohol, or illicit drugs.&nbsp; The patient&#39;s mother has hypothyroidism and his father died of lung cancer.&nbsp; Temperature is 37.8 C (100 F), blood pressure is 110/70 mm Hg, pulse is 110/min, and respirations are 27/min.&nbsp; The oral mucosa is dry.&nbsp; Laboratory results are as follows:</p><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\"><tbody><tr><td style=\"vertical-align:middle;\">Sodium</td><td style=\"vertical-align:middle;\">132 mEq/L</td></tr><tr><td style=\"vertical-align:middle;\">Potassium</td><td style=\"vertical-align:middle;\">5.4 mEq/L</td></tr><tr><td style=\"vertical-align:middle;\">Chloride</td><td style=\"vertical-align:middle;\">96 mEq/L</td></tr><tr><td style=\"vertical-align:middle;\">Bicarbonate</td><td style=\"vertical-align:middle;\">12 mEq/L</td></tr><tr><td style=\"vertical-align:middle;\">Creatinine</td><td style=\"vertical-align:middle;\">1.8 mg/dL</td></tr><tr><td style=\"vertical-align:middle;\">Glucose</td><td style=\"vertical-align:middle;\">375 mg/dL</td></tr></tbody></table><p>Which of the following is the most likely cause of the increased potassium level in this patient?</p>",
            "questionHeader": "",
            "explanationText": "<p><img draggable=\"false\" id=\"1487\" src=\"https://www.uworld.com/media/L16657.jpg\" ></p><p>This young patient with marked hyperglycemia (glucose &gt;300 mg/dL), <a href=\"3915\">anion gap metabolic acidosis</a>, dehydration (eg, dry mucous membranes, tachycardia), and abdominal pain has <strong>diabetic ketoacidosis</strong> (DKA), indicating a new diagnosis of type 1 diabetes mellitus.&nbsp; Calorie and carbohydrate restriction can cause ketosis and precipitate DKA in patients with type 1 diabetes mellitus.</p><p>Most patients with DKA have normal or elevated serum potassium values on laboratory testing, but actually have a <strong>total body potassium deficit</strong>.&nbsp; The overall potassium deficit is due to urinary potassium losses from <strong>osmotic diuresis</strong>, elimination of ketoacid anions as potassium salts (seen only in DKA), and <strong>secondary hyperaldosteronism</strong> resulting from volume contraction, which leads to potassium excretion and reabsorption of sodium in the distal renal tubule <strong>(Choices B, D, and E)</strong>.&nbsp; Despite this deficit, <strong>normal or elevated laboratory potassium measurements</strong> occur due to:</p><ul><li>hyperosmolarity, which draws fluid and potassium passively out of cells into the extracellular space.</li><li>insulin deficiency, which <strong>impairs cellular entry</strong> of potassium by the cells, further increasing extracellular potassium concentration.</li></ul><p>Administration of insulin during treatment drives potassium into cells and can rapidly lead to hypokalemia.&nbsp; For this reason, potassium should be monitored closely and added to intravenous fluids whenever serum potassium is &lt;5.3 mEq/L.</p><p><strong>(Choice A)</strong>&nbsp; Although vegetables and juices can contain high levels of potassium, this patient&#39;s anion gap metabolic acidosis and hyperglycemia point to hyperosmolarity and insulin deficiency as more likely causes of the laboratory findings.</p><p><strong>(Choice F)</strong>&nbsp; Acute onset of abdominal pain and elevated creatinine can be seen in hemolytic uremic syndrome or thrombotic thrombocytopenic purpura, conditions associated with intravascular hemolysis and hyperkalemia (due to destruction of red blood cells).&nbsp; However, this patient&#39;s severe hyperglycemia (blood glucose &gt;300 mg/dL) and anion gap acidosis suggest DKA.</p><p><strong>Educational objective:</strong><br>Diabetic ketoacidosis causes osmotic diuresis and secondary hyperaldosteronism, leading to urinary potassium loss and a total body potassium deficit.&nbsp; However, laboratory potassium values are often normal or elevated.&nbsp; This finding is due to hyperosmolarity, which draws water and potassium into the extracellular space, and insulin deficiency, which impairs cellular uptake of potassium.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 102,
            "subject": "Medicine",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 211,
            "system": "Endocrine, Diabetes & Metabolism",
            "topicId": 6575,
            "topic": "Diabetic ketoacidosis",
            "titleId": 6575,
            "title": "Diabetic ketoacidosis",
            "topicAttributeId": 330582,
            "topicAttribute": "Diabetes mellitus",
            "correctAnswer": "3",
            "userAnswer": "3",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Excessive dietary intake",
                    "choiceNumber": 1,
                    "correctTaken": 1162,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Hypoaldosteronism",
                    "choiceNumber": 2,
                    "correctTaken": 1835,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Impaired cellular uptake",
                    "choiceNumber": 3,
                    "correctTaken": 9348,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Impaired renal excretion",
                    "choiceNumber": 4,
                    "correctTaken": 2761,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Increased renal reabsorption",
                    "choiceNumber": 5,
                    "correctTaken": 783,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Intravascular hemolysis",
                    "choiceNumber": 6,
                    "correctTaken": 184,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": "290,408,true,-1,1*1217,1452,true,-1,1",
            "isCorrect": true,
            "isIncorrect": false,
            "isMarked": false,
            "isOmitted": false,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "521",
                    "mediaDataId": 0,
                    "title": "Diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic state (HHS)",
                    "referenceTypeId": 18,
                    "referenceLink": null,
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 45,
            "othersAvgTimeSpent": 73,
            "notes": null,
            "peopleTaken": 16073,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 58,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 2121,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 1,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 16,
            "questionId": 4516,
            "questionIndex": 4516,
            "questionText": "<p>A 75-year-old man is brought to the emergency department due to a 2-day history of progressive lethargy and confusion.&nbsp; His family reports that he has had fatigue and blurred vision over the last several days.&nbsp; The patient was recently diagnosed with polymyalgia rheumatica and is taking prednisone.&nbsp; Medical history is notable for diet-controlled type 2 diabetes mellitus, hypertension, and hyperlipidemia.&nbsp; Temperature is 37.9 C (100.2 F), blood pressure is 90/60 mm Hg, pulse is 112/min, and respirations are 18/min.&nbsp; Oral mucous membranes are dry.&nbsp; The lungs are clear to auscultation, and the heart has a regular tachycardia with no murmur.&nbsp; The neck is supple.&nbsp; The patient is somnolent but arousable and moves all extremities equally on command.&nbsp; Laboratory results are as follows:</p><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\"><tbody><tr><td style=\"vertical-align:middle;\">Sodium</td><td style=\"vertical-align:middle;\">129 mEq/L</td></tr><tr><td style=\"vertical-align:middle;\">Potassium</td><td style=\"vertical-align:middle;\">3.5 mEq/L</td></tr><tr><td style=\"vertical-align:middle;\">Chloride</td><td style=\"vertical-align:middle;\">94 mEq/L</td></tr><tr><td style=\"vertical-align:middle;\">Bicarbonate</td><td style=\"vertical-align:middle;\">24 mEq/L</td></tr><tr><td style=\"vertical-align:middle;\">Blood urea nitrogen</td><td style=\"vertical-align:middle;\">36 mg/dL</td></tr><tr><td style=\"vertical-align:middle;\">Creatinine</td><td style=\"vertical-align:middle;\">1.9 mg/dL</td></tr><tr><td style=\"vertical-align:middle;\">Estimated glomerular filtration rate</td><td style=\"vertical-align:middle;\">34 mL/min/1.73 m<font size=\"2\"><sup>2</sup></font></td></tr><tr><td style=\"vertical-align:middle;\">Calcium</td><td style=\"vertical-align:middle;\">8.8 mg/dL</td></tr><tr><td style=\"vertical-align:middle;\">Glucose</td><td style=\"vertical-align:middle;\">1,170 mg/dL</td></tr></tbody></table><p>Urinalysis shows trace ketones.&nbsp; Which of the following is the most likely cause of this patient&#39;s altered sensorium?</p>",
            "questionHeader": "",
            "explanationText": "<div id=\"div_t39702\"><table class=\"table-default-style\"><tbody><tr><td colspan=\"2\"><p align=\"center\"><strong>Hyperosmolar hyperglycemic state</strong></p></td></tr><tr><td><p align=\"center\"><strong>Patient<br />characteristics</strong></p></td><td><ul><li>Type 2 diabetes mellitus</li><li>Older age</li></ul></td></tr><tr><td><p align=\"center\"><strong>Inciting<br />factors</strong></p></td><td><ul><li>Acute illness, trauma, infection</li><li>Insulin nonadherence</li><li>Medications: glucocorticoids, diuretics, atypical antipsychotics</li></ul></td></tr><tr><td><p align=\"center\"><strong>Clinical<br />features</strong></p></td><td><p>Subacute or acute onset of:</p><ul><li>Altered mentation</li><li>Hyperglycemic symptoms (eg, polyuria)</li><li>Volume depletion</li></ul></td></tr><tr><td><p align=\"center\"><strong>Laboratory<br />studies</strong></p></td><td><ul><li>Glucose &gt;600 mg/dL (33.3 mmol/L)</li><li>Bicarbonate &gt;18 mEq/L (18 mmol/L)</li><li>Normal anion gap</li><li>Negative or small serum ketones</li><li>Serum osmolality &gt;320 mOsm/kg (320 mmol/kg)</li></ul></td></tr></tbody></table></div><p>This patient with type 2 diabetes mellitus has <strong>hyperosmolar hyperglycemic state</strong> (HHS), characterized by high plasma osmolality and <strong>severe hyperglycemia</strong> (often &gt;1,000 mg/dL) due to relative insulin deficiency and/or elevated counterregulatory hormones (eg, cortisol).&nbsp; Common precipitating factors include:</p><ul><li>Infection</li><li>Medications impacting carbohydrate metabolism (eg, <strong>glucocorticoids</strong>, thiazide diuretics, atypical antipsychotics)</li><li>Interruption of insulin therapy</li><li>Trauma or acute illness (eg, myocardial infarction)</li></ul><p>Severe hyperglycemia causes glycosuria, osmotic diuresis, hypovolemia, and dehydration.&nbsp; With worsening hypovolemia, glomerular filtration rate (GFR) declines, leading to reduced renal glucose excretion and worsening hyperglycemia.&nbsp; Elderly individuals are at increased risk due to altered perception of thirst and restricted fluid intake.&nbsp; <strong>Neurologic symptoms</strong> ranging from confusion to coma are due primarily to <strong>high plasma osmolality</strong>, usually &gt;320 mOsm/kg; this patient&#39;s <a href=\"57778\">calculated osmolality</a> is approximately 336 mOsm/kg (using the reported sodium level, not that corrected for hyperglycemia).&nbsp; In contrast to diabetic ketoacidosis (DKA), which typically develops rapidly over hours, HHS develops over a few days to weeks.</p><p><strong>(Choice A)</strong>&nbsp; Glucocorticoid-induced psychosis is characterized by delusions, hallucinations, disorganized thought processes, and aggression.&nbsp; Lethargy is less typical.</p><p><strong>(Choice C)</strong>&nbsp; Mental status changes in hyponatremia are due to cerebral edema (water flowing from the hypoosmolar extracellular space into brain cells).&nbsp; In HHS, plasma osmolality is elevated due to excess glucose, drawing water out of cells, which lowers plasma sodium (dilution hyponatremia); however, cerebral edema does not occur.&nbsp; The effective sodium concentration can be <a href=\"27942\">corrected for hyperglycemia</a>; this patient&#39;s corrected sodium is approximately 152.</p><p><strong>(Choices D and E)</strong>&nbsp; <a href=\"3915\">Anion gap</a> is also calculated using reported, not corrected, serum sodium.&nbsp; This patient&#39;s normal anion gap and serum bicarbonate make metabolic acidosis, including DKA, unlikely.&nbsp; In HHS, mild ketosis (ie, urine ketones) may occur due to decreased food intake (ie, starvation ketosis); however, unlike DKA, more prominent ketosis does not occur because even relatively low insulin production suppresses ketogenesis.</p><p><strong>(Choice F)</strong>&nbsp; In kidney injury, uremic toxin buildup can cause mild symptoms (eg, fatigue, nausea) when the GFR falls below 60 mL/min/1.73 m<font size=\"2\"><sup>2</sup></font>.&nbsp; However, more severe symptoms, as seen in this patient, would typically be observed only at an estimated GFR &lt;10-20 mL/min/1.73 m<font size=\"2\"><sup>2</sup></font>.</p><p><strong>Educational objective:</strong><br>Hyperosmolar hyperglycemic state in type 2 diabetes mellitus is characterized by severe hyperglycemia and hyperosmolality without significant ketoacidosis.&nbsp; Altered sensorium is due to high plasma osmolality.&nbsp; Common precipitating factors include infection, medications (eg, glucocorticoids), interruption of insulin therapy, trauma, and acute illness.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 102,
            "subject": "Medicine",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 211,
            "system": "Endocrine, Diabetes & Metabolism",
            "topicId": 11854,
            "topic": "Hyperosmolar hyperglycemic state",
            "titleId": 11854,
            "title": "Hyperosmolar hyperglycemic state",
            "topicAttributeId": 330582,
            "topicAttribute": "Diabetes mellitus",
            "correctAnswer": "2",
            "userAnswer": "2",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Glucocorticoid psychosis",
                    "choiceNumber": 1,
                    "correctTaken": 981,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Hyperosmolality",
                    "choiceNumber": 2,
                    "correctTaken": 9571,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Hyponatremia",
                    "choiceNumber": 3,
                    "correctTaken": 2495,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Ketoacidosis",
                    "choiceNumber": 4,
                    "correctTaken": 1788,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Metabolic acidosis",
                    "choiceNumber": 5,
                    "correctTaken": 515,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Uremia",
                    "choiceNumber": 6,
                    "correctTaken": 728,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": "1973,2121,true,-1,1*2210,2254,true,-1,1",
            "isCorrect": true,
            "isIncorrect": false,
            "isMarked": false,
            "isOmitted": false,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "521",
                    "mediaDataId": 0,
                    "title": "Diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic state (HHS)",
                    "referenceTypeId": 18,
                    "referenceLink": null,
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "25342831",
                    "mediaDataId": 0,
                    "title": "Hyperosmolar hyperglycemic state: a historic review of the clinical presentation, diagnosis, and treatment.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/25342831",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 97,
            "othersAvgTimeSpent": 73,
            "notes": null,
            "peopleTaken": 16078,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 60,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 573,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 1,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 17,
            "questionId": 4830,
            "questionIndex": 4830,
            "questionText": "<p>A 13-year-old boy is brought to the office for a well-child visit.&nbsp; The patient is concerned that he is the shortest boy in his class.&nbsp; He is in 7th grade and participates in soccer and baseball.&nbsp; The patient is a picky eater whose diet consists primarily of cereal, fruit, pasta, and pizza.&nbsp; He has seasonal allergies and takes cetirizine and a daily multivitamin.&nbsp; His mother is 165 cm (65 in), and his father is 178 cm (70 in).&nbsp; Height is 140 cm (55 in) and weight is 39 kg (86 lb).&nbsp; The patient&#39;s sexual maturity rating (Tanner stage) is 1.&nbsp; The remainder of the examination is unremarkable.&nbsp; A radiograph of the left wrist reveals a bone age of 10 years.&nbsp; His growth chart is shown below.</p><p><img draggable=\"false\" id=\"32894\" src=\"https://www.uworld.com/media/L58165.jpg\" ></p><p>Which of the following is the most likely diagnosis in this patient?</p>",
            "questionHeader": "",
            "explanationText": "<div id=\"div_t35770\"><table class=\"table-default-style\"><tbody><tr><td colspan=\"2\"><p align=\"center\"><strong>Constitutional delay of growth and puberty</strong></p></td></tr><tr><td><p align=\"center\"><strong>Clinical features</strong></p></td><td><ul><li>Family history of &ldquo;late bloomers&rdquo;</li><li>Delayed puberty</li><li>Short stature; normal growth velocity</li><li>Delayed bone age</li></ul></td></tr><tr><td><p align=\"center\"><strong>Management</strong></p></td><td><ul><li>Reassurance; watchful waiting</li><li>&plusmn; Hormone therapy</li></ul></td></tr><tr><td><p align=\"center\"><strong>Prognosis</strong></p></td><td><ul><li>Puberty onset correlates with family members</li><li>Normal expected adult height</li></ul></td></tr></tbody></table></div><p>This patient has <strong>short stature</strong>, defined as <strong>height at the &#8804;2nd percentile</strong> for sex and age.&nbsp; Short stature is most commonly a normal variant of growth due to constitutional growth delay or familial short stature.</p><p><strong>Constitutional growth delay</strong> can be recognized based on a <strong>delayed bone age</strong>, with a<strong> </strong>linear growth velocity&nbsp;starting at <strong>age &#8805;3</strong>.&nbsp; Affected patients typically have a normal birth weight and height but show a slowed linear growth velocity between age 6 months to 3 years.&nbsp; This results in height at the &#8804;2nd percentile.&nbsp; They subsequently (eg, age &#8805;3) grow at a normal rate (ie, normal growth velocity), so their growth curve remains below but parallel to the lowest percentile line (ie, linear growth curve).&nbsp; Their <strong>puberty</strong> (including the adolescent growth spurt) is <strong>delayed</strong>, and bone age (ie, skeletal maturation) is delayed compared to the chronological age.&nbsp; However, they eventually have a normal growth spurt and reach a <strong>normal adult height</strong>.&nbsp; Management includes reassurance and monitoring of linear velocity.</p><p>In contrast to constitutional growth delay, patients with familial short stature have a bone age that correlates with chronologic age, and puberty is not delayed.&nbsp; Although these patients have normal linear growth velocity (eg, stable percentile) similar to constitutional growth delay, one or both parents also have short stature (unlike in this patient) <strong>(Choice C)</strong>.&nbsp; An affected patient&#39;s adult height remains low.</p><p><strong>(Choice A)</strong>&nbsp; Celiac disease can present with short stature and result in delayed bone age; however, patients typically also have weight loss and gastrointestinal symptoms (eg, diarrhea, abdominal distension).&nbsp; This patient has appropriate weight gain and is otherwise asymptomatic.</p><p><strong>(Choice D)</strong>&nbsp; Patients with growth hormone deficiency have short stature, delayed puberty, and delayed bone age.&nbsp; However, linear growth velocity is slowed, typically presenting as declining height percentiles crossing 2 major percentiles (ie, 50th, 25th).&nbsp; This patient&#39;s height percentile is stable, indicating a normal linear growth velocity.</p><p><strong>(Choice E)</strong>&nbsp; Hypogonadism leading to testosterone deficiency can be congenital (eg, Klinefelter syndrome) or acquired (eg, testicular trauma or infection).&nbsp; Although delayed puberty is common, bone age would be normal.&nbsp; In addition, most patients have gynecomastia (not seen here) due to negative feedback, causing increased LH, FSH, and estradiol.</p><p><strong>(Choice F)</strong>&nbsp; Hypothyroidism can cause declining linear growth velocity and pubertal delay.&nbsp; In contrast, this patient&#39;s linear growth velocity is normal.&nbsp; In addition, he has no clinical symptoms of hypothyroidism, such as fatigue, constipation, or cold intolerance.</p><p><strong>Educational objective:</strong><br>Constitutional growth delay is characterized by short stature (height at the &#8804;2nd percentile) and normal linear growth velocity after age 3.&nbsp; Puberty and bone age are delayed, and adult height is typically normal.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 104,
            "subject": "Pediatrics",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 211,
            "system": "Endocrine, Diabetes & Metabolism",
            "topicId": 23339,
            "topic": "Short stature",
            "titleId": 23339,
            "title": "Short stature",
            "topicAttributeId": 330576,
            "topicAttribute": "Congenital and developmental anomalies",
            "correctAnswer": "2",
            "userAnswer": "4",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Celiac disease",
                    "choiceNumber": 1,
                    "correctTaken": 124,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Constitutional growth delay",
                    "choiceNumber": 2,
                    "correctTaken": 11368,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Familial short stature",
                    "choiceNumber": 3,
                    "correctTaken": 1386,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Growth hormone deficiency",
                    "choiceNumber": 4,
                    "correctTaken": 2111,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Testosterone deficiency",
                    "choiceNumber": 5,
                    "correctTaken": 1404,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Thyroid hormone deficiency",
                    "choiceNumber": 6,
                    "correctTaken": 172,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": "125,140,true,-1,1*179,195,true,-1,1*265,338,true,-1,1*429,549,true,-1,1*675,815,true,-1,1*1360,1776,true,-1,1",
            "isCorrect": false,
            "isIncorrect": true,
            "isMarked": false,
            "isOmitted": false,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "735",
                    "mediaDataId": 0,
                    "title": "Short stature",
                    "referenceTypeId": 18,
                    "referenceLink": null,
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "30969602",
                    "mediaDataId": 0,
                    "title": "Constitutional growth delay.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/30969602",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 125,
            "othersAvgTimeSpent": 58,
            "notes": null,
            "peopleTaken": 16565,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 69,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 4610,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 1,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 18,
            "questionId": 3192,
            "questionIndex": 3192,
            "questionText": "<p>A 4-month-old boy is brought to the emergency department after an episode of generalized tonic-clonic seizure 30 minutes ago.&nbsp; The patient was born at 40 weeks gestation by spontaneous vaginal delivery.&nbsp; He was at the 50th percentile for height and weight, and had a normal physical examination.&nbsp; Since birth, the patient has had 3 episodes of upper respiratory infection and otitis media.&nbsp; His parents and older sister have no medical problems.&nbsp; On examination, the patient is lethargic.&nbsp; He weighs 4.2 kg (9.3 lb, &lt;5th percentile).&nbsp; The anterior fontanelle is flat.&nbsp; Pupils are reactive with normal fundi.&nbsp; His tympanic membranes and pharynx are normal.&nbsp; He has round cheeks and a doll-like face.&nbsp; Heart sounds are normal without murmurs.&nbsp; Lungs are clear.&nbsp; The abdomen is protuberant and the liver is palpable 4 cm below the right costal margin.&nbsp; Extremities are thin.&nbsp; Laboratory results are as follows:</p><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\"><tbody><tr><td>Serum chemistry</td></tr><tr><td>&nbsp;&nbsp;&nbsp;&nbsp;Sodium</td><td>136 mEq/L</td><td></td></tr><tr><td>&nbsp;&nbsp;&nbsp;&nbsp;Chloride</td><td>96 mEq/L</td><td></td></tr><tr><td>&nbsp;&nbsp;&nbsp;&nbsp;Bicarbonate</td><td>16 mEq/L</td><td></td></tr><tr><td>&nbsp;&nbsp;&nbsp;&nbsp;Glucose</td><td>38 mg/dL</td><td></td></tr><tr><td>Lactic acid</td><td>24 mg/dL</td><td>(normal: 6-16 mg/dL)</td></tr></tbody></table><p>Urine dipstick is positive for ketones.&nbsp; Serum triglyceride and uric acid levels are increased.&nbsp; Which of the following is the most likely cause of this patient&#39;s condition?</p>",
            "questionHeader": "",
            "explanationText": "<p><strong>Glucose-6-phosphatase deficiency</strong> (type I glycogen storage disease, von Gierke disease) is caused by deficient glucose-6-phosphatase in the liver, kidneys, and intestinal mucosa.&nbsp; This results in impaired conversion of glycogen to glucose, leading to <strong>glycogen accumulation</strong> in the affected organs.&nbsp; Patients typically present at age 3-4 months with <strong>hypoglycemia</strong> (often resulting in <strong>seizures</strong>) and <strong>lactic acidosis</strong> (due to buildup in the liver).&nbsp; Other laboratory findings include <strong>hyperuricemia</strong> and hyperlipidemia.&nbsp; Physical examination demonstrates a <strong>doll-like</strong> face with rounded cheeks, thin extremities, short stature, and a protuberant abdomen due to <strong>hepatomegaly</strong>.&nbsp; The spleen and heart are not involved.</p><p><strong>(Choice A)</strong>&nbsp; Excessive endogenous insulin production at this age could be a result of persistent hyperinsulinemic hypoglycemia of infancy (PHHI), which would also cause hypoglycemia, poor feeding, and poor tone.&nbsp; However, PHHI is often associated with infants of mothers who are diabetic (whereas this patient&#39;s mother has no medical problems) and usually presents in the first few days of life with macrosomia (rather than failure to thrive).</p><p><strong>(Choice B)</strong>&nbsp; Glucocerebrosidase enzyme deficiency results in Gaucher disease.&nbsp; Glucocerebroside accumulates in macrophages of the liver, spleen, and bone marrow, causing bone pain and cytopenias.&nbsp; Hepatosplenomegaly is present, but hypoglycemia and lactic acidosis are not typical.</p><p><strong>(Choice D)</strong>&nbsp; The inability to break down fatty acid chains is a feature of fatty acid cycle disorders such as medium-chain acyl-CoA dehydrogenase deficiency (MCAD).&nbsp; MCAD results in episodes of hypoketotic hypoglycemia during fasting states (eg, illness).&nbsp; Elevated lactic&nbsp;acid, elevated uric acid, and characteristic facial features are not typically seen.</p><p><strong>(Choice E)</strong>&nbsp; Inadequate total body glycogen stores may occur in newborns as a result of prematurity or intrauterine growth restriction.&nbsp; Hypoglycemia is very common in these newborns; however, it typically occurs within the first 24 hours of life, would not persist at age 4 months, and would not be associated with specific facial features.</p><p><strong>Educational objective:</strong><br>Glucose-6-phosphatase deficiency (type I glycogen storage disease, von Gierke disease) presents at age 3-4 months with hypoglycemia (often with seizures), lactic acidosis, hyperuricemia, and hyperlipidemia.&nbsp; Patients typically have a doll-like face, thin extremities, short stature, and a protuberant abdomen (due to hepatomegaly).</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 104,
            "subject": "Pediatrics",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 211,
            "system": "Endocrine, Diabetes & Metabolism",
            "topicId": 21931,
            "topic": "Glycogen storage disease",
            "titleId": 21931,
            "title": "Glycogen storage disease",
            "topicAttributeId": 330576,
            "topicAttribute": "Congenital and developmental anomalies",
            "correctAnswer": "3",
            "userAnswer": "3",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Excessive endogenous insulin production",
                    "choiceNumber": 1,
                    "correctTaken": 510,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Glucocerebrosidase enzyme deficiency",
                    "choiceNumber": 2,
                    "correctTaken": 2659,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Impaired glycogen to glucose conversion",
                    "choiceNumber": 3,
                    "correctTaken": 9923,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Inability to break fatty acid chains",
                    "choiceNumber": 4,
                    "correctTaken": 2428,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Inadequate total body glycogen stores",
                    "choiceNumber": 5,
                    "correctTaken": 1065,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": "744,1175,true,-1,1*1187,1456,true,-1,1*1622,1813,true,-1,1",
            "isCorrect": true,
            "isIncorrect": false,
            "isMarked": false,
            "isOmitted": false,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "252",
                    "mediaDataId": 0,
                    "title": "Glucose-6-phosphate dehydrogenase deficiency",
                    "referenceTypeId": 18,
                    "referenceLink": null,
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 145,
            "othersAvgTimeSpent": 88,
            "notes": null,
            "peopleTaken": 16585,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 60,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 2407,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 1,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 19,
            "questionId": 15083,
            "questionIndex": 16507,
            "questionText": "<p>A 54-year-old man comes to the office for follow-up for diabetes mellitus.&nbsp; The patient has a 5-year history of type 2 diabetes mellitus treated with metformin.&nbsp; He also has hypertension and underwent coronary stenting for non&ndash;ST-elevation myocardial infarction a month ago.&nbsp; The patient feels well and reports no symptoms.&nbsp; Since the myocardial infarction, he has taken all medications as prescribed and strictly followed lifestyle recommendations.&nbsp; The patient does not use tobacco, alcohol, or recreational drugs.&nbsp; Blood pressure is 128/74 mm Hg and pulse is 68/min.&nbsp; BMI is 32 kg/m<font size=\"2\"><sup>2</sup></font>.&nbsp; Physical examination shows no abnormalities.&nbsp; Serum creatinine is 0.8 mg/dL and hemoglobin A1c is 8.2%.&nbsp; Which of the following medications to lower blood glucose has an added protective effect on this patient&#39;s cardiac and weight-related comorbidities?</p>",
            "questionHeader": "",
            "explanationText": "<div id=\"div_T96139\"><table class=\"table-default-style table-header-footer-style\"><tbody><tr><td colspan=\"2\"><p align=\"center\"><strong>Pharmacologic management of cardiovascular risk in type 2 diabetes mellitus</strong></p></td></tr><tr><td><p align=\"center\"><strong>Antiplatelet therapy</strong></p></td><td><ul><li>Known ASCVD or high ASCVD risk</li><li>Low-dose (75-182 mg) aspirin</li></ul></td></tr><tr><td><p align=\"center\"><strong>Blood pressure management</strong></p></td><td><ul><li>Target &lt;130/80 mm Hg</li><li>ACE inhibitors, ARBs preferred</li></ul></td></tr><tr><td><p align=\"center\"><strong>Statin therapy</strong></p></td><td><ul><li>Known ASCVD</li><li>Age 40-75</li><li>Age 20-39 with increased ASCVD risk</li></ul></td></tr><tr><td><p align=\"center\"><strong>Glucose-lowering<br>therapy</strong></p></td><td><ul><li>Known ASCVD or age &#8805;55 with 2 or more additional risk factors: SGLT2i or GLP-1 agonist</li><li>Heart failure: SGLT2i</li></ul></td></tr><tr><td colspan=\"2\"><strong>ARB</strong> = angiotensin II receptor blocker; <strong>ASCVD</strong> = atherosclerotic cardiovascular disease; <strong>GLP-1</strong> = glucagon-like peptide-1; <strong>SGLT2i</strong> = sodium-glucose cotransporter-2 inhibitor.</td></tr></tbody></table></div><p>This patient with <strong>type 2 diabetes mellitus</strong> has poor glycemic control (hemoglobin A1c &gt;7%) despite metformin monotherapy.&nbsp; He also has significant comorbidities, including <strong>coronary artery disease</strong> (recent myocardial infarction) and <strong>obesity</strong> (BMI &#8805;30 kg/m<font size=\"2\"><sup>2</sup></font>).&nbsp; Therefore, the pharmacologic regimen should be optimized to both address the patient&#39;s comorbid conditions and improve glycemic control.</p><p>The following antidiabetic medications have been shown to <strong>reduce cardiovascular mortality</strong> and <strong>induce weight loss</strong>:</p><ul><li><p><a href=\"2663\">Sodium-glucose cotransporter-2 (SGLT-2) inhibitors</a> (eg, canagliflozin, empagliflozin) cause increased urinary glucose excretion and are associated with lower systemic and intraglomerular pressures.&nbsp; Additional benefits include reduced progression of nephropathy, modest weight loss, and reduced hospitalizations for heart failure.</p></li><li><p><a href=\"2758\">Glucagon-like peptide-1 (GLP-1) receptor agonists</a> (eg, semaglutide, liraglutide) slow gastric emptying, suppress glucagon secretion, and increase glucose-dependent insulin release, with strong glycemic efficacy and significant weight loss.</p></li></ul><p>These two antidiabetic medication classes also carry a low risk for hypoglycemia, and either would be appropriate for this patient.</p><p><strong>(Choices A and D)</strong>&nbsp; Sulfonylureas (eg, glipizide) stimulate pancreatic insulin secretion.&nbsp; Both exogenous insulin and sulfonylureas are associated with weight gain (due to insulin-induced anabolic effects) and increased risk for hypoglycemia.&nbsp; Neither has been shown to reduce cardiovascular mortality or morbidity.</p><p><strong>(Choice B)</strong>&nbsp; Dipeptidyl peptidase-4 inhibitors (eg, sitagliptin) have a mechanism of action related to that of GLP-1 agonists; however, unlike GLP-1 agonists, they are not cardioprotective and are weight neutral.</p><p><strong>(Choice E)</strong>&nbsp; Thiazolidinediones (eg, pioglitazone) decrease gluconeogenesis and improve insulin sensitivity but are associated with weight gain, fluid retention, and increased risk for heart failure.</p><p><strong>Educational objective:</strong><br>Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors are associated with improved cardiovascular outcomes in patients with type 2 diabetes mellitus and comorbid atherosclerotic cardiovascular disease.&nbsp; Both are associated with weight loss and carry a low risk for hypoglycemia.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 102,
            "subject": "Medicine",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 211,
            "system": "Endocrine, Diabetes & Metabolism",
            "topicId": 2603,
            "topic": "Diabetes mellitus",
            "titleId": 2603,
            "title": "Diabetes mellitus",
            "topicAttributeId": 330582,
            "topicAttribute": "Diabetes mellitus",
            "correctAnswer": "3",
            "userAnswer": "3",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Basal insulin",
                    "choiceNumber": 1,
                    "correctTaken": 47,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Dipeptidyl peptidase-4 inhibitor",
                    "choiceNumber": 2,
                    "correctTaken": 487,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Sodium-glucose cotransporter-2 inhibitor",
                    "choiceNumber": 3,
                    "correctTaken": 4505,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Sulfonylurea",
                    "choiceNumber": 4,
                    "correctTaken": 107,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Thiazolidinedione",
                    "choiceNumber": 5,
                    "correctTaken": 103,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": "167,186,true,-1,1*213,233,true,-1,1*292,337,true,-1,1*363,449,true,-1,1*450,471,true,-1,1*1347,1481,true,-1,1*1536,1722,true,-1,1*2006,2095,true,-1,1*2181,2232,true,-1,1*2327,2381,true,-1,1",
            "isCorrect": true,
            "isIncorrect": false,
            "isMarked": false,
            "isOmitted": false,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "526",
                    "mediaDataId": 0,
                    "title": "Noninsulin antihyperglycemic drugs in type 2 diabetes mellitus",
                    "referenceTypeId": 18,
                    "referenceLink": null,
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "29196150",
                    "mediaDataId": 0,
                    "title": "SGLT2 inhibitors with cardiovascular benefits: transforming clinical care in type 2 diabetes mellitus.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/29196150",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 33,
            "othersAvgTimeSpent": 52,
            "notes": null,
            "peopleTaken": 5249,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 86,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 1101,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 1,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 20,
            "questionId": 15878,
            "questionIndex": 17317,
            "questionText": "<p>A 52-year-old woman comes to the clinic for follow-up of type 2 diabetes mellitus that was diagnosed 6 months ago after she was hospitalized for cellulitis of the right lower leg.&nbsp; The patient&#39;s diabetes is managed with insulin in addition to diet and exercise.&nbsp; Her only other medical condition is hypertension, for which she takes antihypertensive medication.&nbsp; The patient&#39;s mother had systemic lupus erythematosus and died at age 60.&nbsp; Serum creatinine is 1.7 mg/dL.&nbsp; Urine albumin/creatinine ratio is elevated at 190 mg/g and was also elevated 3 months ago.&nbsp; Which of the following additional findings would most strongly support a diagnosis of diabetic nephropathy in this patient?</p>",
            "questionHeader": "",
            "explanationText": "<p><strong>Diabetic nephropathy</strong> (DN) is exceedingly common in patients with both type 1 and type 2 diabetes mellitus and is characterized by persistent albuminuria (&#8805;30 mg/g) and/or decreased glomerular filtration rate (GFR) (eg, elevated creatinine).&nbsp; DN is typically slowly progressive for years before clinical signs occur.</p><p>The diagnosis is usually made clinically, with renal biopsy reserved for patients with an unclear presentation.&nbsp; In the absence of signs suggesting another etiology (eg, casts in the urine, rapid progression of renal dysfunction), the diagnosis can be presumed in patients who have <strong>persistent albuminuria and/or decreased GFR</strong> and either of the following:</p><ul><li><p><strong>Prolonged history of diabetes:</strong>&nbsp; Type 1 diabetes is typically clinically obvious at onset; therefore, DN may be assumed those with a disease duration of &#8805;5 years.&nbsp; In contrast, type 2 diabetes is often asymptomatic, so patients may have this disorder for years before the diagnosis, making the duration of the disease difficult to calculate.</p></li><li><p><strong>Proliferative diabetic retinopathy (PDR):</strong>&nbsp; Both PDR (ie, retinal neovascularization) and DN are chronic microvascular complications of diabetes due to persistent hyperglycemia, so the presence of PDR <strong>correlates</strong> with <strong>diabetic kidney disease</strong>.</p></li></ul><p>Therefore, patients may be diagnosed with DN if there is concomitant PDR, regardless of the length of time since the diagnosis.</p><p><strong>(Choice A)</strong>&nbsp; Renal size discrepancy is seen in patients with unilateral chronic kidney disease (eg, renal artery stenosis, ureteral obstruction).&nbsp; With prolonged DN, both kidneys would likely be shrunken and atrophic.</p><p><strong>(Choice B)</strong>&nbsp; Left ventricular hypertrophy correlates with chronic, uncontrolled hypertension.&nbsp; Although uncontrolled hypertension may be seen in patients with chronic kidney disease, it is not specific for DN.</p><p><strong>(Choice C)</strong>&nbsp; Although microscopic hematuria may occur with DN, it is nonspecific and may be seen in a variety of diseases (eg, malignancy, nephritic syndromes).</p><p><strong>(Choice D)</strong>&nbsp; DN usually develops over a prolonged period (years).&nbsp; Rapidly progressive renal dysfunction suggests an alternate diagnosis (eg, lupus nephritis) and further workup.&nbsp; Renal biopsy may be indicated.</p><p><strong>Educational objective:</strong><br>Diabetic nephropathy (DN) is characterized by persistent albuminuria (&#8805;30 mg/g) and/or decreased glomerular filtration rate.&nbsp; In the absence of signs suggestive of another etiology, the diagnosis can be presumed in patients with renal dysfunction and either a prolonged history of diabetes (&#8805;5 years for type 1 diabetes) or proliferative diabetic retinopathy, which correlates with the presence of DN.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 102,
            "subject": "Medicine",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 211,
            "system": "Endocrine, Diabetes & Metabolism",
            "topicId": 2603,
            "topic": "Diabetes mellitus",
            "titleId": 2603,
            "title": "Diabetes mellitus",
            "topicAttributeId": 330582,
            "topicAttribute": "Diabetes mellitus",
            "correctAnswer": "5",
            "userAnswer": "5",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Discrepancy in right and left kidney size",
                    "choiceNumber": 1,
                    "correctTaken": 377,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Left ventricular hypertrophy",
                    "choiceNumber": 2,
                    "correctTaken": 290,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Microscopic hematuria",
                    "choiceNumber": 3,
                    "correctTaken": 2333,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Rapidly progressive renal dysfunction",
                    "choiceNumber": 4,
                    "correctTaken": 2001,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Retinal neovascularization",
                    "choiceNumber": 5,
                    "correctTaken": 8673,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": null,
            "isCorrect": true,
            "isIncorrect": false,
            "isMarked": false,
            "isOmitted": false,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "464",
                    "mediaDataId": 0,
                    "title": "Diabetic kidney disease",
                    "referenceTypeId": 18,
                    "referenceLink": null,
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 86,
            "othersAvgTimeSpent": 55,
            "notes": null,
            "peopleTaken": 13674,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 63,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 6,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 1,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 21,
            "questionId": 17760,
            "questionIndex": 19220,
            "questionText": "<p>A previously healthy, 36-year-old man is hospitalized following a motor vehicle collision.&nbsp; He sustained a concussion and fracture of the right femur, and open reduction and internal fixation of the fracture are planned.&nbsp; Medical history is insignificant, and the patient takes no medications for chronic conditions.&nbsp; Blood pressure is 150/90 mm Hg and pulse is 70/min.&nbsp; Oxygen saturation is 98% on room air.&nbsp; BMI is 24 kg/m<font size=\"2\"><sup>2</sup></font>.&nbsp; Laboratory results are as follows:</p><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\"><tbody><tr><td style=\"vertical-align:middle;\">Hemoglobin</td><td style=\"vertical-align:middle;\">12.7 g/L</td></tr><tr><td style=\"vertical-align:middle;\">Sodium</td><td style=\"vertical-align:middle;\">140 mEq/L</td></tr><tr><td style=\"vertical-align:middle;\">Potassium</td><td style=\"vertical-align:middle;\">3.8 mEq/L</td></tr><tr><td style=\"vertical-align:middle;\">Bicarbonate</td><td style=\"vertical-align:middle;\">24 mEq/L</td></tr><tr><td style=\"vertical-align:middle;\">Chloride</td><td style=\"vertical-align:middle;\">104 mEq/L</td></tr><tr><td style=\"vertical-align:middle;\">Glucose</td><td style=\"vertical-align:middle;\">145 mg/dL</td></tr><tr><td style=\"vertical-align:middle;\">Blood urea nitrogen</td><td style=\"vertical-align:middle;\">22 mg/dL</td></tr><tr><td style=\"vertical-align:middle;\">Creatinine</td><td style=\"vertical-align:middle;\">1.2 mg/dL</td></tr><tr><td style=\"vertical-align:middle;\">Calcium</td><td style=\"vertical-align:middle;\">9.1 mg/dL</td></tr></tbody></table><p>Finger-stick glucose measurement is 156 mg/dL.&nbsp; Hemoglobin A1c is 5.5%.&nbsp; Which of the following is the best next step in management of this patient&#39;s glucose values?</p>",
            "questionHeader": "",
            "explanationText": "<div id=\"div_T60047\"><table class=\"table-default-style\"><tbody><tr><td colspan=\"2\"><p align=\"center\"><strong>Stress hyperglycemia</strong></p></td></tr><tr><td><p align=\"center\"><strong>Presentation</strong></p></td><td><ul><li>Transient hyperglycemia without preexisting diabetes</li></ul></td></tr><tr><td><p align=\"center\"><strong>Risk factors</strong></p></td><td><ul><li>Intensive care unit admission</li><li>Fever, sepsis, severe infection</li><li>Major trauma/hemorrhage</li><li>Hypoxia</li></ul></td></tr><tr><td><p align=\"center\"><strong>Treatment</strong></p></td><td><ul><li>Minimization of glucose in intravenous fluids</li><li>Insulin to maintain blood glucose at 140-180 mg/dL</li></ul></td></tr></tbody></table></div><p>This patient has an elevated blood glucose but a normal hemoglobin A1c (ie, no chronic hyperglycemia).&nbsp; In the context of major trauma, this presentation is consistent with stress hyperglycemia.&nbsp; <strong>Stress hyperglycemia</strong> is a <strong>transient elevation in blood glucose</strong> caused by metabolic stress in patients without preexisting diabetes mellitus.&nbsp; It is common in the intensive care unit and is typically seen in patients with <strong>sepsis, burns, or major trauma/hemorrhage</strong>.</p><p>Severe stress triggers the release of <strong>cortisol and catecholamines</strong> (primarily epinephrine and norepinephrine), which act on the liver to increase glycogenolysis and gluconeogenesis, an effect that can be enhanced by glucagon.&nbsp; The free glucose is then released from the liver into the blood.</p><p><strong>Mild glucose elevations</strong>, such as in this patient, are generally considered to be an adaptive physiologic response and <strong>do not warrant intervention</strong>.&nbsp; However, severe elevations (eg, &gt;180-200 mg/dL) are associated with increased mortality and should be corrected with <strong>short-acting insulin</strong> in most cases <strong>(Choice C)</strong>.&nbsp; A mildly elevated target glucose of 140-180 mg/dL (rather than normoglycemia) is recommended to minimize the risk of insulin-induced hypoglycemia.</p><p><strong>(Choice A)</strong>&nbsp; A calorie-restricted diet is not recommended for critically ill or injured patients, who typically have high metabolic requirements and complex care plans (eg, surgical interventions).</p><p><strong>(Choices B and D)</strong>&nbsp; Sulfonylureas (eg, glipizide) induce continued insulin secretion despite normalization of blood glucose, potentially leading to hypoglycemia.&nbsp; Metformin does not cause hypoglycemia but is not recommended for critically ill patients or those anticipating major surgery due to the risk of lactic acidosis.&nbsp; In general, oral antidiabetic agents are withheld in hospitalized patients until they are fully stabilized and on a predictable diet.</p><p><strong>Educational objective:</strong><br>Stress hyperglycemia is a transient elevation in blood glucose that occurs as a physiologic response to severe illness or injury.&nbsp; Mild elevations do not require treatment.&nbsp; Marked elevations (eg, &gt;180-200 mg/dL) are associated with increased mortality and should be corrected with short-acting insulin, with a target glucose of 140-180 mg/dL.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 106,
            "subject": "Surgery",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 211,
            "system": "Endocrine, Diabetes & Metabolism",
            "topicId": 2603,
            "topic": "Diabetes mellitus",
            "titleId": 2603,
            "title": "Diabetes mellitus",
            "topicAttributeId": 330582,
            "topicAttribute": "Diabetes mellitus",
            "correctAnswer": "5",
            "userAnswer": "3",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Calorie-restricted diet",
                    "choiceNumber": 1,
                    "correctTaken": 711,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Glipizide",
                    "choiceNumber": 2,
                    "correctTaken": 86,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Insulin",
                    "choiceNumber": 3,
                    "correctTaken": 1003,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Metformin",
                    "choiceNumber": 4,
                    "correctTaken": 333,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "No treatment",
                    "choiceNumber": 5,
                    "correctTaken": 14611,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": "216,223,true,-1,1*791,1081,true,-1,1*1238,1539,true,-1,1",
            "isCorrect": false,
            "isIncorrect": true,
            "isMarked": false,
            "isOmitted": false,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "526",
                    "mediaDataId": 0,
                    "title": "Noninsulin antihyperglycemic drugs in type 2 diabetes mellitus",
                    "referenceTypeId": 18,
                    "referenceLink": null,
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "24970271",
                    "mediaDataId": 0,
                    "title": "Metabolic response to the stress of critical illness.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/24970271",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 92,
            "othersAvgTimeSpent": 53,
            "notes": null,
            "peopleTaken": 16744,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 87,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 552,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 1,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 22,
            "questionId": 3123,
            "questionIndex": 3123,
            "questionText": "<p>A 5-month-old girl is brought to the emergency department following a generalized tonic-clonic seizure.&nbsp; The patient has been exclusively formula fed since birth, but over the last few days, she has not been feeding well and has been progressively less interactive.&nbsp; She was born at home at 39 weeks gestation, and the pregnancy and delivery were uncomplicated.&nbsp; The patient did not undergo newborn screening due to parental preferences.&nbsp; Her parents and 4-year-old sister are healthy.&nbsp; Weight and height are at the 40th percentile, and head circumference is at the 2nd percentile.&nbsp; Temperature is 37 C (98.6 F), pulse is 120/min, and respirations are 30/min.&nbsp; The patient is asleep but easily aroused.&nbsp; The anterior fontanelle is open, soft, and flat.&nbsp; There are no dysmorphic features.&nbsp; The abdomen is soft with no hepatosplenomegaly.&nbsp; Skin examination shows an eczematous rash.&nbsp; CT scan of the head reveals no acute findings and no microcalcifications.&nbsp; Laboratory results are as follows:</p><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\"><tbody><tr><td colspan=\"2\">Complete blood count</td></tr><tr><td style=\"padding-left: 2em;\">Hemoglobin</td><td>12.5 g/dL</td></tr><tr><td style=\"padding-left: 2em;\">Platelets</td><td>200,000/mm<font size=\"2\"><sup>3</sup></font></td></tr><tr><td style=\"padding-left: 2em;\">Leukocytes</td><td>12,900/mm<font size=\"2\"><sup>3</sup></font> (normal: 6,000-17,500)</td></tr><tr><td style=\"padding-left: 4em;\">Neutrophils</td><td>57%</td></tr><tr><td style=\"padding-left: 4em;\">Eosinophils</td><td>3%</td></tr><tr><td style=\"padding-left: 4em;\">Lymphocytes</td><td>33%</td></tr><tr><td style=\"padding-left: 4em;\">Monocytes</td><td>7%</td></tr><tr><td colspan=\"2\"></td></tr><tr><td colspan=\"2\">Serum chemistry</td></tr><tr><td style=\"padding-left: 2em;\">Sodium</td><td>137 mEq/L</td></tr><tr><td style=\"padding-left: 2em;\">Potassium</td><td>3.6 mEq/L</td></tr><tr><td style=\"padding-left: 2em;\">Chloride</td><td>102 mEq/L</td></tr><tr><td style=\"padding-left: 2em;\">Bicarbonate</td><td>22 mEq/L</td></tr><tr><td style=\"padding-left: 2em;\">Blood urea nitrogen</td><td>14 mg/dL</td></tr><tr><td style=\"padding-left: 2em;\">Creatinine</td><td>0.6 mg/dL</td></tr><tr><td style=\"padding-left: 2em;\">Glucose</td><td>110 mg/dL</td></tr></tbody></table><p>Which of the following is the most appropriate next step in diagnosis of this patient?</p>",
            "questionHeader": "",
            "explanationText": "<div id=\"div_T80868\"><table class=\"table-default-style\"><tbody><tr><td colspan=\"2\"><p align=\"center\"><strong>Phenylketonuria</strong></p></td></tr><tr><td><p align=\"center\"><strong>Pathophysiology</strong></p></td><td><ul><li>Autosomal recessive mutation in gene for phenylalanine hydroxylase</li><li>Impaired metabolism of phenylalanine to tyrosine &#8594; &#8593; phenylalanine causes neurologic injury</li></ul></td></tr><tr><td><p align=\"center\"><strong>Clinical features</strong></p></td><td><ul><li>Neurologic: microcephaly, developmental delay, seizures, severe intellectual disability</li><li>Nonneurologic: musty body odor, hypopigmentation (eg, skin, hair, eyes), eczema</li></ul></td></tr><tr><td><p align=\"center\"><strong>Diagnosis</strong></p></td><td><ul><li>&#8593; Phenylalanine levels:<ul style=\"list-style-type:circle;\"><li>Universal newborn screening</li><li>Serum amino acid analysis</li></ul></li></ul></td></tr><tr><td><p align=\"center\"><strong>Treatment</strong></p></td><td><ul><li>Phenylalanine-restricted diet (ie, avoidance of protein-rich foods)</li><li>Dietary/supplemental tyrosine</li></ul></td></tr><tr><td><p align=\"center\"><strong>Prognosis</strong></p></td><td><ul><li>Preventable disease manifestations with early treatment</li><li>Delayed diagnosis/treatment &#8594; irreversible neurologic injury</li></ul></td></tr></tbody></table></div><p>This patient has a new-onset <strong>seizure</strong>, which is commonly due to infectious, structural, or metabolic causes.&nbsp; This patient is afebrile with normal complete blood count and brain imaging, making an infectious or structural cause unlikely.&nbsp; A transiently disrupted metabolic process (eg, hypoglycemia, hyponatremia) is also unlikely given the normal electrolytes and glucose.&nbsp; However, her&nbsp;<strong>microcephaly</strong>&nbsp;(eg, head circumference at 2nd percentile) and <strong>lack of newborn screening</strong>&nbsp;raise concern for an <strong>inborn error of metabolism</strong> such as <strong>phenylketonuria</strong> (PKU).</p><p>PKU is a rare autosomal recessive disease in which <a href=\"63207\">phenylalanine hydroxylase deficiency</a> results in an inability to metabolize phenylalanine into tyrosine.&nbsp; Although small amounts of phenylalanine are necessary for growth and development (essential amino acid), <strong>excess phenylalanine</strong> is thought to disrupt normal neuronal development and increase oxidative stress in the brain, causing <strong>irreversible neurologic injury</strong> when untreated.&nbsp; Neurologic findings include microcephaly, seizures, and poor feeding.&nbsp; Other features include <strong>eczema</strong>&nbsp;(as seen in this patient), hypopigmentation, and a musty body odor.</p><p>Patients with PKU are asymptomatic at birth and usually identified via hyperphenylalaninemia (eg, on tandem mass spectrometry) on universal newborn screening, which tests for &gt;20 disorders (eg, metabolic disorders, HIV, cystic fibrosis).&nbsp; Prompt initiation of a phenylalanine-restricted diet (ie, avoiding protein-rich foods) prevents disease manifestations.&nbsp; In undiagnosed or untreated patients, like this girl, serum phenylalanine and its neurotoxic by-products <strong>accumulate</strong>&nbsp;(eg, over weeks to months) when dietary phenylalanine (eg, breast milk, formula) is introduced.&nbsp; Diagnosis in symptomatic patients is typically established via hyperphenylalaninemia on <strong>serum amino acid analysis</strong>.</p><p><strong>(Choice A)</strong>&nbsp; Flow cytometry for lymphocyte subsets can be used to diagnose severe combined immunodeficiency (SCID), which can cause neurologic findings due to CNS infection.&nbsp; However, this patient is afebrile, is easily arousable, and has a flat fontanelle, making infection unlikely.&nbsp; Moreover, patients with SCID typically have lymphopenia and poor growth in height/weight, findings not seen in this girl.</p><p><strong>(Choice B)</strong>&nbsp; Karyotype can be used to diagnose aneuploidies associated with microcephaly and seizures (eg, trisomy 13).&nbsp; This patient&#39;s lack of dysmorphic features makes a genetic syndrome unlikely.</p><p><strong>(Choice C)</strong>&nbsp; Rapid plasma reagin testing screens for congenital syphilis.&nbsp; Symptomatic patients typically have hepatomegaly and a maculopapular rash; neither is seen in this girl.&nbsp; Although CNS involvement can rarely occur, rapidly increasing head circumference with a bulging fontanelle would be expected.</p><p><strong>(Choice E)</strong>&nbsp; Patients with congenital hypothyroidism (normally diagnosed via newborn screening) may develop lethargy and poor feeding if untreated, but seizures would not be seen.&nbsp; Other expected findings include a wide fontanelle and macroglossia.</p><p><strong>Educational objective:</strong><br>Phenylketonuria is characterized by impaired phenylalanine metabolism, leading to the buildup of phenylalanine and its neurotoxic metabolites and irreversible neurologic injury (eg, seizures, microcephaly).&nbsp; Hyperphenylalaninemia via serum amino acid analysis is diagnostic.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 104,
            "subject": "Pediatrics",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 211,
            "system": "Endocrine, Diabetes & Metabolism",
            "topicId": 14660,
            "topic": "Phenylketonuria",
            "titleId": 14660,
            "title": "Phenylketonuria",
            "topicAttributeId": 330576,
            "topicAttribute": "Congenital and developmental anomalies",
            "correctAnswer": "4",
            "userAnswer": "1",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Flow cytometry for lymphocyte subsets",
                    "choiceNumber": 1,
                    "correctTaken": 1473,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Karyotype testing",
                    "choiceNumber": 2,
                    "correctTaken": 1675,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Rapid plasma reagin testing",
                    "choiceNumber": 3,
                    "correctTaken": 3038,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Serum amino acid analysis",
                    "choiceNumber": 4,
                    "correctTaken": 7003,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "TSH level",
                    "choiceNumber": 5,
                    "correctTaken": 3284,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": "102,128,true,-1,1*180,220,true,-1,1*417,494,true,-1,1*573,602,true,-1,1*1939,2120,true,-1,1*2390,2453,true,-1,1",
            "isCorrect": false,
            "isIncorrect": true,
            "isMarked": false,
            "isOmitted": false,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "24385074",
                    "mediaDataId": 0,
                    "title": "Phenylalanine hydroxylase deficiency: diagnosis and management guideline.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/24385074",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "23025760",
                    "mediaDataId": 0,
                    "title": "Universal screening for inherited metabolic diseases in the neonate (and the fetus).",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/23025760",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 143,
            "othersAvgTimeSpent": 112,
            "notes": null,
            "peopleTaken": 16473,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 43,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 2593,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 1,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 23,
            "questionId": 17775,
            "questionIndex": 19235,
            "questionText": "<p>A 45-year-old man comes to the office for follow-up.&nbsp; He was diagnosed with diabetes mellitus 5 years ago and has had good control during most of that time on a program of long-acting and sliding-scale short-acting insulin analogues.&nbsp; However, the patient was admitted to the hospital 6 months ago for a hypoglycemic seizure, and his home glucose readings have been over 200 mg/dL frequently since.&nbsp; Medical history is notable for chronic pancreatitis related to excessive alcohol use.&nbsp; Vital signs and physical examination are normal.&nbsp; Hemoglobin A1c is 8.6%; a year ago, it was 7.2%.&nbsp; When the physician asks about the reasons for the change in glycemic control, the patient says, &#x22;I&#39;m not sure, doctor.&nbsp; I feel pretty good right now.&#x22;&nbsp; Which of the following is the most appropriate statement for initiating a discussion with this patient?</p>",
            "questionHeader": "",
            "explanationText": "<div id=\"div_T60054\"><table class=\"table-default-style\"><tbody><tr><td colspan=\"2\"><p align=\"center\"><strong>Hypoglycemia in insulin therapy</strong></p></td></tr><tr><td><p align=\"center\"><strong>Risk factors</strong></p></td><td><ul><li>Long-standing type 1 diabetes</li><li>Pancreatogenic diabetes</li></ul></td></tr><tr><td><p align=\"center\"><strong>Manifestations</strong></p></td><td><ul><li>Mild to moderate (neurogenic symptoms): anxiety, tremor, palpitations, sweating</li><li>Severe (neuroglycopenic symptoms): confusion, seizure, loss of consciousness</li></ul></td></tr><tr><td><p align=\"center\"><strong>Management<br>strategies</strong></p></td><td><ul><li>Query patients regarding hypoglycemic symptoms</li><li>Individualized glycemic targets</li><li>Flexible insulin dosing regimen</li><li>Emergency glucagon kits</li></ul></td></tr></tbody></table></div><p>This patient had good glycemic control on a multidose insulin regimen but experienced loss of control after a severe episode of <strong>hypoglycemia</strong>.&nbsp; Patients with a diminished glucagon response, such as those with pancreatogenic diabetes (eg, chronic pancreatitis with fibrosis of the islets), can develop rapid and severe hypoglycemia with little warning.&nbsp; Such episodes can lead to confusion, seizure, and loss of consciousness and can be fatal.&nbsp; Even mild hypoglycemia can be <strong>distressing</strong> due to the associated autonomic activation, which can induce anxiety, tremor, palpitations, and sweating.</p><p>Frequent or severe hypoglycemia can encourage behavioral changes to prevent recurrence, such as <strong>increased caloric intake,</strong> leading to weight gain, or <strong>reduced adherence</strong> to insulin management.&nbsp; In light of this, it helps to ask patients in a nonjudgmental manner about <strong>behavioral changes</strong> (eg, reducing insulin dose) they might be making to avoid hypoglycemia.&nbsp; Management strategies include less-stringent glycemic targets, flexible insulin regimens, and prescription of emergency glucagon kits.</p><p><strong>(Choice A)</strong>&nbsp; Although heavy alcohol use can impair glycemic control, there are no other indicators of current alcohol intake in this patient, and the time course suggests overcompensation for hypoglycemia as the primary cause.&nbsp; Once the behavioral factors that can affect diabetes control are addressed, discussions regarding continuing care for alcohol use disorder could be considered, if appropriate.</p><p><strong>(Choice B)</strong>&nbsp; Although this patient&#39;s home readings and hemoglobin A1c suggest that tighter glycemic control is desirable, the reasons for loss of control should be better understood before any changes are made to his insulin regimen.</p><p><strong>(Choice D)</strong>&nbsp; The patient reports no anxiety or mood symptoms to warrant referral to a mental health professional.&nbsp; The physician should first attempt to understand the patient&#39;s reasons for loss of glycemic control and consider changes in diabetic management before making a referral to another provider.</p><p><strong>(Choice E)</strong>&nbsp; Insulin therapy can be cumbersome and painful to administer, leading to nonadherence.&nbsp; However, this patient&#39;s loss of control dates to his hospital stay for hypoglycemia.</p><p><strong>Educational objective:</strong><br>Severe hypoglycemia can cause confusion, seizure, loss of consciousness, and death.&nbsp; Even mild hypoglycemia can be distressing due to the associated autonomic activation (eg, anxiety, palpitations, sweating).&nbsp; Frequent or severe hypoglycemia can encourage behavioral changes to prevent recurrence, such as increased caloric intake or less rigorous insulin management, which may impair glycemic control.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 102,
            "subject": "Medicine",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 211,
            "system": "Endocrine, Diabetes & Metabolism",
            "topicId": 24827,
            "topic": "Physician patient communication",
            "titleId": 24827,
            "title": "Physician patient communication",
            "topicAttributeId": 330582,
            "topicAttribute": "Diabetes mellitus",
            "correctAnswer": "3",
            "userAnswer": "5",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "&#x22;Heavy alcohol use can cause high blood glucose.&nbsp; I am concerned that you might be drinking excessively again.&#x22;",
                    "choiceNumber": 1,
                    "correctTaken": 422,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "&#x22;It is normal for diabetes to worsen over time.&nbsp; Increasing your insulin dose should get your blood sugar back under control.&#x22;",
                    "choiceNumber": 2,
                    "correctTaken": 213,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "&#x22;Some people who have experienced frighteningly low blood glucose often reduce their insulin dose.&nbsp; Do you think this is happening with you?&#x22;",
                    "choiceNumber": 3,
                    "correctTaken": 13240,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "&#x22;The last 6 months must have been very stressful for you.&nbsp; It will probably help to talk to a counselor about your emotions.&#x22;",
                    "choiceNumber": 4,
                    "correctTaken": 186,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "&#x22;You have had good control with your insulin in the past.&nbsp; Is it becoming hard to give yourself a shot so frequently?&#x22;",
                    "choiceNumber": 5,
                    "correctTaken": 3543,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": "105,128,true,-1,1*598,810,true,-1,1*1406,1540,true,-1,1",
            "isCorrect": false,
            "isIncorrect": true,
            "isMarked": false,
            "isOmitted": false,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "527",
                    "mediaDataId": 0,
                    "title": "Insulin therapy in diabetes mellitus management",
                    "referenceTypeId": 18,
                    "referenceLink": null,
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "26439754",
                    "mediaDataId": 0,
                    "title": "Fear of hypoglycemia in adults with type 1 diabetes: impact of therapeutic advances and strategies for preventiona review.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/26439754",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "1582382",
                    "mediaDataId": 0,
                    "title": "Fear of hypoglycemia: relationship to physical and psychological symptoms in patients with insulin-dependent diabetes mellitus.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/1582382",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 99,
            "othersAvgTimeSpent": 59,
            "notes": null,
            "peopleTaken": 17604,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 75,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 1244,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 1,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 24,
            "questionId": 3600,
            "questionIndex": 3600,
            "questionText": "<p>A week-old boy is brought to the emergency department due to vomiting and poor feeding.&nbsp; His mother received appropriate prenatal care, and the full-term infant was delivered at home.&nbsp; Temperature is 36.7 C (98 F), blood pressure is 40/24 mm Hg, pulse is 164/min, and respirations are 46/min.&nbsp; Physical examination is notable for sunken eyes, a depressed anterior fontanelle, and dry mucous membranes.&nbsp; Capillary refill is 3 seconds, and skin turgor is decreased.&nbsp; No abdominal masses are noted.&nbsp; Genital examination shows a normal uncircumcised penis with bilateral testes palpable in the scrotum.&nbsp; Laboratory results are as follows:</p><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\"><tbody><tr><td colspan=\"2\">Serum chemistry</td></tr><tr><td>&nbsp;&nbsp;&nbsp;&nbsp;Sodium</td><td>128 mEq/L</td></tr><tr><td>&nbsp;&nbsp;&nbsp;&nbsp;Potassium</td><td>5.8 mEq/L</td></tr><tr><td>&nbsp;&nbsp;&nbsp;&nbsp;Blood urea nitrogen</td><td>25 mg/dL</td></tr><tr><td>&nbsp;&nbsp;&nbsp;&nbsp;Creatinine</td><td>0.7 mg/dL</td></tr></tbody></table><p>Which of the following is most likely to be increased in this patient?</p>",
            "questionHeader": "",
            "explanationText": "<p><img draggable=\"false\" id=\"678\" src=\"https://www.uworld.com/media/L11357.png\" ></p><p>This infant has classic <strong>congenital adrenal hyperplasia</strong> (CAH) caused by <strong>21-hydroxylase deficiency</strong>, which results in:</p><ul><li><p>Inhibited conversion of progesterone to 11-deoxycorticosterone, a precursor to aldosterone:&nbsp; Decreased aldosterone causes <strong>dehydration</strong> (eg, sunken fontanelle, dry mucosa) and <strong>salt-wasting</strong> (eg, hypotension, hyponatremia, hyperkalemia) <strong>(Choices A and C)</strong>.</p></li><li><p>Inhibited conversion of 17-hydroxyprogesterone to 11-deoxycortisol, a precursor to cortisol:&nbsp; Decreased cortisol results in fasting hypoglycemia <strong>(Choice D)</strong>.</p></li><li><p>Increased conversion of 17-hydroxyprogesterone to androstenedione, a precursor to testosterone:&nbsp; Increased testosterone causes <strong>virilization</strong> and ambiguous genitalia in female infants.&nbsp; Male infants typically have no abnormal newborn genital findings, although they may have an enlarged penis or scrotal hyperpigmentation.</p></li></ul><p>Newborn screening allows early detection of classic CAH, and a significantly <strong>elevated 17-hydroxyprogesterone</strong> level confirms the diagnosis.&nbsp; Treatment involves glucocorticoid and mineralocorticoid replacement.</p><p><strong>(Choice E)</strong>&nbsp; LH is decreased in patients with classic CAH as elevated testosterone provides negative feedback to the hypothalamic-pituitary axis and inhibits LH secretion.</p><p><strong>Educational objective:</strong><br>Deficiency of 21-hydroxylase is the most common cause of congenital adrenal hyperplasia and classically presents with dehydration, salt-wasting, and virilization.&nbsp; Elevated 17-hydroxyprogesterone levels are diagnostic.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 104,
            "subject": "Pediatrics",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 211,
            "system": "Endocrine, Diabetes & Metabolism",
            "topicId": 10495,
            "topic": "Congenital adrenal hyperplasia",
            "titleId": 10495,
            "title": "Congenital adrenal hyperplasia",
            "topicAttributeId": 330576,
            "topicAttribute": "Congenital and developmental anomalies",
            "correctAnswer": "2",
            "userAnswer": "1",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "11-deoxycorticosterone",
                    "choiceNumber": 1,
                    "correctTaken": 217,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "17-hydroxyprogesterone",
                    "choiceNumber": 2,
                    "correctTaken": 910,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Aldosterone",
                    "choiceNumber": 3,
                    "correctTaken": 254,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Cortisol",
                    "choiceNumber": 4,
                    "correctTaken": 101,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Luteinizing hormone",
                    "choiceNumber": 5,
                    "correctTaken": 17,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": "242,382,true,-1,1*496,548,true,-1,1*656,880,true,-1,1",
            "isCorrect": false,
            "isIncorrect": true,
            "isMarked": false,
            "isOmitted": false,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "571",
                    "mediaDataId": 0,
                    "title": "Congenital adrenal hyperplasia",
                    "referenceTypeId": 18,
                    "referenceLink": null,
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "23624029",
                    "mediaDataId": 0,
                    "title": "Diagnosis and management of classical congenital adrenal hyperplasia.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/23624029",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 76,
            "othersAvgTimeSpent": 88,
            "notes": null,
            "peopleTaken": 1499,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 61,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 1407,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 1,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 25,
            "questionId": 11342,
            "questionIndex": 12495,
            "questionText": "<p>A 16-year-old girl is brought to the clinic for evaluation of fatigue.&nbsp; The symptoms began about 6 months ago.&nbsp; She has had no fever, cough, vomiting, diarrhea, weight loss, or depressed mood.&nbsp; The patient is doing well in school.&nbsp; She also reports intermittent pain in her arms and legs over the past 2 years.&nbsp; The patient has no significant medical history and takes no medications.&nbsp; She was adopted at age 3, and her family history is unknown.&nbsp; Height and weight are at the 5th percentile for age.&nbsp; Temperature is 36.7 C (98.1 F), blood pressure is 110/70 mm Hg, pulse is 78/min, and respirations are 14/min.&nbsp; There is no nasal congestion, and the oropharynx appears normal.&nbsp; Cardiac examination shows normal S1 and S2 without murmurs.&nbsp; The lungs are clear without wheezing or crackles.&nbsp; The abdomen is soft and nontender.&nbsp; The liver is palpable 4 cm below the right costal margin, and the spleen is palpable 10 cm below the left costal margin.&nbsp; Skin examination shows no rashes or jaundice.&nbsp; Lymph nodes appear unremarkable.&nbsp; Pubic hair and breast development are consistent with Tanner stage 1.&nbsp; Laboratory results are as follows:</p><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\"><tbody><tr><td colspan=\"2\" style=\"vertical-align:middle;\">Complete blood count</td></tr><tr><td style=\"vertical-align:middle;\">&nbsp;&nbsp;&nbsp;&nbsp;Hemoglobin</td><td style=\"vertical-align:middle;\">8.6 g/dL</td></tr><tr><td style=\"vertical-align:middle;\">&nbsp;&nbsp;&nbsp;&nbsp;Platelets</td><td style=\"vertical-align:middle;\">78,000/mm<font size=\"2\"><sup>3</sup></font></td></tr><tr><td style=\"vertical-align:middle;\">&nbsp;&nbsp;&nbsp;&nbsp;Leukocytes</td><td style=\"vertical-align:middle;\">8,200/mm<font size=\"2\"><sup>3</sup></font></td></tr></tbody></table><p>Which of the following is the most likely diagnosis in this patient?</p>",
            "questionHeader": "",
            "explanationText": "<div id=\"div_t31630\"><table class=\"table-default-style table-header-footer-style\" style=\"width:74.28%\"><tbody><tr><td colspan=\"2\" style=\"width:100.0%;\"><p align=\"center\"><strong>Gaucher disease</strong></p></td></tr><tr><td style=\"width:21.52%;\"><p align=\"center\"><strong>Etiology</strong></p></td><td style=\"width:78.48%;\"><ul><li>Autosomal recessive, &uarr;&nbsp;prevalence in Ashkenazi Jews</li><li>Glucocerebrosidase deficiency &rarr; glucocerebroside accumulation in macrophages</li></ul></td></tr><tr><td style=\"width:21.52%;\"><p align=\"center\"><strong>Clinical<br />features</strong></p></td><td style=\"width:78.48%;\"><ul><li>Can present at any age</li><li>Visceral organ involvement: splenomegaly (severe), hepatomegaly</li><li>Bone/bone marrow infiltration<ul style=\"list-style-type:circle;\"><li>Anemia, thrombocytopenia</li><li>Bone pain</li></ul></li><li>Failure to thrive, delayed puberty</li></ul></td></tr><tr><td style=\"width:21.52%;\"><p align=\"center\"><strong>Management</strong></p></td><td style=\"width:78.48%;\"><ul><li>Enzyme replacement</li></ul></td></tr><tr><td colspan=\"2\" style=\"width:21.52%;\"></td></tr></tbody></table></div><p>This patient&#39;s presentation is most consistent with <strong>Gaucher disease</strong>, the most common lysosomal storage disease.&nbsp; In Gaucher disease, glucocerebrosidase deficiency results in the <strong>accumulation of glucocerebroside</strong> in lipid-laden <strong>macrophages</strong> of <strong>different tissues</strong>.&nbsp; The range of presenting manifestations can be broad due to varied organ involvement:</p><ul><li><p><strong>Bone marrow</strong> infiltration results in <strong>thrombocytopenia</strong> and <strong>anemia</strong>, which is likely the cause of this patient&#39;s chronic fatigue.&nbsp; Leukopenia may also be present.</p></li><li><p>Visceral organ involvement leads to <strong>splenomegaly</strong>, which is typically more prominent than <strong>hepatomegaly</strong>.&nbsp; Blood cell destruction due to splenic enlargement can also contribute to cytopenias.</p></li><li><p>Skeletal involvement causes diffuse <strong>bony pain</strong> and may result in joint collapse or pathologic fractures.</p></li><li><p><strong>Delayed puberty</strong> (eg, absence of breast development by age 13) and <strong>poor growth</strong> (eg, &#8804;5th percentile for height and weight) are common findings in children.</p></li></ul><p>A high degree of suspicion for the diagnosis must be maintained both because of the varied manifestations and because onset may occur from <strong>infancy through adulthood</strong>.</p><p><strong>(Choice A)</strong>&nbsp; Anorexia nervosa should be considered in an adolescent with low weight, delayed puberty, and fatigue; anemia can also occur over time due to nutritional deficiencies.&nbsp; However, hepatosplenomegaly is inconsistent with this diagnosis.</p><p><strong>(Choice B)</strong>&nbsp; Fanconi anemia (inherited bone marrow failure due to defective DNA repair) causes short stature and anemia.&nbsp; In contrast to Gaucher disease, pancytopenia is common (ie, decreased leukocytes would be expected), and severe splenomegaly is atypical.&nbsp; Moreover, diagnosis is typically in early childhood due to associated congenital malformations (eg, hypoplastic thumbs) and developmental delays.</p><p><strong>(Choice D)</strong>&nbsp; Parvovirus infection can cause fatigue, joint pain, and cytopenias (from transient viral-induced bone marrow suppression); aplastic crisis can also occur in patients with an underlying hemolytic disorder (eg, sickle cell disease).&nbsp; However, these symptoms are typically acute and self-limited, unlike this patient&#39;s chronic symptoms.&nbsp; In addition, poor growth and pubertal delay raise concern for a systemic disorder, making parvovirus unlikely.</p><p><strong>(Choice E)</strong>&nbsp; Turner syndrome (XO genotype) can present as short stature and pubertal delay in girls.&nbsp; However, this patient&#39;s bone pain, hepatosplenomegaly, and cytopenias are not seen in this condition.</p><p><strong>Educational objective:</strong><br>Gaucher disease is a lysosomal storage disease that can present from infancy to adulthood and is due to glucocerebroside accumulation in macrophages of the bones, liver, and spleen.&nbsp; This accumulation results in cytopenias, bone pain, and hepatosplenomegaly.&nbsp; Poor growth and pubertal delay are other common findings in children.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 104,
            "subject": "Pediatrics",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 211,
            "system": "Endocrine, Diabetes & Metabolism",
            "topicId": 20352,
            "topic": "Gauchers Disease",
            "titleId": 20352,
            "title": "Gauchers Disease",
            "topicAttributeId": 330576,
            "topicAttribute": "Congenital and developmental anomalies",
            "correctAnswer": "3",
            "userAnswer": "2",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Anorexia nervosa",
                    "choiceNumber": 1,
                    "correctTaken": 803,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Fanconi anemia",
                    "choiceNumber": 2,
                    "correctTaken": 3907,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Gaucher disease",
                    "choiceNumber": 3,
                    "correctTaken": 5808,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Parvovirus infection",
                    "choiceNumber": 4,
                    "correctTaken": 604,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Turner syndrome",
                    "choiceNumber": 5,
                    "correctTaken": 2811,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": "139,183,true,-1,1*225,353,true,-1,1*354,388,true,-1,1*1242,1282,true,-1,1*1800,2193,true,-1,1",
            "isCorrect": false,
            "isIncorrect": true,
            "isMarked": true,
            "isOmitted": false,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "909",
                    "mediaDataId": 0,
                    "title": "Prenatal genetic testing",
                    "referenceTypeId": 18,
                    "referenceLink": null,
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "33759681",
                    "mediaDataId": 0,
                    "title": "Hematological manifestations and complications of Gaucher disease.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/33759681",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 108,
            "othersAvgTimeSpent": 82,
            "notes": null,
            "peopleTaken": 13933,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 42,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 1773,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 1,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 26,
            "questionId": 4514,
            "questionIndex": 4514,
            "questionText": "<p>A 12-year-old girl is brought to the emergency department by her parents for assessment of confusion and rapid breathing.&nbsp; Three days ago the patient developed rhinorrhea, cough, and fever, which have since resolved.&nbsp; The parents say that over the past 48 hours the patient has had increased urination, abdominal pain, and fatigue progressing to somnolence.&nbsp; On arrival, the patient&#39;s temperature is 36.7 C (98 F), blood pressure is 110/70 mm Hg, pulse is 138/min, respirations are 36/min, and pulse oximetry is 99% on room air.&nbsp; On physical examination, she is ill-appearing with tachypnea, subcostal retractions, and dry mucous membranes.&nbsp; There is diffuse abdominal tenderness without rebound.&nbsp; Laboratory results are as follows:</p><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\"><tbody><tr><td colspan=\"2\">Complete blood count</td></tr><tr><td>&nbsp;&nbsp;&nbsp;&nbsp;Hematocrit</td><td>42%</td></tr><tr><td>&nbsp;&nbsp;&nbsp;&nbsp;Leukocytes</td><td>13,000/mm<font size=\"2\"><sup>3</sup></font></td></tr><tr><td colspan=\"2\" height=\"15\"></td></tr><tr><td colspan=\"2\">Serum chemistry</td></tr><tr><td>&nbsp;&nbsp;&nbsp;&nbsp;Sodium</td><td>129 mEq/L</td></tr><tr><td>&nbsp;&nbsp;&nbsp;&nbsp;Potassium</td><td>4.8 mEq/L</td></tr><tr><td>&nbsp;&nbsp;&nbsp;&nbsp;Chloride</td><td>98 mEq/L</td></tr><tr><td>&nbsp;&nbsp;&nbsp;&nbsp;Bicarbonate</td><td>9 mEq/L</td></tr><tr><td>&nbsp;&nbsp;&nbsp;&nbsp;Blood urea nitrogen</td><td>24 mg/dL</td></tr><tr><td>&nbsp;&nbsp;&nbsp;&nbsp;Creatinine</td><td>1.2 mg/dL</td></tr><tr><td>&nbsp;&nbsp;&nbsp;&nbsp;Glucose</td><td>450 mg/dL</td></tr></tbody></table><p>Which of the following is most likely decreased in this patient?</p>",
            "questionHeader": "",
            "explanationText": "<div id=\"div_t39741\"><table class=\"table-default-style\"><tbody><tr><td colspan=\"2\"><p align=\"center\"><strong>Diabetic ketoacidosis in children </strong></p></td></tr><tr><td><p align=\"center\"><strong>Clinical features </strong></p></td><td><ul><li>Polyuria/nocturia</li><li>Polydipsia, polyphagia</li><li>Vomiting, abdominal pain</li><li>Weight loss, fatigue</li><li>Kussmaul respirations (deep, rapid breathing)</li><li>Dehydration</li></ul></td></tr><tr><td><p align=\"center\"><strong>Laboratory findings </strong></p></td><td><ul><li>Glucose &gt;200 mg/dL</li><li>Bicarbonate &lt;15 mEq/L</li><li>pH &lt;7.3</li><li>Anion gap &gt;14</li><li>Serum/urine ketones</li></ul></td></tr><tr><td><p align=\"center\"><strong>Management </strong></p></td><td><ul><li>10 mL/kg isotonic fluid bolus over 1 hour</li><li>Insulin infusion + isotonic fluids with potassium</li></ul></td></tr><tr><td><p align=\"center\"><strong>Complications </strong></p></td><td><ul><li>Cerebral edema</li></ul></td></tr></tbody></table></div><p>This patient with <strong>hyperglycemia</strong> and an <strong>anion gap metabolic acidosis</strong> has <strong>diabetic ketoacidosis</strong> (DKA), likely due to undiagnosed type 1 diabetes mellitus.&nbsp; <strong>Infection</strong>&nbsp;(eg, upper respiratory infection with fever, cough, and rhinorrhea in this patient)&nbsp;frequently precipitates DKA due to increased catecholamine, cortisol, and glucagon release.&nbsp; Presenting symptoms typically include <strong>polyuria</strong>, polydipsia, <strong>abdominal pain</strong>, and fatigue.&nbsp; On examination, patients are often <strong>dehydrated</strong> and breathing rapidly (ie, Kussmaul respirations) to compensate for the metabolic acidosis.</p><p>During DKA, serum glucose exceeds the threshold for reabsorption by the kidneys, resulting in glucosuria and an osmotic diuresis.&nbsp; This diuresis is accompanied by a net renal loss of potassium with <strong>depletion of total body potassium stores</strong>.&nbsp; However, serum potassium levels may be normal (as seen in this patient) or elevated because acidemia and decreased insulin activity cause a <a href=\"1487\">potassium shift</a> to the extracellular fluid compartment.</p><p>Treatment involves gradual fluid repletion and insulin administration.&nbsp; Insulin promotes potassium redistribution to the intracellular fluid compartment.&nbsp; Therefore, intravenous fluids are supplemented with potassium to prevent hypokalemia.</p><p><strong>(Choice A)</strong>&nbsp; Osmotic diuresis associated with DKA causes a reduction in effective circulating blood volume, which activates the renin-angiotensin-aldosterone system.&nbsp; Blood urea nitrogen and creatinine are often acutely elevated due to hypovolemia, as seen in this patient.</p><p><strong>(Choice B)</strong>&nbsp; DKA is characterized by an increase in circulating free fatty acids due to an underlying relative excess of glucagon to insulin and consequent increase in lipolysis.</p><p><strong>(Choice C)</strong>&nbsp; Hyperglycemia in DKA contributes not only to osmotic diuresis and hypovolemia but also to serum hyperosmolality.&nbsp; These effects generally promote pituitary vasopressin release.</p><p><strong>(Choice D)</strong>&nbsp; Hepatic gluconeogenesis increases in DKA due to increased circulating glucagon, catecholamines, and cortisol.</p><p><strong>(Choice F)</strong>&nbsp; Hyperglycemia in DKA causes an osmotic diuresis with increased urinary excretion of glucose, ketones, sodium, potassium, and phosphate.</p><p><strong>Educational objective:</strong><br>Diabetic ketoacidosis (DKA) presents with polyuria, abdominal pain, and fatigue and is often precipitated by infection.&nbsp; Laboratory results demonstrate hyperglycemia and an anion gap metabolic acidosis.&nbsp; DKA is characterized by an osmotic diuresis that reduces total body potassium even though serum potassium may be normal or elevated.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 104,
            "subject": "Pediatrics",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 211,
            "system": "Endocrine, Diabetes & Metabolism",
            "topicId": 6575,
            "topic": "Diabetic ketoacidosis",
            "titleId": 6575,
            "title": "Diabetic ketoacidosis",
            "topicAttributeId": 330582,
            "topicAttribute": "Diabetes mellitus",
            "correctAnswer": "5",
            "userAnswer": "5",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Blood renin activity",
                    "choiceNumber": 1,
                    "correctTaken": 713,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Circulating free fatty acids",
                    "choiceNumber": 2,
                    "correctTaken": 1265,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Hypothalamic vasopressin production",
                    "choiceNumber": 3,
                    "correctTaken": 1098,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Liver glucose production",
                    "choiceNumber": 4,
                    "correctTaken": 1945,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Total body potassium",
                    "choiceNumber": 5,
                    "correctTaken": 10506,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Urine solute excretion",
                    "choiceNumber": 6,
                    "correctTaken": 1170,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": "250,312,true,-1,1*345,386,true,-1,1*452,466,true,-1,1*2540,2623,true,-1,1",
            "isCorrect": true,
            "isIncorrect": false,
            "isMarked": false,
            "isOmitted": false,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "521",
                    "mediaDataId": 0,
                    "title": "Diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic state (HHS)",
                    "referenceTypeId": 18,
                    "referenceLink": null,
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "25092935",
                    "mediaDataId": 0,
                    "title": "Improving care for pediatric diabetic ketoacidosis.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/25092935",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 58,
            "othersAvgTimeSpent": 85,
            "notes": null,
            "peopleTaken": 16697,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 63,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 627,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 1,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 27,
            "questionId": 11214,
            "questionIndex": 12366,
            "questionText": "<p>A 52-year-old woman comes to the office for follow-up of type 2 diabetes mellitus.&nbsp; The patient has had diabetes for 10 years, and it is currently managed with metformin, canagliflozin, dulaglutide, and insulin glargine.&nbsp; Home morning fasting blood glucose levels have ranged between 85 and 115 mg/dL over the past 3 months.&nbsp; Blood pressure is 128/72 mm Hg and pulse is 79/min.&nbsp; BMI is 41 kg/m<font size=\"2\"><sup>2</sup></font>.&nbsp; Laboratory results are normal except for a hemoglobin A1c of 8.1% and a nonfasting glucose of 290 mg/dL.&nbsp; Which of the following best explains the suboptimal glycemic control in this patient?</p>",
            "questionHeader": "",
            "explanationText": "<p><img  draggable=\"false\" id=\"8312\" src=\"https://www.uworld.com/media/highresdefault/L32107.jpg\"  ></p><p><strong>Hemoglobin A1c</strong> reflects <strong>average</strong> glucose levels over the life-span of hemoglobin (about 3 months) and should be &#8804;7% for most patients with type 2 diabetes mellitus.</p><p>Hemoglobin A1c is influenced by both fasting and postprandial glucose concentrations.&nbsp; This patient&#39;s hemoglobin A1c is <strong>elevated despite an acceptable morning fasting glucose</strong> (target range: 80-130 mg/dL).&nbsp; She also has a markedly elevated <strong>nonfasting glucose</strong> (290 mg/dL).&nbsp; Therefore, this patient likely has frequent <strong>postprandial hyperglycemia,</strong> leading to impaired overall glycemic control.</p><p>Management requires better control of postprandial hyperglycemia without inducing fasting hypoglycemia.&nbsp; This goal can generally be achieved through a basal-bolus insulin regimen:</p><ul><li><p><strong>Basal insulin</strong> (ie, insulin glargine) supplies a steady influx of insulin (ie, without a true peak), which maintains <strong>fasting</strong> glucose control through suppression of hepatic gluconeogenesis.</p></li><li><p><strong>Rapid-acting insulin</strong> (eg, insulin aspart) is typically given just before meals; it peaks within 15-30 minutes and controls <strong>postprandial hyperglycemia</strong>.</p></li></ul><p>This patient&#39;s already controlled fasting glucose (eg, 85-115 mg/dL) suggests adequate basal insulin coverage.&nbsp; To adequately treat her postprandial hyperglycemia, rapid-acting insulin should be added <strong>(Choice B)</strong>.</p><p><strong>(Choice A)</strong>&nbsp; The dawn phenomenon causes early-morning (2-8 AM) fasting hyperglycemia due to the circadian increase in growth hormone and cortisol secretion; in many patients, it can be managed by increasing the basal insulin dose.&nbsp; This patient&#39;s suboptimal glycemic control results from inadequate postprandial control rather than early-morning hyperglycemia (ie, her fasting glucose taken in the morning is within normal levels).</p><p><strong>(Choice C)</strong>&nbsp; Insulin-neutralizing antibodies against exogenous insulin may be suspected when a patient has&nbsp; fasting and nonfasting hyperglycemia despite very high insulin doses; however, this patient&#39;s fasting glucose is adequately controlled with basal insulin.&nbsp; In general, insulin-neutralizing antibodies are rare when a recombinant insulin analogue (eg, glargine) is used but was more common in the past with bovine and porcine insulin.</p><p><strong>Educational objective:</strong><br>Patients with diabetes mellitus who have an elevated hemoglobin A1c despite normal fasting glucose levels may have postprandial hyperglycemia.&nbsp; A combined regimen, including a long-acting basal insulin (to control fasting glucose) and a rapid-acting premeal insulin (to control postprandial glucose), can improve glycemic control.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 102,
            "subject": "Medicine",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 211,
            "system": "Endocrine, Diabetes & Metabolism",
            "topicId": 2603,
            "topic": "Diabetes mellitus",
            "titleId": 2603,
            "title": "Diabetes mellitus",
            "topicAttributeId": 330582,
            "topicAttribute": "Diabetes mellitus",
            "correctAnswer": "4",
            "userAnswer": "4",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Dawn phenomenon",
                    "choiceNumber": 1,
                    "correctTaken": 1715,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Inadequate basal insulin coverage",
                    "choiceNumber": 2,
                    "correctTaken": 3512,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Insulin-neutralizing antibodies",
                    "choiceNumber": 3,
                    "correctTaken": 912,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Postprandial hyperglycemia",
                    "choiceNumber": 4,
                    "correctTaken": 7599,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": null,
            "isCorrect": true,
            "isIncorrect": false,
            "isMarked": false,
            "isOmitted": false,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "527",
                    "mediaDataId": 0,
                    "title": "Insulin therapy in diabetes mellitus management",
                    "referenceTypeId": 18,
                    "referenceLink": null,
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "26928912",
                    "mediaDataId": 0,
                    "title": "Diagnosis and management of diabetes: synopsis of the 2016 American Diabetes Association standards of medical care in diabetes.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/26928912",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 70,
            "othersAvgTimeSpent": 52,
            "notes": null,
            "peopleTaken": 13738,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 55,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 588,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 1,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 28,
            "questionId": 2190,
            "questionIndex": 2190,
            "questionText": "<p>A 60-year-old man comes to the office due to edema of his face and ankles for the past 2 weeks.&nbsp; He has had no chest pain or breathlessness.&nbsp; The patient has a 15-year history of type 2 diabetes mellitus, which is currently managed with exercise, dietary modification, and oral medications.&nbsp; A month ago, his hemoglobin A1c was 6.9%.&nbsp; Temperature is 37 C (98.6 F), blood pressure is 146/87 mm Hg, pulse is 75/min, and respirations are 15/min.&nbsp; Physical examination shows periorbital edema and bilateral pitting edema around the ankles.&nbsp; The remainder of the examination is normal.&nbsp; Laboratory results are as follows:</p><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\"><tbody><tr><td style=\"vertical-align:middle;\">Serum chemistry</td><td style=\"vertical-align:middle;\"></td></tr><tr><td style=\"vertical-align:middle;\">&nbsp;&nbsp;&nbsp; Sodium</td><td style=\"vertical-align:middle;\">140 mEq/L</td></tr><tr><td style=\"vertical-align:middle;\">&nbsp;&nbsp;&nbsp; Potassium</td><td style=\"vertical-align:middle;\">4.3 mEq/L</td></tr><tr><td style=\"vertical-align:middle;\">&nbsp;&nbsp;&nbsp; Bicarbonate</td><td style=\"vertical-align:middle;\">20 mEq/L</td></tr><tr><td style=\"vertical-align:middle;\">&nbsp;&nbsp;&nbsp; Blood glucose</td><td style=\"vertical-align:middle;\">120 mg/dL</td></tr><tr><td style=\"vertical-align:middle;\">&nbsp;&nbsp;&nbsp; Blood urea nitrogen</td><td style=\"vertical-align:middle;\">37 mg/dL</td></tr><tr><td style=\"vertical-align:middle;\">&nbsp;&nbsp;&nbsp; Creatinine</td><td style=\"vertical-align:middle;\">2.4 mg/dL</td></tr><tr><td style=\"vertical-align:middle;\">&nbsp;&nbsp;&nbsp; Total cholesterol</td><td style=\"vertical-align:middle;\">300 mg/dL</td></tr></tbody></table><p>ECG is normal.&nbsp; Urine protein is 3,700 mg/24 hr.&nbsp; Estimated glomerular filtration rate is 28 mL/min/1.73 m<font size=\"2\"><sup>2</sup></font>.&nbsp; Which of the following measures would have the greatest impact in slowing the progression of this patient&#39;s kidney disease?</p>",
            "questionHeader": "",
            "explanationText": "<div id=\"div_T80538\"><table class=\"table-default-style table-header-footer-style\"><tbody><tr><td colspan=\"2\"><p align=\"center\"><strong>Diabetic kidney disease</strong></p></td></tr><tr><td><p align=\"center\"><strong>Clinical findings</strong></p></td><td><ul><li>Persistent albuminuria (&gt;3 months apart)</li><li>Initial hyperfiltration followed by progressive decline in GFR</li><li>Hypertension usually present</li></ul></td></tr><tr><td><p align=\"center\"><strong>Evaluation</strong></p></td><td><ul><li>Screen at the time of diagnosis in type 2 DM</li><li>Screen 5 years after the diagnosis in type 1 DM</li><li>Serum creatinine</li><li>Urine spot albumin to creatinine ratio (or 24-hour urine protein)</li><li>Urinalysis/urine microscopy (to exclude other causes)</li></ul></td></tr><tr><td><p align=\"center\"><strong>Management/prevention</strong></p></td><td><ul><li>Intensive glycemic control<ul style=\"list-style-type:circle;\"><li>Target hemoglobin A1c &#8804;7% (for most patients)</li><li>SGLT2 inhibitor preferred; GLP-1 agonist</li></ul></li><li>Blood pressure control<ul style=\"list-style-type:circle;\"><li>Target blood pressure &lt;130/80 mm Hg</li><li>ACE inhibitor preferred (or angiotensin II receptor blocker)</li></ul></li><li>General cardiovascular risk management<ul style=\"list-style-type:circle;\"><li>Smoking cessation</li><li>Lipid management</li></ul></li></ul></td></tr><tr><td colspan=\"2\"><p><strong>DM</strong> = diabetes mellitus; <strong>GFR</strong> = glomerular filtration rate; <strong>GLP-1</strong> = glucagon-like peptide-1; <strong>SGLT2</strong> = sodium-glucose cotransporter-2.</p></td></tr></tbody></table></div><p>This patient has long-standing type 2 diabetes mellitus complicated by significant <strong>diabetic kidney disease (DKD)</strong>.&nbsp; Initially, DKD is characterized by <a href=\"2229\">hyperfiltration</a> (ie, increased glomerular filtration rate [GFR]); however, as the disease progresses, GFR decreases, manifesting as a rising serum creatinine level.&nbsp; Concurrently, glomerular protein losses lead to moderately increased albuminuria (urine protein excretion 30-300 mg/24 hr; previously termed microalbuminuria) and eventually severely increased albuminuria (&gt;300 mg/24 hr).&nbsp; As in this patient, advanced DKD can present with frank proteinuria and nephrotic syndrome.</p><p>In patients with type 2 diabetes, <strong>intensive blood pressure control</strong> is associated with reduced progression of DKD; a blood pressure (BP) target of &lt;130/80 mm Hg is recommended for most patients.&nbsp; <a href=\"51622\">ACE inhibitors or angiotensin II receptor blockers</a> are the preferred antihypertensive drugs; these agents lower systemic and intraglomerular pressures, which may be renoprotective.</p><p><strong>(Choices A and B)</strong>&nbsp; Intensive lipid control with statins can reduce the risk for coronary heart disease; however, lipid-lowering therapy has not clearly been shown to reduce the progression of nephropathy.&nbsp; Low-dose aspirin also may reduce the incidence of cardiovascular events but would not slow the progression of nephropathy.</p><p><strong>(Choice D)</strong>&nbsp; Intensive glycemic management to a target hemoglobin A1c &lt;7% can slow the progression of DKD; however, this patient has good overall glycemic control (A1c of 6.9%), and further lowering is associated with an increased risk for hypoglycemia and may actually increase the risk for cardiac events.&nbsp; Although sodium-glucose cotransporter 2 inhibitors also reduce the risk of DKD progression in patients with type 2 diabetes, these drugs are more effective when used in patients with an estimated GFR of &#8805;30 mL/min/1.73 m<font size=\"2\"><sup>2</sup></font>.</p><p><strong>(Choice E)</strong>&nbsp; A moderate restriction in protein intake (eg, &lt;1 g/kg/day) in patients with type 2 diabetes may slow the progression of DKD, but the benefits are small.&nbsp; Very low protein intake is not advised because patients with diabetes often have some degree of protein wasting at baseline and additional, complex dietary requirements.</p><p><strong>Educational objective:</strong><br>Strict blood pressure control, particularly using ACE inhibitors or angiotensin II receptor blockers, can reduce the progression of diabetic kidney disease (DKD).&nbsp; Tight glycemic control with a target hemoglobin A1c &lt;7% also can prevent progression of DKD; further lowering is associated with an increased risk of hypoglycemia and possibly cardiac events.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 102,
            "subject": "Medicine",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 211,
            "system": "Endocrine, Diabetes & Metabolism",
            "topicId": 6433,
            "topic": "Diabetic kidney disease",
            "titleId": 6433,
            "title": "Diabetic kidney disease",
            "topicAttributeId": 330582,
            "topicAttribute": "Diabetes mellitus",
            "correctAnswer": "3",
            "userAnswer": "3",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Aggressive lipid management",
                    "choiceNumber": 1,
                    "correctTaken": 1117,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Aspirin therapy",
                    "choiceNumber": 2,
                    "correctTaken": 145,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Intensive blood pressure control",
                    "choiceNumber": 3,
                    "correctTaken": 8612,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Intensive glycemic control with insulin",
                    "choiceNumber": 4,
                    "correctTaken": 3108,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Very low-protein diet",
                    "choiceNumber": 5,
                    "correctTaken": 713,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": "72,112,true,-1,1*216,308,true,-1,1*2560,2773,true,-1,1",
            "isCorrect": true,
            "isIncorrect": false,
            "isMarked": false,
            "isOmitted": false,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "464",
                    "mediaDataId": 0,
                    "title": "Diabetic kidney disease",
                    "referenceTypeId": 18,
                    "referenceLink": null,
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "24780456",
                    "mediaDataId": 0,
                    "title": "Blood pressure, hypertension, RAAS blockade, and drug therapy in diabetic kidney disease.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/24780456",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 127,
            "othersAvgTimeSpent": 68,
            "notes": null,
            "peopleTaken": 13695,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 63,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 1642,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 1,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 29,
            "questionId": 15877,
            "questionIndex": 17316,
            "questionText": "<p>A 45-year-old man comes to the office for follow-up of type 2 diabetes mellitus.&nbsp; Since his diagnosis 4 years ago, the patient has followed a healthy diet and has taken metformin and atorvastatin as prescribed.&nbsp; Ophthalmologic examination conducted a month ago revealed no evidence of diabetic retinopathy.&nbsp; Blood pressure is 118/76 mm Hg, consistent with average home blood pressure readings, and pulse is 70/min.&nbsp; BMI is 30 kg/m<font size=\"2\"><sup>2</sup></font>.&nbsp; Heart rate is regular; no murmur is present.&nbsp; The lungs are clear to auscultation.&nbsp; Foot examination shows normal pulses and intact sensation to vibration, pressure, and pinprick.&nbsp; Hemoglobin A1c is 6.8%, creatinine is 0.9 mg/dL, and urine albumin/creatinine ratio is &lt;30 mg/g.&nbsp; What is the most appropriate next step in management of this patient?</p>",
            "questionHeader": "",
            "explanationText": "<div id=\"div_t53231\"><table class=\"table-default-style table-header-footer-style\"><tbody><tr><td colspan=\"2\"><p align=\"center\"><strong>Health maintenance in diabetes mellitus</strong></p></td></tr><tr><td><p align=\"center\"><strong>Glycemic control</strong></p></td><td><ul><li>Check A1c every 3-6 months</li><li>Goal A1c:<ul style=\"list-style-type:circle;\"><li>&le;7% (younger, otherwise healthy)</li><li>&le;8% (older, limited life expectancy, comorbidities)</li></ul></li></ul></td></tr><tr><td><p align=\"center\"><strong>Nephropathy<br />screening</strong></p></td><td><ul><li>Annual random urine albumin/creatinine ratio*<ul style=\"list-style-type:circle;\"><li>Normal value: &lt;30 mg/g</li></ul></li><li>Periodic serum creatinine level</li></ul></td></tr><tr><td><p align=\"center\"><strong>Retinopathy<br />screening</strong></p></td><td><ul><li>Dilated eye examination every 1-2 years*</li></ul></td></tr><tr><td><p align=\"center\"><strong>Neuropathy<br />screening</strong></p></td><td><ul><li>Visual inspection at each visit</li><li>Annual comprehensive foot examination</li></ul></td></tr><tr><td><p align=\"center\"><strong>Cardiovascular<br />risk reduction</strong></p></td><td><ul><li>Address lifestyle factors (eg, tobacco, obesity, diet &amp; exercise)</li><li>Annual lipid &amp; BP screening</li><li>Aspirin and statin (depending on other risk factors)</li></ul></td></tr><tr><td colspan=\"2\"><p>*Begin at time of diagnosis for type 2 diabetes mellitus &amp; within 5 years after diagnosis for type 1.</p><p><strong>BP</strong> = blood pressure.</p></td></tr></tbody></table></div><p>Routine health maintenance in diabetes mellitus includes monitoring for <strong>microvascular complications</strong> via the following:</p><ul><li>Annual urine albumin/creatinine ratio (nephropathy screening)</li><li>Annual dilated eye examination (retinopathy screening)</li><li>Periodic foot examinations to test sensation and vibration (neuropathy screening)</li></ul><p>These complications are prevented or mitigated by achieving adequate glycemic control (ie, hemoglobin A1c &#8804;7%), managing concurrent risk factors (eg, hypertension), and, in certain cases, prescribing pharmaceutical agents that slow complication progression.</p><p>The earliest sign of diabetic nephropathy is <strong>albuminuria</strong>, defined as urine albumin/creatinine ratio <strong>&#8805;30 mg/g</strong>, and hypertension is an exacerbating factor.&nbsp; When <strong>either albuminuria or hypertension</strong> is present, <strong>ACE inhibitors</strong> (eg, lisinopril) or <strong>angiotensin II receptor blockers</strong> (ARBs) are indicated to control blood pressure and/or slow the progression of diabetic nephropathy.&nbsp; Sodium-glucose cotransporter-2 inhibitors (eg, dapagliflozin) also slow nephropathy progression and may be used when glycemic control is suboptimal or when cardiac comorbidities (eg, heart failure) are present.</p><p>This patient has neither hypertension nor microalbuminuria; therefore, neither ACE inhibitors nor ARBs are indicated <strong>(Choice D)</strong>.&nbsp; Hemoglobin A1c is at the goal of &#8804;7%, and he has no cardiac comorbidities; therefore, no additional diabetic medication is needed <strong>(Choices B and C)</strong>.&nbsp; The patient is already taking a statin for macrovascular risk reduction and pursues a healthy lifestyle.&nbsp; Other than weight loss (BMI is 30 kg/m<font size=\"2\"><sup>2</sup></font>), no therapeutic changes are needed at this time.</p><p><strong>(Choice A)</strong>&nbsp; Clopidogrel is used in the secondary prevention of ischemic stroke (ie, in patients with history of stroke).</p><p><strong>Educational objective:</strong><br>Patients with type 2 diabetes mellitus should be screened annually for albuminuria (urine albumin/creatinine ratio &gt;30 mg/g), an early sign of diabetic nephropathy.&nbsp; Patients with diabetes mellitus and albuminuria or hypertension should be treated with ACE inhibitors or angiotensin II receptor blockers to lower blood pressure and/or slow the progression of nephropathy.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 102,
            "subject": "Medicine",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 211,
            "system": "Endocrine, Diabetes & Metabolism",
            "topicId": 2603,
            "topic": "Diabetes mellitus",
            "titleId": 2603,
            "title": "Diabetes mellitus",
            "topicAttributeId": 330582,
            "topicAttribute": "Diabetes mellitus",
            "correctAnswer": "5",
            "userAnswer": "5",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Add clopidogrel",
                    "choiceNumber": 1,
                    "correctTaken": 148,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Add dapagliflozin",
                    "choiceNumber": 2,
                    "correctTaken": 2722,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Add glimepiride",
                    "choiceNumber": 3,
                    "correctTaken": 1001,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Add lisinopril",
                    "choiceNumber": 4,
                    "correctTaken": 1895,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "No additional medications",
                    "choiceNumber": 5,
                    "correctTaken": 14336,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": "1949,2066,true,-1,1*2436,2545,true,-1,1*1736,1948,true,-1,1*905,1103,true,-1,1*124,208,true,-1,1",
            "isCorrect": true,
            "isIncorrect": false,
            "isMarked": false,
            "isOmitted": false,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "526",
                    "mediaDataId": 0,
                    "title": "Noninsulin antihyperglycemic drugs in type 2 diabetes mellitus",
                    "referenceTypeId": 18,
                    "referenceLink": null,
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "33298422",
                    "mediaDataId": 0,
                    "title": "11.  Microvascular complications and foot care: standards of medical care in diabetes2021.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/33298422",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "29794446",
                    "mediaDataId": 0,
                    "title": "Effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality and renal outcomes in patients with diabetes and albuminuria: a systematic review and meta-analysis.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/29794446",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 48,
            "othersAvgTimeSpent": 52,
            "notes": null,
            "peopleTaken": 20102,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 71,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 555,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 1,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 30,
            "questionId": 10401,
            "questionIndex": 11367,
            "questionText": "<p>A 56-year-old man comes to the office for follow up. He has type 2 diabetes mellitus of 15 years&#39; duration, hypertension, and hyperlipidemia.&nbsp; His diabetes mellitus is currently managed with metformin and glimepiride.&nbsp; Hemoglobin A1c level is 8.5%.&nbsp; Switching to insulin therapy to attain better glycemic control is discussed with the patient.&nbsp; Achieving a goal hemoglobin A1c of 6.5% with use of insulin is most likely to reduce the risk of which of the following complications over the next 5 years?</p>",
            "questionHeader": "",
            "explanationText": "<div id=\"div_t35298\"><table class=\"table-default-style\"><tbody><tr><td colspan=\"2\" style=\"text-align: center;\"><strong>Effect of intensive glycemic control in type 2 diabetes</strong></td></tr><tr><td><p style=\"text-align: center;\"><strong>Macrovascular complications</strong></p><p style=\"text-align: center;\">(eg, acute myocardial infarction, stroke)</p></td><td><p align=\"center\">No change (short-term)</p></td></tr><tr><td><p align=\"center\"><strong>Microvascular complications</strong></p><p align=\"center\">(eg, nephropathy, retinopathy)</p></td><td><p align=\"center\">Improve</p></td></tr><tr><td><p align=\"center\"><strong>Mortality</strong></p></td><td><p align=\"center\">No change or increased</p></td></tr></tbody></table></div><p>Chronic hyperglycemia in diabetes mellitus is linked to increased mortality and morbidity from microvascular (eg, retinopathy, nephropathy) and macrovascular (eg, cardiovascular disease) complications.&nbsp; However, use of pharmaceutical interventions to achieve <strong>glycemic control</strong> appears to have <strong>mixed effects</strong> on reduction of mortality and macrovascular complications.</p><p>Major randomized controlled trials (eg, United Kingdom Prospective Diabetes Study [UKPDS], Action to Control Cardiovascular Risk in Diabetes [ACCORD]) suggest that <strong>intensive glycemic control</strong> (ie, hemoglobin A1c between 6.0% and 7.0%) with insulin and/or sulfonylureas (eg, glipizide) significantly <strong>improves microvascular</strong> endpoints, such as <strong>retinopathy</strong> and nephropathy.</p><p>In contrast, these trials suggest that intensive glycemic control <strong>does not reduce macrovascular complications</strong> (eg, stroke, myocardial infarction) or <strong>all-cause mortality (Choices A, C, and E)</strong>.&nbsp; Strict glycemic control with insulin is also associated with significantly <strong>increased risk of hypoglycemia (Choice B)</strong>.&nbsp; Furthermore, the ACCORD trial showed that very intensive glycemic targets (ie, A1c between 6.0% and 6.5%) appear to <strong>increase</strong> risk of all-cause and cardiac mortality.</p><p>Given the established benefits of glycemic control on the risk of microvascular complications and the potential risk of overly strict glycemic control, the recommended target hemoglobin A1c for most nonelderly patients is 7.0%.&nbsp; In addition, efforts to reduce the risk of macrovascular complications should also include careful management of other lifestyle and cardiac risk factors (ie, smoking, blood pressure, lipids).</p><p><strong>Educational objective:</strong><br>In patients with diabetes mellitus, intensive blood glucose control with insulin decreases the risk of microvascular complications (eg, retinopathy, nephropathy) but has an uncertain effect on macrovascular outcomes (eg, stroke, myocardial infarction) and mortality.&nbsp; Very strict glycemic control (eg, goal A1c &#8804;6.5%) is associated with increased risk of hypoglycemia and increased cardiovascular mortality.&nbsp; Therefore, the recommended target hemoglobin A1c for most nonelderly patients is 7.0%</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 102,
            "subject": "Medicine",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 211,
            "system": "Endocrine, Diabetes & Metabolism",
            "topicId": 9395,
            "topic": "Diabetic retinopathy",
            "titleId": 9395,
            "title": "Diabetic retinopathy",
            "topicAttributeId": 330582,
            "topicAttribute": "Diabetes mellitus",
            "correctAnswer": "4",
            "userAnswer": "3",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "All-cause mortality",
                    "choiceNumber": 1,
                    "correctTaken": 6336,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Hypoglycemia",
                    "choiceNumber": 2,
                    "correctTaken": 120,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Myocardial infarction",
                    "choiceNumber": 3,
                    "correctTaken": 2935,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Retinopathy",
                    "choiceNumber": 4,
                    "correctTaken": 6918,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Stroke",
                    "choiceNumber": 5,
                    "correctTaken": 560,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": "734,794,true,-1,1",
            "isCorrect": false,
            "isIncorrect": true,
            "isMarked": false,
            "isOmitted": false,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "462",
                    "mediaDataId": 0,
                    "title": "Macrovascular and microvascular complications of diabetes",
                    "referenceTypeId": 18,
                    "referenceLink": null,
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "22996182",
                    "mediaDataId": 0,
                    "title": "Individualizing targets and tactics for high-risk patients with type 2 diabetes: practical lessons from ACCORD and other cardiovascular trials.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/22996182",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 107,
            "othersAvgTimeSpent": 29,
            "notes": null,
            "peopleTaken": 16869,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 41,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 445,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 1,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 31,
            "questionId": 2184,
            "questionIndex": 2184,
            "questionText": "<p>A 27-year-old man with type 1 diabetes mellitus that was diagnosed 15 years ago comes to the emergency department due to abdominal pain, nausea, and vomiting.&nbsp; The patient takes insulin glargine at night and insulin lispro before meals 3 times a day, but has not been compliant with his insulin injections.&nbsp; He stopped taking his insulin for the last 2 days due to not feeling well and inability to eat.&nbsp; The patient&#39;s medical history is otherwise unremarkable.&nbsp; He does not use tobacco or alcohol.&nbsp; Temperature is 36 C (96.8 F), blood pressure is 102/60 mm Hg, pulse is 110/min, and respirations are 26/min.&nbsp; The patient appears lethargic and dehydrated.&nbsp; The lungs are clear to auscultation.&nbsp; The abdomen is soft, nontender, and nondistended.&nbsp; Laboratory results are as follows:</p><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\"><tbody><tr><td>Sodium</td><td>128 mEq/L</td></tr><tr><td>Potassium</td><td>5.4 mEq/L</td></tr><tr><td>Chloride</td><td>90 mEq/L</td></tr><tr><td>Bicarbonate</td><td>10 mEq/L</td></tr><tr><td>Blood glucose</td><td>550 mg/dL</td></tr></tbody></table><p>Which of the following is the most appropriate next step in management of this patient?</p>",
            "questionHeader": "",
            "explanationText": "<div id=\"div_t32192\"><table class=\"table-default-style table-header-footer-style\"><tbody><tr><td colspan=\"2\"><p align=\"center\"><strong>Management of diabetic ketoacidosis</strong></p></td></tr><tr><td><p align=\"center\"><strong>IV fluids</strong></p></td><td><ul><li>Infusion of 0.9% normal saline</li><li>Add dextrose 5% when serum glucose is &le;200&nbsp;mg/dL</li></ul></td></tr><tr><td><p align=\"center\"><strong>Insulin</strong></p></td><td><ul><li>Start continuous <strong>IV</strong> insulin infusion; hold if K &lt;3.3&nbsp;mEq/L</li><li>Switch to <strong>SQ</strong> (basal bolus) insulin for the following: able to eat, glucose &lt;200&nbsp;mg/dL, anion&nbsp;gap &lt;12&nbsp;mEq/L &amp; serum HCO<sub>3</sub><sup>&minus;</sup>&nbsp;&ge;15 mEq/L</li><li>Overlap SQ &amp; IV insulin by 1-2&nbsp;hr</li></ul></td></tr><tr><td><p align=\"center\"><strong>Potassium</strong></p></td><td><ul><li>Add IV K if serum K<sup>+</sup>&nbsp;&lt;5.3&nbsp;mEq/L; hold if &ge;5.3&nbsp;mEq/L</li><li>Nearly all patients K<sup>+</sup> depleted, even with hyperkalemia</li></ul></td></tr><tr><td><p align=\"center\"><strong>Bicarbonate</strong></p></td><td><ul><li>Consider for patients with pH&nbsp;&le;6.9</li></ul></td></tr><tr><td><p align=\"center\"><strong>Phosphate</strong></p></td><td><ul><li>Consider for serum phosphate &lt;1.0&nbsp;mg/dL, cardiac dysfunction, or respiratory depression</li><li>Monitor serum calcium frequently</li></ul></td></tr><tr><td colspan=\"2\"><p><strong>IV</strong> = intravenous; <strong>SQ</strong> = subcutaneous.</p></td></tr></tbody></table></div><p>This patient with nausea, vomiting, and abdominal pain has <strong>metabolic acidosis</strong> (low bicarbonate) with an <strong>elevated anion gap</strong> (sodium &ndash; [chloride + bicarbonate]; 128 &ndash; [90 + 10] = 28 [normal 10-14]).&nbsp; In light of his hyperglycemia and type 1 diabetes, this is consistent with <strong>diabetic ketoacidosis</strong>&nbsp;(DKA).&nbsp; DKA can be precipitated by discontinuation of insulin, especially in the setting of infection or other stressors.&nbsp; It is more common in patients with type 1 diabetes due to absolute insulin deficiency, which leads to accumulation of ketoacids.&nbsp; A diagnosis can often be made provisionally based on bedside capillary blood glucose and confirmed with venous glucose, serum or urine ketones, and arterial blood gas analysis.</p><p>Essential measures in DKA include:</p><ol><li>Hydration to restore intravascular volume, with <strong>0.9% (normal) saline</strong> recommended in the first 1-2 hours</li><li>Correction of hyperglycemia and ketosis with <strong>intravenous regular insulin</strong></li><li>Serial assessment of electrolytes, especially potassium</li><li>Treatment of the underlying precipitating factors</li></ol><p>Insulin deficiency causes an extracellular shift of potassium, and serum potassium levels may be normal or elevated despite a total body deficit.&nbsp; Administration of insulin drives potassium into cells, resulting in hypokalemia.&nbsp; Potassium should be added to intravenous fluids once serum potassium is &lt;5.3 mEq/L.&nbsp; When glucose reaches &lt;200 mg/dL, patients also should be given dextrose-containing fluids to avoid hypoglycemia, but insulin should be continued to ensure resolution of ketosis.</p><p><strong>(Choice A)</strong>&nbsp; After intravascular volume is restored, if serum sodium is normal or elevated, the intravenous fluid is changed to 0.45% saline.&nbsp; Normal saline is used initially regardless of sodium levels.</p><p><strong>(Choices B and E)</strong>&nbsp; A solution of 5% dextrose provides only limited volume resuscitation because as dextrose is metabolized the solution becomes hypotonic, promoting water shift out of the intravascular space.&nbsp; NPH and glargine have a long duration of action and do not allow rapid dose titration; they are usually restarted when DKA has resolved.&nbsp; Finally, intravenous insulin is preferred to subcutaneous insulin (except in very mild DKA) due to the latter&#39;s unpredictable absorption (erratic skin perfusion).</p><p><strong>(Choice C)</strong>&nbsp; Patients with DKA can have pseudohyponatremia due to hyperglycemia; this patient&#39;s corrected sodium (observed sodium + ~2 mEq/L for every 100 mg/dL glucose is over 100 mg/dL) is normal (128 + ~2 x 4.5 = 128 + ~9 = ~137 mEq/L).&nbsp; Hypertonic saline is reserved for moderate to severe (true) hyponatremia.</p><p><strong>(Choice F)</strong>&nbsp; In most patients with DKA, administration of bicarbonate is not beneficial and may lead to cerebral edema, reduced tissue oxygenation, hypokalemia, and alkalosis.&nbsp; Bicarbonate is reserved for severe acidosis (pH &#8804;6.9), plasma bicarbonate &lt;5 mEq/L, or severe hyperkalemia.</p><p><strong>Educational objective:</strong><br>Essential measures in diabetic ketoacidosis include:</p><ol><li>Hydration to restore intravascular volume, with 0.9% (normal) saline recommended in the first 1-2 hours</li><li>Correction of hyperglycemia and ketosis with intravenous regular insulin</li><li>Serial assessment of electrolytes, especially potassium</li><li>Treatment of the underlying precipitating factors</li></ol>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 102,
            "subject": "Medicine",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 211,
            "system": "Endocrine, Diabetes & Metabolism",
            "topicId": 6575,
            "topic": "Diabetic ketoacidosis",
            "titleId": 6575,
            "title": "Diabetic ketoacidosis",
            "topicAttributeId": 330582,
            "topicAttribute": "Diabetes mellitus",
            "correctAnswer": "4",
            "userAnswer": "4",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "0.45% saline and regular insulin infusion",
                    "choiceNumber": 1,
                    "correctTaken": 678,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "5% dextrose and NPH insulin subcutaneously",
                    "choiceNumber": 2,
                    "correctTaken": 443,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Hypertonic saline and regular insulin infusion",
                    "choiceNumber": 3,
                    "correctTaken": 1160,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Normal saline and regular insulin infusion",
                    "choiceNumber": 4,
                    "correctTaken": 9378,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Normal saline and resume his home insulin regimen",
                    "choiceNumber": 5,
                    "correctTaken": 209,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Sodium bicarbonate infusion",
                    "choiceNumber": 6,
                    "correctTaken": 191,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": "3294,3567,true,-1,1*2668,2804,true,-1,1*2815,2968,true,-1,1*1991,2255,true,-1,1*354,387,true,-1,1*563,683,true,-1,1*223,353,true,-1,1*202,222,true,-1,1",
            "isCorrect": true,
            "isIncorrect": false,
            "isMarked": false,
            "isOmitted": false,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "521",
                    "mediaDataId": 0,
                    "title": "Diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic state (HHS)",
                    "referenceTypeId": 18,
                    "referenceLink": null,
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "19564476",
                    "mediaDataId": 0,
                    "title": "Hyperglycemic crisis in adult patients with diabetes mellitus.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/19564476",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 61,
            "othersAvgTimeSpent": 54,
            "notes": null,
            "peopleTaken": 12059,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 78,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 2066,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 1,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 32,
            "questionId": 16562,
            "questionIndex": 18006,
            "questionText": "<p>A 68-year old man is brought to the emergency room by his daughter due to slurred speech and weakness for the last 12 hours.&nbsp; He has a history of primary hypertension, type 2 diabetes mellitus, and obesity.&nbsp; Three days ago, the patient completed a course of oral prednisone due to severe poison ivy.&nbsp; Temperature is 36.7 C (98 F), blood pressure is 99/80 mm Hg, and pulse is 99/min.&nbsp; BMI is 35 kg/m<font size=\"2\"><sup>2</sup></font>.&nbsp; On examination, the patient is oriented only to place and is unable to consistently follow commands.&nbsp; The mucous membranes are dry.&nbsp; Neurologic examination reveals dysarthria and muffled speech.&nbsp; The remainder of the physical examination is normal.&nbsp; Laboratory results are as follows:</p><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\"><tbody><tr><td>Sodium</td><td>128 mEq/L</td></tr><tr><td>Potassium</td><td>4.8 mEq/L</td></tr><tr><td>Chloride</td><td>98 mEq/L</td></tr><tr><td>Bicarbonate</td><td>24 mEq/L</td></tr><tr><td>Blood urea nitrogen</td><td>39 mEq/L</td></tr><tr><td>Creatinine</td><td>1.3 mg/dL</td></tr><tr><td>Glucose</td><td>911 mg/dL</td></tr></tbody></table><p>CT scan of the head is normal.&nbsp; Intravenous access is secured, and an infusion of normal saline and regular insulin is started.&nbsp; Which of the following is the best next step in management?</p>",
            "questionHeader": "",
            "explanationText": "<div id=\"div_t54589\"><table class=\"table-default-style\"><tbody><tr><td colspan=\"2\"><p align=\"center\"><strong>Hyperosmolar hyperglycemic state</strong></p></td></tr><tr><td><p align=\"center\"><strong>Diagnostic criteria</strong></p></td><td><ul><li>Severe hyperglycemia (eg, &gt;600 mg/dL)</li><li>Hyperosmolality (eg, calculated serum osmolality &gt;320 mOsm/kg)</li><li>No significant ketosis (serum &beta;-hydroxybutyrate &lt;3.0 mmol/L, urine ketones &le;1+)</li><li>No significant metabolic acidosis (pH &ge;7.3, serum bicarbonate &ge;15 mEq/L, normal anion gap)</li></ul></td></tr><tr><td><p align=\"center\"><strong>Patient<br />characteristics</strong></p></td><td><ul><li>Type 2 diabetes mellitus</li><li>Older age</li></ul></td></tr><tr><td><p align=\"center\"><strong>Clinical<br />symptoms</strong></p></td><td><ul><li>Gradual hyperglycemic symptoms (eg, polyuria, polydipsia)</li><li>Altered mentation (eg, obtundation, focal deficits, seizures)</li></ul></td></tr><tr><td><p align=\"center\"><strong>Initial<br />management</strong></p></td><td><ul><li>Aggressive hydration (balanced crystalloid solution, normal saline)</li><li>Intravenous insulin</li><li>Replace potassium if &lt;5.3 mEq/L (normal measured K<sup>+</sup> may mask actual total body deficit)</li></ul></td></tr></tbody></table></div><p>This older patient with type 2 diabetes mellitus likely has <strong>hyperosmolar hyperglycemic state (HHS)</strong> triggered by recent prednisone use.&nbsp; In HHS, marked hyperglycemia (often &gt;800 mg/dL) and severely elevated <a href=\"27034\">plasma osmolality</a> (&gt;320 mOsm/kg) cause dehydration (evidenced by hypotension, dry mucous membranes, elevated blood urea nitrogen-to-creatinine ratio), altered mental status (eg, obtundation, lethargy), and focal neurological signs (eg, dysarthria, seizures).&nbsp; Immediate management includes normal saline and insulin infusion and <strong>potassium repletion</strong> when potassium is &lt;5.3 mEq/L.</p><p>Although laboratory potassium measurements are typically normal or slightly elevated, a <strong>total body potassium deficit</strong> of 300-600 mEq is present in most patients with HHS as well as in diabetic ketoacidosis (DKA):</p><ul><li>Potassium deficit is caused by glucose-induced <strong>osmotic diuresis</strong> (which leads to urinary potassium losses) and secondary hyperaldosteronism from volume contraction.</li><li>Normal or slightly elevated laboratory potassium measurements are due to hyperosmolality, which draws fluid and potassium into the extracellular space, and insulin deficiency, which reduces cellular uptake of potassium.</li></ul><p>If potassium is not replenished, life-threatening hypokalemia can result after insulin and intravenous fluid administration, both of which lower plasma osmolality and cause rapid potassium influx into cells.&nbsp; Therefore, in both HHS and DKA, potassium should be frequently monitored and supplemented intravenously when serum potassium falls below 5.3 mEq/L <strong>(Choice D)</strong>.</p><p><strong>(Choice A)</strong>&nbsp; Focal neurological signs (eg, dysarthria) are typically associated with stroke; however, they can also be seen in HHS (possibly from hyperglycemia-induced cerebral injury or inflammation).&nbsp; Given this patient&#39;s marked hyperglycemia, HHS is the more likely diagnosis.&nbsp; In addition, this patient has had symptoms for 12 hours and is outside the window of tissue plasminogen activator administration for acute stroke.</p><p><strong>(Choice B)</strong>&nbsp; Although infection is a potential trigger for HHS, potassium repletion should not be delayed given the risk of rapid hypokalemia.&nbsp; Moreover, this patient&#39;s recent prednisone use is a more likely cause of HHS.</p><p><strong>(Choice E)</strong>&nbsp; Secondary adrenal insufficiency from glucocorticoid withdrawal (eg, prednisone) can cause altered mentation, hypotension, and hyponatremia.&nbsp; However, hypoglycemia (rather than this patient&#39;s severe hyperglycemia) would be expected.&nbsp; This patient&#39;s hyponatremia is more likely a result of markedly elevated blood glucose (ie, <a href=\"27942\">hyperosmolar hyponatremia</a>).</p><p><strong>Educational objective:</strong><br>In hyperosmolar hyperglycemic state, severely elevated glucose (&gt;600 mg/dL) and plasma osmolality are present, causing altered mentation and focal neurological signs.&nbsp; Due to osmotic diuresis and insulin deficiency, total body potassium is often depleted despite normal or slightly elevated serum potassium values.&nbsp; Therefore, in addition to insulin and intravenous fluids, potassium repletion should be given when serum potassium is &lt;5.3 mEq/L.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 102,
            "subject": "Medicine",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 211,
            "system": "Endocrine, Diabetes & Metabolism",
            "topicId": 11854,
            "topic": "Hyperosmolar hyperglycemic state",
            "titleId": 11854,
            "title": "Hyperosmolar hyperglycemic state",
            "topicAttributeId": 330582,
            "topicAttribute": "Diabetes mellitus",
            "correctAnswer": "3",
            "userAnswer": "3",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Administration of tissue plasminogen activator",
                    "choiceNumber": 1,
                    "correctTaken": 228,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Broad-spectrum antibiotics",
                    "choiceNumber": 2,
                    "correctTaken": 165,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Intravenous potassium",
                    "choiceNumber": 3,
                    "correctTaken": 11332,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "No additional intervention",
                    "choiceNumber": 4,
                    "correctTaken": 2781,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Serum cortisol measurement",
                    "choiceNumber": 5,
                    "correctTaken": 2340,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": "2148,2283,true,-1,1*206,263,true,-1,1*297,354,true,-1,1",
            "isCorrect": true,
            "isIncorrect": false,
            "isMarked": false,
            "isOmitted": false,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "521",
                    "mediaDataId": 0,
                    "title": "Diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic state (HHS)",
                    "referenceTypeId": 18,
                    "referenceLink": null,
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "28372715",
                    "mediaDataId": 0,
                    "title": "Management of hyperglycemic crises: diabetic ketoacidosis and hyperglycemic hyperosmolar state.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/28372715",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "14693938",
                    "mediaDataId": 0,
                    "title": "Hyperglycemic crises in diabetes.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/14693938",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 65,
            "othersAvgTimeSpent": 67,
            "notes": null,
            "peopleTaken": 16846,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 67,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 813,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 1,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 33,
            "questionId": 3795,
            "questionIndex": 3795,
            "questionText": "<p>A 65-year-old man comes to the office due to recurrent falls.&nbsp; For the last several months, the patient has had a sensation of imbalance that is worse at night but has no associated pain or motor weakness.&nbsp; Medical history is notable for type 2 diabetes mellitus diagnosed 20 years ago and hypertension diagnosed 10 years ago.&nbsp; The patient was found to have nonproliferative diabetic retinopathy at his last ophthalmologic visit.&nbsp; Current medications include insulin, metformin, rosuvastatin, and ramipril.&nbsp; He does not use tobacco but drinks 1 or 2 beers daily and, often, more on weekends.&nbsp; Physical examination shows decreased proprioception and vibration sense in the feet.&nbsp; Ankle jerk reflexes are absent.&nbsp; Finger-to-nose and heel-to-shin tests are normal, but the patient sways and tends to fall when his eyes are closed.&nbsp; Bilateral hammer toe deformities are present.&nbsp; The remainder of the examination is unremarkable.&nbsp; Which of the following processes is predominantly responsible for this patient&#39;s neurologic symptoms?</p>",
            "questionHeader": "",
            "explanationText": "<div id=\"div_t51150\"><table class=\"table-default-style table-header-footer-style\" style=\"width:606px\"><tbody><tr><td colspan=\"3\"><p align=\"center\"><strong>Distal sensory peripheral neuropathy in diabetes mellitus</strong></p></td></tr><tr><td></td><td style=\"width: 40%;\"><p align=\"center\"><strong>Large fiber neuropathy*</strong></p></td><td style=\"width: 40%;\"><p align=\"center\"><strong>Small fiber neuropathy*</strong></p></td></tr><tr><td style=\"width: 20%;\"><p align=\"center\"><strong>Sensory<br>function</strong></p></td><td><ul><li>Pressure, proprioception &amp; balance</li></ul></td><td><ul><li>Pain &amp; temperature</li></ul></td></tr><tr><td><p align=\"center\"><strong>Major<br>symptoms</strong></p></td><td><ul><li>Numbness &amp; poor balance</li></ul></td><td><ul><li>Burning &amp; stabbing pain</li></ul></td></tr><tr><td><p align=\"center\"><strong>Examination<br>findings</strong></p></td><td><ul><li>Diminished/absent ankle reflexes</li><li>Reduced/absent vibration, light touch &amp; proprioception</li></ul></td><td><ul><li>Reduced pinprick sensation</li><li>Ankle reflexes possibly preserved</li></ul></td></tr><tr><td colspan=\"3\"><p>*Patients can have mixed large &amp; small fiber neuropathy.</p></td></tr></tbody></table></div><p><strong>Diabetes mellitus</strong> is the most common cause of peripheral neuropathy, with the risk related to the duration of the disease and glycemic status.&nbsp; Neuronal injury in diabetes is due to a number of factors, including microvascular injury, demyelination, oxidative stress, and deposition of glycation end products.&nbsp; The use of metformin, which decreases intestinal absorption of vitamin B<font size=\"2\"><sub>12</sub></font>, can also contribute.&nbsp; This leads to a length-dependent axonopathy, with clinical features occurring first in the longest nerves (eg, feet).</p><p>Symmetric distal <strong>sensorimotor polyneuropathy</strong> is the most common neuropathy in patients with diabetes; the clinical features depend on the type of nerve fibers involved.</p><ul><li><strong>Small fiber</strong> injury is characterized by the predominance of <strong>positive symptoms</strong> (eg, pain, paresthesia, allodynia) <strong>(Choice B)</strong>.</li><li><strong>Large fiber</strong> involvement is characterized by the predominance of <strong>negative symptoms</strong> (eg, numbness, loss of proprioception and vibration sense, diminished ankle reflexes).</li></ul><p>This patient primarily has features of large fiber involvement, with <strong>loss of position sense</strong> causing gait imbalance (worsened with eye closure due to lack of visual compensation) and weakness of the intrinsic muscles of the feet leading to foot deformities (eg, hammer toe deformity).</p><p><strong>(Choice C)</strong>&nbsp; Degeneration of the cerebellar hemispheres (eg, due to alcohol use) can cause gait disturbances due to incoordination of the limbs.&nbsp; However, most patients have additional abnormalities, including dysmetria (eg, abnormal finger-to-nose test), dysarthric speech, and intention tremor.</p><p><strong>(Choice D)</strong>&nbsp; Proprioception and vibration sense are carried by the posterior column of the spinal cord, and lesions there may resemble large fiber neuropathy.&nbsp; In contrast, the anterolateral system (eg, lateral spinothalamic tract) carries primarily pain and temperature sensation.</p><p><strong>(Choice E)</strong>&nbsp; Patchy demyelination may occur in diabetic neuropathy.&nbsp; Diffuse demyelination is seen in Guillain-Barr&eacute; syndrome and chronic inflammatory demyelinating polyneuropathy and is usually associated with more severe motor weakness.</p><p><strong>Educational objective:</strong><br>Sensorimotor polyneuropathy in diabetes is characterized by length-dependent axonopathy.&nbsp; Small fiber involvement causes pain, paresthesia, and allodynia, whereas large fiber injury causes numbness, loss of proprioception and vibration sense, and diminished ankle reflexes.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 102,
            "subject": "Medicine",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 211,
            "system": "Endocrine, Diabetes & Metabolism",
            "topicId": 6440,
            "topic": "Diabetic neuropathy",
            "titleId": 6440,
            "title": "Diabetic neuropathy",
            "topicAttributeId": 330582,
            "topicAttribute": "Diabetes mellitus",
            "correctAnswer": "1",
            "userAnswer": "1",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Axonopathy of large nerve fibers",
                    "choiceNumber": 1,
                    "correctTaken": 5821,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Axonopathy of small nerve fibers",
                    "choiceNumber": 2,
                    "correctTaken": 5206,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Degeneration of cerebellar hemispheres",
                    "choiceNumber": 3,
                    "correctTaken": 1524,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Degeneration of lateral spinothalamic tract",
                    "choiceNumber": 4,
                    "correctTaken": 1087,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Diffuse demyelination of nerve fibers of the lower extremities",
                    "choiceNumber": 5,
                    "correctTaken": 2685,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": "380,406,true,-1,1*325,379,true,-1,1*2078,2224,true,-1,1*1487,1770,true,-1,1*641,1024,true,-1,1",
            "isCorrect": true,
            "isIncorrect": false,
            "isMarked": false,
            "isOmitted": false,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "465",
                    "mediaDataId": 0,
                    "title": "Diabetic neuropathy",
                    "referenceTypeId": 18,
                    "referenceLink": null,
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "26989220",
                    "mediaDataId": 0,
                    "title": "Physiology in medicine: neuromuscular consequences of diabetic neuropathy.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/26989220",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 115,
            "othersAvgTimeSpent": 67,
            "notes": null,
            "peopleTaken": 16323,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 36,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 879,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 1,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 34,
            "questionId": 15842,
            "questionIndex": 17281,
            "questionText": "<p>A 7-day-old African American boy is being evaluated in the hospital.&nbsp; He was admitted yesterday due to sepsis after being brought to the emergency department with fever and vomiting.&nbsp; The patient is receiving intravenous antibiotics, and blood cultures grew <em>Escherichia coli</em>.&nbsp; He had been breastfeeding prior to admission, but feeds are being held due to vomiting.&nbsp; The patient was born at term, and there were no complications during the pregnancy and delivery.&nbsp; Temperature is 38.2 C (100.8 F) and pulse is 158/min.&nbsp; Examination shows jaundice.&nbsp; The liver is palpable 4 cm below the costal margin.&nbsp; Laboratory results are as follows:</p><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\"><tbody><tr><td colspan=\"2\" style=\"vertical-align:middle;\">Complete blood count</td></tr><tr><td style=\"vertical-align:middle;\">&nbsp;&nbsp;&nbsp;&nbsp;Hemoglobin</td><td style=\"vertical-align:middle;\">12 g/dL (normal: 13.4-19.9)</td></tr><tr><td style=\"vertical-align:middle;\">&nbsp;&nbsp;&nbsp;&nbsp;Mean corpuscular volume</td><td style=\"vertical-align:middle;\">98 &micro;m<font size=\"2\"><sup>3 </sup></font>(normal: 88-123)</td></tr><tr><td style=\"vertical-align:middle;\">&nbsp;&nbsp;&nbsp;&nbsp;Platelets</td><td style=\"vertical-align:middle;\">260,000/mm<font size=\"2\"><sup>3</sup></font></td></tr><tr><td style=\"vertical-align:middle;\">&nbsp;&nbsp;&nbsp;&nbsp;Leukocytes</td><td style=\"vertical-align:middle;\">15,000/mm<font size=\"2\"><sup>3</sup></font></td></tr><tr><td style=\"vertical-align:middle;\">&nbsp;&nbsp;&nbsp;&nbsp;Mean corpuscular hemoglobin concentration</td><td style=\"vertical-align:middle;\">33% Hb/cell</td></tr><tr><td colspan=\"2\" style=\"vertical-align:middle;\">Liver function studies</td></tr><tr><td style=\"vertical-align:middle;\">&nbsp;&nbsp;&nbsp;&nbsp;Total bilirubin</td><td style=\"vertical-align:middle;\">13 mg/dL (normal: &#8804;12)</td></tr><tr><td style=\"vertical-align:middle;\">&nbsp;&nbsp;&nbsp;&nbsp;Direct bilirubin</td><td style=\"vertical-align:middle;\">2 mg/dL</td></tr><tr><td style=\"vertical-align:middle;\">&nbsp;&nbsp;&nbsp;&nbsp;Aspartate aminotransferase (SGOT)</td><td style=\"vertical-align:middle;\">182 U/L (normal: 47-150)</td></tr><tr><td style=\"vertical-align:middle;\">&nbsp;&nbsp;&nbsp;&nbsp;Alanine aminotransferase (SGPT)</td><td style=\"vertical-align:middle;\">160 U/L (normal: 13-45)</td></tr><tr><td colspan=\"2\" style=\"vertical-align:middle;\">Immunologic and rheumatologic studies</td></tr><tr><td style=\"vertical-align:middle;\">&nbsp;&nbsp;&nbsp;&nbsp;Direct Coombs</td><td style=\"vertical-align:middle;\">negative</td></tr></tbody></table><p>Which of the following is the most likely cause for this patient&#39;s condition?</p>",
            "questionHeader": "",
            "explanationText": "<div id=\"div_t53446\"><table class=\"table-default-style table-footer-only-style\"><tbody><tr><td colspan=\"2\"><p align=\"center\"><strong>Galactosemia</strong></p></td></tr><tr><td style=\"width: 30%;\"><p align=\"center\"><strong>Etiology</strong></p></td><td><ul><li>GALT deficiency</li><li>Autosomal recessive</li><li>Galactose accumulation after lactose or galactose ingestion</li></ul></td></tr><tr><td><p align=\"center\"><strong>Clinical findings</strong></p></td><td><ul><li>Jaundice &amp; hepatomegaly</li><li>Vomiting &amp; poor feeding/failure to thrive</li><li>Cataracts</li><li>Increased risk for <em>Escherichia coli</em> sepsis</li></ul></td></tr><tr><td><p align=\"center\"><strong>Laboratory findings</strong></p></td><td><ul><li>&uarr; Bilirubin, AST, ALT</li><li>&darr; Glucose</li><li>Metabolic acidosis</li><li>+ Urine reducing substance</li></ul></td></tr><tr><td><p align=\"center\"><strong>Diagnosis</strong></p></td><td><ul><li>May be identified on newborn screening</li><li>Absent red blood cell GALT activity</li></ul></td></tr><tr><td><p align=\"center\"><strong>Treatment</strong></p></td><td><ul><li>Galactose-free diet (eg, soy-based formula)</li></ul></td></tr><tr><td colspan=\"2\"><p><strong>ALT</strong>&nbsp;=&nbsp;alanine aminotransferase; <strong>AST</strong>&nbsp;=&nbsp;aspartate aminotransferase; <strong>GALT</strong>&nbsp;=&nbsp;galactose 1-phosphate uridylyltransferase.</p></td></tr></tbody></table></div><p>This patient&#39;s presentation is consistent with <strong>galactosemia</strong>, an autosomal recessive disorder caused by <a href=\"27637\">galactose-1-phosphate uridylyltransferase (GALT) deficiency</a>.&nbsp; Deficiency results in an <strong>inability to metabolize galactose to glucose</strong>, leading to galactose accumulation in tissues.</p><p>Symptoms of poor feeding and <strong>vomiting</strong> develop in the first few days of life after the introduction of galactose, which is found in breast milk and cow&#39;s milk&ndash;based formula.&nbsp; Galactose accumulation also leads to <strong>jaundice</strong> and <strong>hepatomegaly</strong> (hepatic dysfunction), and cataract formation may occur.&nbsp; Because excessive galactose can impair leukocyte function and superoxide release, patients are also at increased risk for <em><strong>Escherichia coli</strong></em>&nbsp;<strong>sepsis</strong>, which may be the initial presentation of galactosemia in some neonates.</p><p>Supportive laboratory findings include hypoglycemia, metabolic acidosis (from renal tubular damage due to galactose accumulation), <strong>elevated transaminases</strong>, and <strong>conjugated</strong> and/or <strong>unconjugated hyperbilirubinemia</strong>.&nbsp; Although elevated direct bilirubin reflects hepatic involvement, unconjugated hyperbilirubinemia is likely due to the accumulation of galactose 1-phosphate in red blood cells (RBCs), promoting erythrocyte death (ie, <strong>hemolytic anemia</strong>).</p><p>Absent RBC GALT activity confirms the diagnosis.&nbsp; Treatment is dietary elimination of galactose by using a soy-based formula.</p><p><strong>(Choice B)</strong>&nbsp; Glucose-6-phosphate dehydrogenase deficiency is characterized by inadequate NADPH production and can cause neonatal jaundice (due to unconjugated hyperbilirubinemia) and hemolytic anemia.&nbsp; However, this patient&#39;s <em>E coli</em> sepsis and elevated transaminases make this diagnosis less likely than galactosemia.</p><p><strong>(Choice C)</strong>&nbsp; Wiskott-Aldrich syndrome is an immunodeficiency disorder caused by a loss-of-function mutation in the <em>WAS</em> gene.&nbsp; Patients are predisposed to recurrent infections but have eczema and thrombocytopenia.&nbsp; This patient&#39;s platelet count is normal.</p><p><strong>(Choice D)</strong>&nbsp; Spherocytosis, which causes jaundice and hemolytic anemia, is due to a mutation in the proteins (eg, spectrin, ankyrin) linking the RBC membrane to its cytoskeleton.&nbsp; Laboratory evaluation would show normal transaminases and increased mean corpuscular hemoglobin concentration, findings not seen in this patient.</p><p><strong>(Choice E)</strong>&nbsp; Although sickle cell disease can cause hemolytic anemia and jaundice (due to unconjugated hyperbilirubinemia), its presentation typically occurs after age 6 months, when gamma chain (found in fetal hemoglobin) production decreases and <a href=\"19082\">beta-globin chain production</a> increases.&nbsp; Hepatomegaly and elevated transaminases would not be expected.</p><p><strong>Educational objective:</strong><br>Galactosemia is characterized by the inability to metabolize galactose (found in breast and cow&#39;s milk) to glucose, resulting in galactose accumulation and hypoglycemia.&nbsp; Patients may have vomiting, jaundice, hepatomegaly, and <em>Escherichia coli</em> sepsis.&nbsp; Hyperbilirubinemia may be conjugated (ie, liver dysfunction) and/or unconjugated (ie, hemolytic anemia).</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 104,
            "subject": "Pediatrics",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 211,
            "system": "Endocrine, Diabetes & Metabolism",
            "topicId": 21901,
            "topic": "Galactosemia",
            "titleId": 21901,
            "title": "Galactosemia",
            "topicAttributeId": 330576,
            "topicAttribute": "Congenital and developmental anomalies",
            "correctAnswer": "1",
            "userAnswer": "1",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Inability to metabolize galactose to glucose",
                    "choiceNumber": 1,
                    "correctTaken": 5212,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Inadequate NADPH production for oxidative injury protection",
                    "choiceNumber": 2,
                    "correctTaken": 3359,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Loss-of-function mutation in the <em>WAS</em> gene",
                    "choiceNumber": 3,
                    "correctTaken": 815,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Mutation in proteins linking the red blood cell membrane to its cytoskeleton",
                    "choiceNumber": 4,
                    "correctTaken": 1306,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Single amino acid substitution within the beta-globin chain",
                    "choiceNumber": 5,
                    "correctTaken": 2970,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": "2018,2207,true,-1,1*1880,2005,true,-1,1*1215,1433,true,-1,1*1487,1564,true,-1,1*1644,1879,true,-1,1",
            "isCorrect": true,
            "isIncorrect": false,
            "isMarked": false,
            "isOmitted": false,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "426",
                    "mediaDataId": 0,
                    "title": "Galactosemia",
                    "referenceTypeId": 18,
                    "referenceLink": null,
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "21321007",
                    "mediaDataId": 0,
                    "title": "Galactosemia presenting as recurrent sepsis.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/21321007",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "20351709",
                    "mediaDataId": 0,
                    "title": "Early and severe indirect hyperbilirubinemia as a manifestation of galactosemia.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/20351709",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 67,
            "othersAvgTimeSpent": 89,
            "notes": null,
            "peopleTaken": 13662,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 38,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 1374,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 1,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 35,
            "questionId": 3797,
            "questionIndex": 3797,
            "questionText": "<p>A 65-year-old woman comes to the office due to nausea, abdominal bloating, and early satiety for the past 3 months.&nbsp; The patient has abdominal discomfort, especially after eating, that is partially relieved after vomiting of undigested food.&nbsp; She has no fever but has lost 5 kg (11 lb) over this period.&nbsp; The patient has type 2 diabetes mellitus, diabetic retinopathy, and degenerative joint disease.&nbsp; She has had no abdominal surgeries.&nbsp; Medications include metformin, basal-bolus insulin, and ibuprofen as needed.&nbsp; The patient does not drink alcohol.&nbsp; Vital signs are within normal limits.&nbsp; On physical examination, the abdomen is soft with mild tenderness in the epigastric region.&nbsp; Bowel sounds are active throughout.&nbsp; There is no hepatosplenomegaly or abdominal masses.&nbsp; Hemoglobin A1c is 8.4%.&nbsp; Abdominal x-ray reveals no obstruction.&nbsp; Upper gastrointestinal endoscopy, performed after overnight fasting, demonstrates partially digested food but is otherwise normal.&nbsp; Which of the following would be most helpful in treating this patient&#39;s condition?</p>",
            "questionHeader": "",
            "explanationText": "<div id=\"div_t38224\"><table class=\"table-default-style\"><tbody><tr><td colspan=\"2\"><p align=\"center\"><strong>Gastroparesis</strong></p></td></tr><tr><td><p align=\"center\"><strong>Causes</strong></p></td><td><ul><li>Diabetes mellitus (autonomic neuropathy)</li><li>Medications (eg, opioids, anticholinergic drugs)</li><li>Traumatic/postsurgical injury (ie, vagus nerve injury)</li><li>Neurologic (eg, multiple sclerosis, spinal cord injury)</li><li>Idiopathic/postviral</li></ul></td></tr><tr><td><p align=\"center\"><strong>Clinical features</strong></p></td><td><ul><li>Nausea &amp; vomiting, epigastric abdominal pain</li><li>Early satiety, bloating, weight loss</li><li>Labile glucose (diabetes mellitus)</li><li>Epigastric distension &amp; succussion splash</li></ul></td></tr><tr><td><p align=\"center\"><strong>Diagnosis</strong></p></td><td><ul><li>Exclude obstruction: upper endoscopy &plusmn; CT/MR enterography</li><li>Assess motility: nuclear gastric emptying study</li></ul></td></tr><tr><td><p align=\"center\"><strong>Treatment</strong></p></td><td><ul><li>Frequent small meals (low fat, soluble fiber only)</li><li>Promotility drugs (eg, metoclopramide, erythromycin)</li><li>Gastric electrical stimulation &amp;/or jejunal feeding tube (refractory symptoms)</li></ul></td></tr></tbody></table></div><p>This patient has symptoms suggestive of <strong>diabetic gastroparesis</strong>, a syndrome characterized by delayed gastric emptying in the absence of mechanical obstruction.&nbsp; <strong>Chronic hyperglycemia</strong> in patients with uncontrolled diabetes (eg, elevated hemoglobin A1c in this patient) may lead to <strong>autonomic neuropathy</strong>, which causes uncoordinated smooth muscle contractions and ineffective gastric motility.&nbsp; This slows the rate at which food leaves the stomach, often causing <strong>nausea</strong>, postprandial <strong>emesis, early satiety, </strong>bloating, and abdominal pain; in severe cases, <strong>weight loss</strong> can occur (as seen in this patient).&nbsp; Although not diagnostic of gastroparesis, upper endoscopy may reveal food in the stomach despite an overnight fast.&nbsp; After ruling out mechanical obstruction (performed in this patient with upper endoscopy), the diagnosis can be confirmed with a gastric-emptying scan.</p><p>Treatment of diabetic gastroparesis includes:</p><ul><li>Optimization of glycemic control</li><li>Dietary modification (eg, smaller, more frequent meals; decreased fat and insoluble fiber intake)</li><li>Medications that improve gastric emptying</li></ul><p><strong>Metoclopramide</strong> has both prokinetic and antiemetic properties that relieve symptoms of diabetic gastroparesis.&nbsp; Although often effective, it is associated with a small (&lt;1%) risk of extrapyramidal adverse effects (eg, dystonia) and tardive dyskinesia (eg, involuntary movements).&nbsp; Other options include erythromycin, whose use is limited by tachyphylaxis, and domperidone, which rarely causes cardiac arrythmias, QTc prolongation, and hyperprolactinemia.</p><p><strong>(Choice A)</strong>&nbsp; Small intestinal bacterial overgrowth can develop in patients with diabetes due to impaired intestinal peristalsis.&nbsp; Although bloating is common and weight loss may rarely occur, diarrhea would be expected, and vomiting is not seen.&nbsp; Retained food after an overnight fast is not characteristic.</p><p><strong>(Choices B and E)</strong>&nbsp; Large peptic ulcers, which can be caused by&nbsp;<em>Helicobacter pylori</em> or nonsteroidal anti-inflammatory drugs, can result in gastric outlet obstruction (GOO) with symptoms similar to those of gastroparesis&nbsp;(eg, early satiety, postprandial emesis, weight loss).&nbsp; Proton pump inhibitors (and antibiotics for those with <em>H pylori</em> infection) would be recommended.&nbsp; However, upper endoscopy would visualize the obstruction (eg, luminal narrowing), making GOO unlikely in this patient.</p><p><strong>(Choice D)</strong>&nbsp; Pancreatic enzyme replacement is used to treat chronic pancreatitis, which is characterized by recurrent abdominal pain, steatorrhea, and, sometimes, hyperglycemia due to islet cell destruction.&nbsp; Postprandial vomiting and the finding of retained food during endoscopy are not consistent with this diagnosis.</p><p><strong>Educational objective:</strong><br>Diabetic gastroparesis (ie, delayed gastric emptying) presents with nausea, postprandial emesis, early satiety, bloating, and abdominal pain in the setting of poor glycemic control.&nbsp; Treatment requires optimization of diabetic control, dietary modification (eg, smaller, more frequent meals; decreased fat and insoluble fiber intake), and medications that improve gastric emptying (eg, metoclopramide).</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 102,
            "subject": "Medicine",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 211,
            "system": "Endocrine, Diabetes & Metabolism",
            "topicId": 18165,
            "topic": "Gastroparesis",
            "titleId": 18165,
            "title": "Gastroparesis",
            "topicAttributeId": 330582,
            "topicAttribute": "Diabetes mellitus",
            "correctAnswer": "3",
            "userAnswer": "3",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Antibiotics to treat small intestinal bacterial overgrowth",
                    "choiceNumber": 1,
                    "correctTaken": 599,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "<em>Helicobacter pylori</em> eradication therapy",
                    "choiceNumber": 2,
                    "correctTaken": 712,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Metoclopramide",
                    "choiceNumber": 3,
                    "correctTaken": 11104,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Pancreatic enzyme supplements",
                    "choiceNumber": 4,
                    "correctTaken": 2721,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Proton pump inhibitor therapy",
                    "choiceNumber": 5,
                    "correctTaken": 991,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": "2625,3097,true,-1,1*1672,1844,true,-1,1*1955,2298,true,-1,1*1072,1149,true,-1,1*141,195,true,-1,1*196,250,true,-1,1*92,140,true,-1,1*263,272,true,-1,1*373,407,true,-1,1*408,449,true,-1,1*480,565,true,-1,1*680,758,true,-1,1",
            "isCorrect": true,
            "isIncorrect": false,
            "isMarked": false,
            "isOmitted": false,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "370",
                    "mediaDataId": 0,
                    "title": "Gastroparesis",
                    "referenceTypeId": 18,
                    "referenceLink": null,
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "23147521",
                    "mediaDataId": 0,
                    "title": "Clinical guideline: management of gastroparesis.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/23147521",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 46,
            "othersAvgTimeSpent": 63,
            "notes": null,
            "peopleTaken": 16127,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 69,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 971,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 1,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 36,
            "questionId": 2186,
            "questionIndex": 2186,
            "questionText": "<p>A 70-year-old man is brought to the emergency department after his daughter found him lethargic and confused in his home.&nbsp; He has had a &#x22;cold&#x22; for the past 2 days.&nbsp; The patient lives alone and ambulates with a walker after a stroke 5 years ago.&nbsp; His daughter lives nearby and helps him with his daily activities of living.&nbsp; On arrival, temperature is 38 C (100.4 F), blood pressure is 90/65 mm Hg, pulse is 112/min, and respirations are 24/min.&nbsp; Mucous membranes are dry.&nbsp; The airway is maintained, and oxygen is administered.&nbsp; Intravenous access is secured, and blood and urine samples are drawn.&nbsp; Laboratory results are as follows:</p><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\"><tbody><tr><td colspan=\"2\" style=\"vertical-align:middle;\">Serum chemistry</td></tr><tr><td style=\"vertical-align:middle;\">&nbsp;&nbsp;&nbsp;&nbsp;Sodium</td><td style=\"vertical-align:middle;\">134 mEq/L</td></tr><tr><td style=\"vertical-align:middle;\">&nbsp;&nbsp;&nbsp;&nbsp;Potassium</td><td style=\"vertical-align:middle;\">5.9 mEq/L</td></tr><tr><td style=\"vertical-align:middle;\">&nbsp;&nbsp;&nbsp;&nbsp;Chloride</td><td style=\"vertical-align:middle;\">101 mEq/L</td></tr><tr><td style=\"vertical-align:middle;\">&nbsp;&nbsp;&nbsp;&nbsp;Bicarbonate</td><td style=\"vertical-align:middle;\">22 mEq/L</td></tr><tr><td style=\"vertical-align:middle;\">&nbsp;&nbsp;&nbsp;&nbsp;Blood urea nitrogen</td><td style=\"vertical-align:middle;\">110 mg/dL</td></tr><tr><td style=\"vertical-align:middle;\">&nbsp;&nbsp;&nbsp;&nbsp;Glucose</td><td style=\"vertical-align:middle;\">1,000 mg/dL</td></tr><tr><td colspan=\"2\" style=\"vertical-align:middle;\"></td></tr><tr><td colspan=\"2\" style=\"vertical-align:middle;\">Arterial blood gases</td></tr><tr><td style=\"vertical-align:middle;\">&nbsp;&nbsp;&nbsp;&nbsp;pH</td><td style=\"vertical-align:middle;\">7.40</td></tr><tr><td style=\"vertical-align:middle;\">&nbsp;&nbsp;&nbsp;&nbsp;PaCO<font size=\"2\"><sub>2</sub></font></td><td style=\"vertical-align:middle;\">38 mm Hg</td></tr><tr><td style=\"vertical-align:middle;\">&nbsp;&nbsp;&nbsp;&nbsp;PaO<font size=\"2\"><sub>2</sub></font></td><td style=\"vertical-align:middle;\">90 mm Hg</td></tr></tbody></table><p>Which of the following is the best immediate treatment for this patient?</p>",
            "questionHeader": "",
            "explanationText": "<div id=\"div_t54589\"><table class=\"table-default-style\"><tbody><tr><td colspan=\"2\"><p align=\"center\"><strong>Hyperosmolar hyperglycemic state</strong></p></td></tr><tr><td><p align=\"center\"><strong>Diagnostic criteria</strong></p></td><td><ul><li>Severe hyperglycemia (eg, &gt;600 mg/dL)</li><li>Hyperosmolality (eg, calculated serum osmolality &gt;320 mOsm/kg)</li><li>No significant ketosis (serum &beta;-hydroxybutyrate &lt;3.0 mmol/L, urine ketones &le;1+)</li><li>No significant metabolic acidosis (pH &ge;7.3, serum bicarbonate &ge;15 mEq/L, normal anion gap)</li></ul></td></tr><tr><td><p align=\"center\"><strong>Patient<br />characteristics</strong></p></td><td><ul><li>Type 2 diabetes mellitus</li><li>Older age</li></ul></td></tr><tr><td><p align=\"center\"><strong>Clinical<br />symptoms</strong></p></td><td><ul><li>Gradual hyperglycemic symptoms (eg, polyuria, polydipsia)</li><li>Altered mentation (eg, obtundation, focal deficits, seizures)</li></ul></td></tr><tr><td><p align=\"center\"><strong>Initial<br />management</strong></p></td><td><ul><li>Aggressive hydration (balanced crystalloid solution, normal saline)</li><li>Intravenous insulin</li><li>Replace potassium if &lt;5.3 mEq/L (normal measured K<sup>+</sup> may mask actual total body deficit)</li></ul></td></tr></tbody></table></div><p>This patient has severe hyperglycemia and mental status changes (lethargy, confusion), findings consistent with <strong>hyperosmolar hyperglycemic state (HHS)</strong>.&nbsp; He also has prominent evidence of dehydration, with hypotension, tachycardia, and dry mucous membranes, likely due to osmotic diuresis from severely elevated <a href=\"27034\">plasma osmolality</a> (eg, &gt;320 mOsm/kg).&nbsp; Therefore, the best immediate step in treatment is <strong>aggressive fluid replacement</strong> with isotonic <strong>normal saline (NS)</strong>, which replenishes extracellular volume, lowers plasma osmolality, and increases tissue perfusion and responsiveness to insulin.</p><p>HHS often occurs in a setting of type 2 diabetes.&nbsp; Compared with diabetic ketoacidosis (DKA), HHS is associated with higher glucose levels (often &gt;1,000 mg/dL in HHS, 300-500 mg/dL in DKA), normal anion gap and pH, and absent ketoacids.&nbsp; Dehydration is more severe in HHS (up to 8-10 L of total body water losses) due to higher plasma osmolality and resulting osmotic diuresis.</p><p>In the first hour of treatment, NS should be used for resuscitation regardless of sodium levels.&nbsp; The fluid can be changed to 0.45% NS after the second or third hour if the <a href=\"27942\">corrected serum sodium</a> is normal or high on repeat laboratory testing <strong>(Choice A)</strong>.</p><p><strong>(Choices B and F)</strong>&nbsp; Insulin therapy is a mainstay in the management of HHS.&nbsp; However, <strong>intravenous regular insulin</strong> is preferred because hypovolemia and systemic vasoconstriction in HHS can lead to erratic absorption of long-acting insulin.&nbsp; Although subcutaneous insulin can sometimes be administered in patients with mild DKA, it would not be appropriate for this patient with HHS and marked hypovolemia.</p><p><strong>(Choice D) </strong> Despite demonstrating elevated potassium levels on laboratory testing, many patients with HHS actually have a total body potassium deficit (due to hyperosmolarity and urinary losses generated by osmotic diuresis).&nbsp; Insulin administration drives potassium into cells; therefore, such patients need supplemental potassium to prevent rapid unmasking of hypokalemia.&nbsp; However, potassium repletion is only indicated if the initial serum potassium level is less than 5.3 mEq/L.&nbsp; This patient&#39;s potassium is 5.9 mEq/L; therefore, supplemental potassium is not indicated.</p><p><strong>(Choice E)</strong>&nbsp; Infusion of sodium bicarbonate is sometimes used in patients with DKA and severe acidosis (pH &lt;6.9).&nbsp; Because ketoacid accumulation or acidosis is not present in this patient with HHS, bicarbonate supplementation is not required.</p><p><strong>Educational objective:</strong><br>Hyperosmolar hyperglycemic state is characterized by severe hyperglycemia and hyperosmolarity, mental status changes, and normal anion gap.&nbsp; Osmotic diuresis leads to marked deficits in total body water; therefore, treatment should begin with immediate intravenous fluid resuscitation with normal saline.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 102,
            "subject": "Medicine",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 211,
            "system": "Endocrine, Diabetes & Metabolism",
            "topicId": 11854,
            "topic": "Hyperosmolar hyperglycemic state",
            "titleId": 11854,
            "title": "Hyperosmolar hyperglycemic state",
            "topicAttributeId": 330582,
            "topicAttribute": "Diabetes mellitus",
            "correctAnswer": "3",
            "userAnswer": "3",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "0.45% saline",
                    "choiceNumber": 1,
                    "correctTaken": 649,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Long-acting insulin analogue",
                    "choiceNumber": 2,
                    "correctTaken": 697,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Normal saline",
                    "choiceNumber": 3,
                    "correctTaken": 10442,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Potassium chloride",
                    "choiceNumber": 4,
                    "correctTaken": 265,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Sodium bicarbonate",
                    "choiceNumber": 5,
                    "correctTaken": 306,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Subcutaneous insulin",
                    "choiceNumber": 6,
                    "correctTaken": 3691,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": "2069,2209,true,-1,1*1575,1716,true,-1,1*1217,1338,true,-1,1",
            "isCorrect": true,
            "isIncorrect": false,
            "isMarked": false,
            "isOmitted": false,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "521",
                    "mediaDataId": 0,
                    "title": "Diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic state (HHS)",
                    "referenceTypeId": 18,
                    "referenceLink": null,
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "19564476",
                    "mediaDataId": 0,
                    "title": "Hyperglycemic crises in adult patients with diabetes.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/19564476",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 71,
            "othersAvgTimeSpent": 63,
            "notes": null,
            "peopleTaken": 16050,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 65,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 358,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 1,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 37,
            "questionId": 2189,
            "questionIndex": 2189,
            "questionText": "<p>A 28-year-old man with type 1 diabetes mellitus comes to the emergency department due to abdominal pain, nausea, and vomiting for the past 2 days.&nbsp; The patient has a history of medical noncompliance and has not used insulin for the past 5 days.&nbsp; Temperature is 36.7 C (98.1 F), blood pressure is 96/62 mm Hg, pulse is 112/min, and respirations are 26/min.&nbsp; Examination shows dry mucous membranes.&nbsp; The abdomen is soft with mild, diffuse tenderness.&nbsp; Laboratory results are as follows:</p><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\"><tbody><tr><td colspan=\"2\" style=\"vertical-align:middle;\">Serum chemistry</td></tr><tr><td style=\"vertical-align:middle; padding-left:2em;\">Sodium</td><td style=\"vertical-align:middle;\">134 mEq/L</td></tr><tr><td style=\"vertical-align:middle; padding-left:2em;\">Potassium</td><td style=\"vertical-align:middle;\">5.2 mEq/L</td></tr><tr><td style=\"vertical-align:middle; padding-left:2em;\">Chloride</td><td style=\"vertical-align:middle;\">97 mEq/L</td></tr><tr><td style=\"vertical-align:middle; padding-left:2em;\">Bicarbonate</td><td style=\"vertical-align:middle;\">12 mEq/L</td></tr><tr><td style=\"vertical-align:middle; padding-left:2em;\">Glucose</td><td style=\"vertical-align:middle;\">400 mg/dL</td></tr><tr><td colspan=\"2\" style=\"vertical-align:middle;\"></td></tr><tr><td colspan=\"2\" style=\"vertical-align:middle;\">Arterial blood gases</td></tr><tr><td style=\"vertical-align:middle; padding-left:2em;\">pH</td><td style=\"vertical-align:middle;\">7.19</td></tr><tr><td style=\"vertical-align:middle; padding-left:2em;\">PaO<font size=\"2\"><sub>2</sub></font></td><td style=\"vertical-align:middle;\">84 mm Hg</td></tr><tr><td style=\"vertical-align:middle; padding-left:2em;\">PaCO<font size=\"2\"><sub>2</sub></font></td><td style=\"vertical-align:middle;\">25 mm Hg</td></tr></tbody></table><p>Serum and urine are positive for ketones.&nbsp; Which of the following is the best index to monitor the response to treatment of this patient&#39;s condition?</p>",
            "questionHeader": "",
            "explanationText": "<div id=\"div_T87381\"><table class=\"table-default-style table-header-footer-style\"><tbody><tr><td colspan=\"2\"><p align=\"center\"><strong>Management of diabetic ketoacidosis</strong></p></td></tr><tr><td><p align=\"center\" style=\"margin-left:.1in;\"><strong>Fluids</strong></p></td><td><ul><li>Initial: give isotonic intravenous fluids</li><li>Subsequent:<ul style=\"list-style-type:circle;\"><li>Continue isotonic fluids if serum Na<sup>+</sup> &lt;135 mEq/L</li><li>Switch to half normal saline if serum Na<sup>+</sup> &#8805;135 mEq/L</li><li>Add dextrose when serum glucose &lt;200 mg/dL</li></ul></li></ul></td></tr><tr><td><p align=\"center\" style=\"margin-left:.1in;\"><strong>Insulin</strong></p></td><td><ul><li>Reduce insulin infusion rate when serum glucose &lt;200 mg/dL</li><li>Hold insulin infusion if serum K<sup>+</sup> &lt;3.3 mEq/L</li><li>Switch to subcutaneous insulin on DKA resolution*</li></ul></td></tr><tr><td><p align=\"center\" style=\"margin-left:.1in;\"><strong>Potassium</strong></p></td><td><ul><li>Give replacement when serum K<sup>+</sup> &lt;5.3 mEq/L**</li></ul></td></tr><tr><td><p align=\"center\" style=\"margin-left:.1in;\"><strong>Bicarbonate</strong></p></td><td><ul><li>Consider replacement for severe DKA with blood pH &#8804;6.9</li></ul></td></tr><tr><td colspan=\"2\"><p>*Normalization of anion gap &amp; patient able to eat.</p><p>**Due to total body potassium depletion and risk of insulin-induced hypokalemia.</p><p><strong>DKA</strong> = diabetic ketoacidosis.</p></td></tr></tbody></table></div><p>This patient&#39;s presentation (hyperglycemia with anion gap metabolic acidosis) is consistent with <strong>diabetic ketoacidosis</strong> (DKA).&nbsp; Treatment of DKA includes prompt intravenous fluid resuscitation, insulin to lower serum glucose and ketones, and electrolyte replacement.&nbsp; Frequent clinical and laboratory monitoring is indicated: the <strong>anion gap</strong>, electrolytes, and venous pH are measured every 2-4 hours, and serum glucose is measured hourly.</p><p>A primary derangement in DKA is anion gap <strong>metabolic acidosis</strong> generated by the unmeasured <strong>ketoacid anions</strong> acetoacetate and beta-hydroxybutyrate.&nbsp; Beta-hydroxybutyrate is derived from the reduction of acetoacetic acid and can become the predominant ketoacid in severe DKA.&nbsp; With volume resuscitation and correction of hyperosmolality and hyperglycemia, these ketoacids disappear and the anion <strong>gap normalizes</strong>, pointing to <strong>resolution of ketosis</strong>.&nbsp; Posttreatment hyperchloremic acidosis may occur due to infusion of normal saline; however, the anion gap will be normal.</p><p>Resolution of DKA is further supported by normalization of the venous pH and serum beta-hydroxybutyrate levels, rise in serum bicarbonate, and tolerance of oral food intake.&nbsp; Measurement of serum and urine glucose alone is inappropriate for monitoring response to treatment because ketosis and acidemia may still be present even when glucose levels drop below 200-250 mg/dL <strong>(Choice D)</strong>.</p><p><strong>(Choice A)</strong>&nbsp; <a href=\"27034\">Effective plasma osmolality</a> is often severely elevated in DKA due to dehydration and hyperglycemia.&nbsp; With prompt volume resuscitation and intravenous insulin treatment, serum osmolality may normalize, but ketosis and anion gap acidosis may still be present.&nbsp; Therefore, serum osmolality is not a sensitive marker for monitoring resolution of ketonemia.</p><p><strong>(Choices B and E)</strong>&nbsp; Urine ketone testing primarily measures acetoacetate, not beta-hydroxybutyrate.&nbsp; Therefore, although measurement of urine or serum acetoacetate is appropriate for DKA diagnosis, these tests should not be used to monitor for DKA resolution.&nbsp; In addition, ketone byproducts are often persistently elevated in the urine, even after ketoacidosis resolution.&nbsp; Measurement of serum beta-hydroxybutyrate (not acetoacetate), along with measurement of the anion gap, is an accurate method for monitoring ketosis resolution.</p><p><strong>Educational objective:</strong><br>The most accurate markers indicating resolution of diabetic ketoacidosis are the serum anion gap and serum beta-hydroxybutyrate levels.&nbsp; The anion gap estimates the unmeasured anion concentration in the blood and returns to normal with the disappearance of ketoacid anions.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 102,
            "subject": "Medicine",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 211,
            "system": "Endocrine, Diabetes & Metabolism",
            "topicId": 6575,
            "topic": "Diabetic ketoacidosis",
            "titleId": 6575,
            "title": "Diabetic ketoacidosis",
            "topicAttributeId": 330582,
            "topicAttribute": "Diabetes mellitus",
            "correctAnswer": "3",
            "userAnswer": "5",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Effective plasma osmolality",
                    "choiceNumber": 1,
                    "correctTaken": 88,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Serum acetoacetate",
                    "choiceNumber": 2,
                    "correctTaken": 180,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Serum anion gap",
                    "choiceNumber": 3,
                    "correctTaken": 1259,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Urine glucose",
                    "choiceNumber": 4,
                    "correctTaken": 24,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Urine ketones",
                    "choiceNumber": 5,
                    "correctTaken": 156,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": "500,554,true,-1,1*339,383,true,-1,1*444,487,true,-1,1*982,1151,true,-1,1*1594,1715,true,-1,1*1757,2089,true,-1,1*2485,2724,true,-1,1",
            "isCorrect": false,
            "isIncorrect": true,
            "isMarked": false,
            "isOmitted": false,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "521",
                    "mediaDataId": 0,
                    "title": "Diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic state (HHS)",
                    "referenceTypeId": 18,
                    "referenceLink": null,
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "25061324",
                    "mediaDataId": 0,
                    "title": "Management of adult diabetic ketoacidosis.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/25061324",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 39,
            "othersAvgTimeSpent": 70,
            "notes": null,
            "peopleTaken": 1706,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 74,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 1677,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 1,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 38,
            "questionId": 27010,
            "questionIndex": 115068,
            "questionText": "<p>A 26-year-old woman comes to the office due to intermittent episodes of weakness, dizziness, and irritability over the past 2 months.&nbsp; The symptoms occur if she skips a meal or does not eat for several hours.&nbsp; The patient currently feels well and has had no other symptoms.&nbsp; Family history includes hyperparathyroidism in her mother.&nbsp; The patient does not use tobacco, alcohol, or recreational drugs.&nbsp; Vital signs and physical examination are normal.&nbsp; BMI is 24.5 kg/m<font size=\"2\"><sup>2</sup></font>.&nbsp; Nonfasting fingerstick blood glucose in the office is 95 mg/dL.&nbsp; Which of the following is the most appropriate next step in diagnosis of this patient?</p>",
            "questionHeader": "",
            "explanationText": "<p><img  draggable=\"false\" id=\"72532\" src=\"https://www.uworld.com/media/highresdefault/L104605.jpg\"  ></p><p>This patient&#39;s symptoms (eg, sweating, neurologic symptoms) that occur during fasting are suggestive of <strong>hypoglycemia</strong>.&nbsp; However, she does not have diabetes mellitus, and symptomatic hypoglycemia (ie, glucose &lt;55 mg/dL) is <strong>rare</strong> in patients who do not have diabetes mellitus and are not critically ill.&nbsp; Therefore, hypoglycemia should be <strong>confirmed objectively</strong> before pursuing a detailed evaluation.</p><p>Establishing true hypoglycemia requires fulfillment of the <strong>Whipple triad</strong>, as follows:</p><ul><li><p><strong>Typical hypoglycemic symptoms</strong>, including <strong>neurogenic</strong> (eg, tremor, sweating) or <strong>neuroglycopenic</strong> (eg, confusion, irritability) components.</p></li><li><p><strong>Low blood glucose</strong> confirmed when symptoms occur.</p></li><li><p><strong>Resolution</strong> of symptoms after normalization of blood glucose.</p></li></ul><p>Hypoglycemia may not occur during every fast, and a single normal glucose level is insufficient to rule out a hypoglycemic disorder, especially if the patient was asymptomatic at the time of the test.&nbsp; Therefore, the best next step is to <strong>measure serum glucose when the patient is symptomatic</strong> (eg, using a home glucometer) <strong>(Choice E)</strong>.&nbsp; A low blood glucose level (&lt;55 mg/dL) with resolution of symptoms after a meal would confirm symptomatic hypoglycemia, whereas a normal glucose level (&#8805;65 mg/dL) would rule it out.</p><p>If the diagnosis remains in doubt (ie, equivocal reading between 55 and 64 mg/dL), the patient may undergo a <strong>medically supervised</strong> (eg, in the hospital) <strong>72-hour fasting test</strong>, in which serial glucose measurements are taken while the patient is given only noncaloric fluids.&nbsp; Failure of blood glucose to fall to &lt;45 mg/dL with prolonged fasting indicates that a hypoglycemic disorder is unlikely.</p><p><strong>(Choice B)</strong>&nbsp; Elevated serum insulin and C-peptide levels during a hypoglycemic episode suggest abnormal endogenous insulin secretion (eg, insulinoma).&nbsp; This should be assessed only if the patient&#39;s testing confirms the Whipple triad.</p><p><strong>(Choice C)</strong>&nbsp; Factitious hypoglycemia can result from the surreptitious use of insulin or oral antidiabetic drugs (eg, sulfonylureas).&nbsp; Hypoglycemia should be confirmed before investigating for factitious sulfonylurea use.</p><p><strong>(Choice D)</strong>&nbsp; Serum cortisol and ACTH concentrations are measured in the evaluation of adrenal insufficiency, which can cause hypoglycemia associated with fatigue, weight loss, hypotension, and electrolyte abnormalities (eg, hyponatremia, hyperkalemia).&nbsp; However, hypoglycemia should be confirmed prior to testing for the cause.</p><p><strong>Educational objective:</strong><br>Suspected symptomatic hypoglycemia in patients without diabetes mellitus should be confirmed prior to further work-up.&nbsp; Establishing true hypoglycemia requires fulfillment of the Whipple triad, which includes typical hypoglycemic symptoms, documented low blood glucose (&lt;55 mg/dL) when symptoms occur, and symptom resolution with normalization of blood glucose.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 102,
            "subject": "Medicine",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 211,
            "system": "Endocrine, Diabetes & Metabolism",
            "topicId": 2740,
            "topic": "Hypoglycemia",
            "titleId": 2740,
            "title": "Hypoglycemia",
            "topicAttributeId": 330582,
            "topicAttribute": "Diabetes mellitus",
            "correctAnswer": "1",
            "userAnswer": "1",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Advise fingerstick blood glucose checks when symptoms occur",
                    "choiceNumber": 1,
                    "correctTaken": 618,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Obtain nonfasting serum insulin and C-peptide level now",
                    "choiceNumber": 2,
                    "correctTaken": 588,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Obtain serum assay for sulfonylureas now",
                    "choiceNumber": 3,
                    "correctTaken": 21,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Obtain serum cortisol and ACTH concentrations now",
                    "choiceNumber": 4,
                    "correctTaken": 42,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Reassure the patient and schedule periodic follow-up",
                    "choiceNumber": 5,
                    "correctTaken": 186,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": "1279,1672,true,-1,1",
            "isCorrect": true,
            "isIncorrect": false,
            "isMarked": false,
            "isOmitted": false,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "27099902",
                    "mediaDataId": 0,
                    "title": "Non-diabetic hypoglycemia.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/27099902",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 57,
            "othersAvgTimeSpent": 85,
            "notes": null,
            "peopleTaken": 1455,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 42,
            "isSubmitted": false,
            "isActive": false,
            "activeStatusId": 3,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 438,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 1,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 39,
            "questionId": 2192,
            "questionIndex": 2192,
            "questionText": "<p>A 55-year-old man comes to the office for follow-up.&nbsp; The patient has a 5-year history of type 2 diabetes mellitus and hypertension and had an acute myocardial infarction 2 years ago.&nbsp; He reports no symptoms but says he is frustrated at his inability to lose weight despite lifestyle modifications.&nbsp; The patient is on the maximum dose of&nbsp;metformin.&nbsp; He does not use tobacco, alcohol, or recreational drugs.&nbsp; Blood pressure is 126/70 mm Hg and pulse is 74/min.&nbsp; BMI is 32 kg/m<font size=\"2\"><sup>2</sup></font>.&nbsp; Physical examination is otherwise unremarkable.&nbsp; Laboratory results are as follows:</p><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\"><tbody><tr><td style=\"vertical-align:middle;\">Blood urea nitrogen</td><td style=\"vertical-align:middle;\">14 mg/dL</td></tr><tr><td style=\"vertical-align:middle;\">Serum creatinine</td><td style=\"vertical-align:middle;\">1.0 mg/dL</td></tr><tr><td style=\"vertical-align:middle;\">Fasting blood glucose</td><td style=\"vertical-align:middle;\">156 mg/dL</td></tr><tr><td style=\"vertical-align:middle;\">Hemoglobin A1c</td><td style=\"vertical-align:middle;\">8.3%</td></tr></tbody></table><p>An additional medication is prescribed to improve glycemic control, assist with weight loss, and reduce cardiovascular mortality.&nbsp; Which of the following medications was most likely prescribed for this patient?</p>",
            "questionHeader": "",
            "explanationText": "<div id=\"div_T51149\"><table class=\"table-default-style\"><tbody><tr><td colspan=\"2\"><p align=\"center\"><strong>Type 2 diabetes and comorbid cardiovascular disease</strong></p></td></tr><tr><td><p align=\"center\"><strong>Lifestyle</strong></p></td><td><ul><li>Smoking cessation, regular exercise</li><li>Reduced saturated fat, refined sugar intake</li></ul></td></tr><tr><td><p align=\"center\"><strong>Cardioprotective antidiabetic agents</strong></p></td><td><ul><li>GLP-1 receptor agonists (eg, liraglutide)</li><li>SGLT-2 inhibitors (eg, empagliflozin)</li></ul></td></tr><tr><td><p align=\"center\"><strong>Lipid/antiplatelet therapy</strong></p></td><td><ul><li>Statins</li><li>Low-dose aspirin</li></ul></td></tr><tr><td><p align=\"center\"><strong>Blood pressure control</strong></p></td><td><ul><li>Goal BP &lt;130-140/80-90 mm Hg</li><li>ACE inhibitor/ARB preferred</li></ul></td></tr><tr><td colspan=\"2\"><p><strong>ACE</strong> = angiotensin converting enzyme; <strong>ARB</strong> = angiotensin receptor blocker; <strong>BP</strong> = blood pressure; <strong>GLP-1</strong> = glucagon-like peptide-1; <strong>SGLT-2</strong> = sodium-glucose cotransporter-2.</p></td></tr></tbody></table></div><p>Obesity and cardiovascular disease are common comorbidities in patients with type 2 diabetes mellitus.&nbsp; This patient has suboptimal glycemic control on metformin (a first-line diabetic treatment) and requires additional therapy; he should ideally be given an add-on diabetic agent that <strong>reduces cardiovascular mortality</strong>, induces <strong>weight loss</strong>, and carries a <strong>low risk for hypoglycemia</strong> (which increases coronary ischemia&ndash;related mortality).&nbsp; Suitable agents include <strong>glucagon-like peptide-1 receptor agonists</strong> (GLP-1RAs) and certain <strong>sodium-glucose cotransporter-2 (SGLT-2) inhibitors</strong>:</p><ul><li><p><a href=\"2758\">GLP-1RAs</a> (eg, exenatide, liraglutide) regulate glucose by increasing <strong>glucose-dependent insulin release</strong> (ie, low risk for hypoglycemia) and suppressing glucagon.&nbsp; They also slow gastric emptying, which decreases appetite and causes weight loss.</p></li><li><p><a href=\"2663\">SGLT-2 inhibitors</a> (eg, canagliflozin, empagliflozin) increase renal glucose and sodium excretion, leading to mild weight loss and mild diuresis.&nbsp; Because renal glucose filtration is proportional to serum glucose level, hypoglycemia is rare.&nbsp; These agents also reduce heart failure&ndash;related mortality and progression of diabetic nephropathy.</p></li></ul><p><strong>(Choice A)</strong>&nbsp; Dipeptidyl peptidase-4 inhibitors (eg, sitagliptin) prevent degradation of GLP-1 and therefore function like GLP-1RAs.&nbsp; However, they are less potent than GLP-1RAs and are not associated with weight loss or cardioprotective effects.</p><p><strong>(Choices C and D)</strong>&nbsp; Adding insulin or a sulfonylurea (eg, glimepiride) would improve glycemic control but is associated with significant weight gain and risk for hypoglycemia.&nbsp; Compared to GLP-1RAs or SGLT2 inhibitors, these agents are less preferred for patients with obesity and coronary artery disease.</p><p><strong>(Choice E)</strong>&nbsp; Thiazolidinediones (eg, pioglitazone) are associated with weight gain, fluid retention, and increased risk for heart failure in patients with underlying heart disease.&nbsp; Pioglitazone should be avoided in this patient.</p><p><strong>Educational objective:</strong><br>Obesity and cardiovascular disease are common comorbidities in patients with type 2 diabetes mellitus.&nbsp; In these patients, glucagon-like peptide-1 receptor agonists and/or certain sodium-glucose cotransporter-2 inhibitors can be added to decrease cardiovascular mortality, induce weight loss, and minimize the risk for hypoglycemia.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 102,
            "subject": "Medicine",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 211,
            "system": "Endocrine, Diabetes & Metabolism",
            "topicId": 2603,
            "topic": "Diabetes mellitus",
            "titleId": 2603,
            "title": "Diabetes mellitus",
            "topicAttributeId": 330582,
            "topicAttribute": "Diabetes mellitus",
            "correctAnswer": "2",
            "userAnswer": "2",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Dipeptidyl peptidase-4 inhibitor",
                    "choiceNumber": 1,
                    "correctTaken": 1307,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Glucagon-like peptide-1 agonist",
                    "choiceNumber": 2,
                    "correctTaken": 13892,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Long-acting insulin",
                    "choiceNumber": 3,
                    "correctTaken": 382,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Sulfonylurea",
                    "choiceNumber": 4,
                    "correctTaken": 925,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Thiazolidinedione",
                    "choiceNumber": 5,
                    "correctTaken": 893,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": "364,392,true,-1,1",
            "isCorrect": true,
            "isIncorrect": false,
            "isMarked": false,
            "isOmitted": false,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "526",
                    "mediaDataId": 0,
                    "title": "Noninsulin antihyperglycemic drugs in type 2 diabetes mellitus",
                    "referenceTypeId": 18,
                    "referenceLink": null,
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "28413990",
                    "mediaDataId": 0,
                    "title": "Effect of glucagon-like peptide-1 receptor agonists on all-cause mortality and cardiovascular outcomes: a meta-analysis.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/28413990",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "31189511",
                    "mediaDataId": 0,
                    "title": "Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/31189511",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "32865377",
                    "mediaDataId": 0,
                    "title": "Cardiovascular and renal outcomes with empagliflozin in heart failure.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/32865377",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 112,
            "othersAvgTimeSpent": 45,
            "notes": null,
            "peopleTaken": 17399,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 80,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 376,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 1,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 40,
            "questionId": 17773,
            "questionIndex": 19233,
            "questionText": "<p>A 40-year-old man with type 1 diabetes mellitus comes to the office due to recurrent hypoglycemia.&nbsp; A month ago, the patient was seen in the emergency department due to unconsciousness associated with a blood glucose level of 34 mg/dL.&nbsp; Since then, he has had several blood glucose readings &lt;50 mg/dL that he corrected by drinking fruit juice; however, he had no tremor, sweating, or palpitations during the episodes.&nbsp; Medications include insulin glargine, insulin lispro, lisinopril, hydrochlorothiazide, and simvastatin.&nbsp; Vital signs and physical examination are normal.&nbsp; Hemoglobin A1c is 8.1% and serum creatinine is 1.1 mg/dL.&nbsp; Which of the following is the most likely cause of hypoglycemia unawareness in this patient?</p>",
            "questionHeader": "",
            "explanationText": "<p><img draggable=\"false\" id=\"40153\" src=\"https://www.uworld.com/media/L66274.png\" ></p><p>Patients with <strong>type 1 diabetes mellitus</strong> can develop <strong>hypoglycemia</strong> because exogenous insulin continues to be absorbed from the injection site despite falling glucose levels; those with long-standing diabetes (ie, &gt;5 yr) often also have alpha cell failure, which can lead to decreased glucagon secretion and exacerbate hypoglycemia.&nbsp; Normally, hypoglycemia prompts a catecholamine (eg, epinephrine) surge, which <a href=\"2507\">increases hepatic glucose production</a> and triggers many of the characteristic neurogenic hypoglycemic symptoms (eg, arousal, tremor).&nbsp; However, patients with <strong>long-standing diabetes</strong> often have a <strong>blunted autonomic response</strong> to hypoglycemia, with reduced hypoglycemia awareness.</p><p>This blunted autonomic response is worse in patients who frequently have low circulating glucose levels.&nbsp; Such <strong>recurrent or severe hypoglycemia</strong> reduces the glucose-raising effects of epinephrine and <strong>suppresses the symptoms</strong> related to the catecholamine surge; in turn, this increases the risk for progressively worse hypoglycemic episodes (ie, <strong>hypoglycemia-associated autonomic failure</strong>).</p><p>Management requires strict avoidance of hypoglycemia to restore awareness.&nbsp; Judicious timing of insulin administration and carbohydrate ingestion (eg, in relation to physical activity) is necessary.</p><p><strong>(Choices A, B, and D)</strong>&nbsp; Thiazide diuretics (eg, hydrochlorothiazide) and statins (eg, simvastatin) can raise blood glucose levels, making glycemic control somewhat more difficult.&nbsp; In contrast, ACE inhibitors (eg, lisinopril) increase insulin sensitivity and can occasionally induce hypoglycemia.&nbsp; However, these agents do not significantly affect hypoglycemia awareness.</p><p><strong>Educational objective:</strong><br>Hypoglycemia normally prompts a catecholamine (eg, epinephrine) surge, which increases hepatic glucose production and triggers hypoglycemic symptoms.&nbsp; Recurrent or severe hypoglycemia in patients with long-standing diabetes reduces the glucose-raising effects of epinephrine and suppresses the symptoms related to the catecholamine surge, increasing the risk for progressively worsening hypoglycemic episodes.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 102,
            "subject": "Medicine",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 211,
            "system": "Endocrine, Diabetes & Metabolism",
            "topicId": 2740,
            "topic": "Hypoglycemia",
            "titleId": 2740,
            "title": "Hypoglycemia",
            "topicAttributeId": 330582,
            "topicAttribute": "Diabetes mellitus",
            "correctAnswer": "3",
            "userAnswer": "1",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Hydrochlorothiazide use",
                    "choiceNumber": 1,
                    "correctTaken": 523,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Lisinopril use",
                    "choiceNumber": 2,
                    "correctTaken": 317,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Previous severe hypoglycemia",
                    "choiceNumber": 3,
                    "correctTaken": 1153,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Simvastatin use",
                    "choiceNumber": 4,
                    "correctTaken": 113,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": "202,360,true,-1,1*1321,1668,true,-1,1",
            "isCorrect": false,
            "isIncorrect": true,
            "isMarked": false,
            "isOmitted": false,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "736",
                    "mediaDataId": 0,
                    "title": "Hypoglycemia in adults",
                    "referenceTypeId": 18,
                    "referenceLink": null,
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "24095133",
                    "mediaDataId": 0,
                    "title": "Hypoglycemia-associated autonomic failure in diabetes.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/24095133",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 81,
            "othersAvgTimeSpent": 72,
            "notes": null,
            "peopleTaken": 2106,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 55,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 1359,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 1,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        }
    ],
    "abstractList": null,
    "deckList": [
        {
            "deckId": 9788456,
            "deckName": "Notes",
            "deckColor": "#36c8a3",
            "isDefault": true,
            "dateCreated": "01/01/0001 12:00:00 AM",
            "noOfFlashCards": 4,
            "groupId": null,
            "studySettingsId": null,
            "lastStudyDate": null,
            "isCustomStudyDeck": false,
            "parentDeckId": null,
            "customStudySettings": null,
            "subscriptionId": 0
        }
    ],
    "newExamYearQuestionList": null,
    "flashCardList": null,
    "questionModes": [
        {
            "id": 1,
            "name": "UNUSED"
        }
    ],
    "subscriptionElapsedTime": 0.0,
    "isFacultyControlled": null,
    "endCATTest": null,
    "questionSourceIds": null
}